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1.1 G-protein coupled receptors 
1.1.1 Brief history 
It was in the early 20th century that binding of biologically active molecules to “specific sites 
on cells” was postulated for the first time by Langley and his student Dale. It is noteworthy 
that their studies included two of the most important families of receptors, the ion channel 
receptors and the G-protein coupled receptors (GPCRs).1 Now we know that with about 800 
genes, GPCRs, also refered to as seven-transmembrane domaine receptors or heptahelical 
receptors, represent the largest family of cell surface receptors encoded in the human 
genome, including approximately 400 chemosensory (olfactory and taste) receptors.2,3 
Within the next 50 years the work of Langley and Dale was refined to the concept of classical 
receptor pharmacology by pioneers like e.g. Black and Furchgott.4 The β2-adrenergic 
receptor was the first GPCR to be cloned in 1986 and represents the starting point for a 
molecular understanding of GPCRs.5 Another milestone in the field of GPCR research was 
achieved in 2000, when Palczewski and coworkers published the first high-resolution X-ray 
crystal structure of a GPCR, the bovine rhodopsin.6 So far, high-resolution structures are 
available for 25 GPCRs, including β-adrenoceptors (avian β1-AR7 and human β2-AR8), 
muscarinic acetylcholine receptors (human M2R9 and rat M3R10), opioid receptors (human 
nociceptin receptor11, human κ-OR12, mouse µ-OR13 and mouse δ-OR14) and the histamine 
H1R.15 The importance and significance of GPCRs in biomedical research was underlined in 
2012 when Brian Kobilka and Robert Lefkowitz were awarded the Nobel Prize for their work 
in the GPCR field.    
 
1.1.2 GPCRs as drug targets 
Drugs binding to GPCRs show therapeutic benefit in a broad variety of indications, such as 
pain, bronchial asthma, cardiovascular diseases and neurological disorders. Although 
addressing only a small number of these membrane proteins,16 more than 30 % of the 
approximately 500 most important approved drugs bind to GPCRs, making them the most 
successful therapeutic targets.17 Endogenous ligands were identified for more than 200 
GPCRs, including hormones and neurotransmitters.18-20 The endogenous ligands of around 
140 GPCRs are yet unidentified.21 These so-called orphan GPCRs represent promising 
potential new drug targets. 
 
1.1.3 GPCR structure and classification 
Characteristic of all GPCRs are seven hydrophobic transmembrane (TM) domains, with an 
extracellular amino terminus and an intracellular carboxyl terminus (Fig 1.1). GPCRs share 
the highest homology within the TM domains, whereas the carboxyl terminus, the 
intracellular loop between TM5 and TM6 and the amino terminus represent the most variable 
structures.22 The extracellular parts and the transmembrane regions are important for ligand 
binding, whereas the intracellular regions are crucial for signaling and for feedback 
modulation of receptor function.23 Under evolutionary aspects, Fredriksson et al. classified 
GPCRs into five families: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin 
(GRAFS).18 The rhodopsin family, by far the largest group, can be subdivided into four main 
groups: α, β, γ and δ. The histamine receptors belong to the α group. The rhodopsin family 
shows several characteristic features like the NSxxNPxxY motif in TM7, the DRY motif or 
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D(E)-R-Y(F) at the bottom of TM3, close to IL2.18 Most ligands for the rhodopsin family 
receptors bind between the TM helices.24 
 
 
Figure 1.1. Schematic representation of a prototype class A GPCR (IL = intracellular loop; EL = extracellular 
loop; 1-7 = transmembrane domains) 
 
 
1.1.4 GPCR activation and signaling 
1.1.4.1 Classical model 
Upon binding of an agonist, the receptor in its active form is functioning as a nucleotide 
exchange factor on the α subunit of heterotrimeric G-proteins, triggering the exchange of 
GDP by GTP. Thereby, the Gα subunit dissociates from the Gβγ subunit and both subunits 
interact with effector proteins, resulting in an increase or decrease in second messenger 
concentrations. The G-protein returns to its inactive state upon cleavage of GTP to GDP by 
the intrinsic GTPase activity of the Gα subunit (Fig. 1.2).23  
 
 
Figure 1.2. G-Protein cycle upon receptor activation by an agonist (adopted from Seifert et al. 2005).25 
 
The classical model of activation of GPCRs is the ternary complex model.26 This model was 
extended by the finding that numerous receptors are capable of activating G-proteins in the 
absence of agonists.27  According to this extended ternary complex model (Fig.1.3A), the 
receptor exists in an inactive (Ri) and in an active (Ra) conformation. The level of basal 
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receptor activity is given by the equilibrium between the active and the inactive state. Ligands 
are classified according to their ability to shift the equilibrium. Agonists show higher affinity 
for Ra and stabilize the active conformation, leading to G-protein activation. Neutral 
antagonists bind to Ri and Ra with the same affinity and, therefore, they do not alter the 
equilibrium. In contrast, inverse agonists stabilize the inactive receptor conformation.27,28  
 
 
Figure 1.3. (A) Extended ternary complex model (L = ligand; Ra = active state of the receptor; Ri = inactive state 
of the receptor; G = G-protein) (adopted from Rajagopal et al.)29 (B) Effects produced by different ligands in a 
biological system (adopted from Kenakin).30  
 
1.1.4.1.1 G-proteins  
Heterotrimeric G-proteins consist of a 39-52 kDa GTP-binding Gα subunit and a Gβγ subunit. 
In the inactive state, the Gβγ dimer is non-covalently bound to the Gα subunit. There are 16 
known mammalian Gα subunits and they are grouped into four families (Gαi/o, Gαs, Gαq/11 and 
Gα12/13).23 Furthermore, there are 5 known Gβ- and 12 known Gγ subunits. In vitro most Gβ 
and Gγ subunits can form stable heterodimers. In combination with the diversity of the Gα 
subunits, this provides the potential of numerous combinations to form functional 
heterotrimeric G-proteins. Still, the role of subunit diversity of G-proteins is not fully 
understood.31 
1.1.4.1.2 G-protein regulated effectors 
In principle, the interaction between receptor and G-protein is not strictly specific. G-protein 
mediated signaling can depend on the cellular background 31 and, moreover, some GPCRs 
are capable of coupling to multiple G-proteins.32,33 An overview of typical signaling patterns of 
GPCRs is given in Figure 1.4. 
Activated G-proteins regulate the function of different effectors. The most widely studied 
effector are isoforms of adenylyl cyclase (AC). All of the nine ACs are activated by the Gαs 
subunit, resulting in an increase in intracellular cAMP. It is noteworthy that some of the ACs 
can additionally be influenced by Gβγ subunits via calcium-calmodulin.23 The Gαs family 
includes the ubiquitously expressed Gαs subunit and the olfactory α subunit Gαolf. 
The G-proteins of the Gαi/o family are widely expressed, and the main function of the Gαi 
subunit is the inhibition of most of the ACs. The role of this family of G-proteins has 
extensively been studied with pertussis toxin (PTX), resulting in ADP-ribosylation and 
preventing the coupling of Gαi to the receptor.34 Because of high expression, the activation of 
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Gαi leads to a release of high amounts of βγ subunits. Therefore, Gαi activation is believed to 
be the major pathway resulting in Gβγ mediated signaling.35 
The Gαq and Gα11 subunits are almost ubiquitously expressed, whereas Gα14 and Gα15/16 
show a rather limited expression pattern.35 Gαq/11 coupled receptors do not discriminate 
between the Gαq and the Gα11 subunit.36,37 Both subunits are efficient activators of the 
isoforms β1, β3 and β4 of PLC, but not of the β2 isoform.38 While the role of Gαq and Gα11 in 
biological processes
 
is well understood, the function of the other two members of the Gαq/11 
family is still unclear.35  
The investigation of the function of the G12/13 family is compromised by the lack of selective 
inhibitors. G12 and G13 are often stimulated by receptors simultaneously activating Gαq/11. 
Studies revealed that G12/G13 can alter a variety of downstream effectors including 
phospholipase A2 (PLA2) and the Na+/H+ exchanger.39,40 Moreover, they regulate the 
formation of actomyosin-based structures and modulate their contractility by increasing the 
activity of the small GTPase RhoA (Ras homolog gene family, member A).41 
 
 
 
Figure 1.4. Typical pattern of GPCRs coupling. (A) Gs mediated signaling (AC = adenylyl cyclase; ATP = 
adenosine triphosphate; cAMP = cyclic adenosine monophosphate) (B) Gi/o mediated signaling (GIRK = G-
protein-regulated inward rectifier potassium channel; PI-3-K = phosphoinositide-3-kinase; PLC-ß = 
phospholipase C-β (C) Gq/11 and G12/13 mediated signaling (DAG = diacylglycerol; GDP = guanosine diphosphate; 
GTP = guanosine triphosphate; IP3 = inositol 1,4,5-trisphosphate; PIP2 = phosphatidylinositol 4,5-bisphosphate; 
PKC = protein kinase C; Rho-GEF = Rho-guanine nucleotide exchange factor; RhoA = Ras homolog gene 
family, member A) (adopted and modified from Wettschureck et al. 2005).35 
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1.2 Histamine and its receptors 
1.2.1 The biogenic amine histamine  
1.2.1.1 Brief history 
More than 100 years ago, the British physiologist Sir Henry Dale discovered histamine as a 
constituent of ergot. Subsequently, histamine was identified as endogenous substance in the 
body (“histos” = “tissue”).42 During the next decade, the pharmacological effects of histamine 
were extensively studied, and in 1937 the first antihistamines were synthesized by Daniel 
Bovet and Anne-Marie Staub.43 Five years later, the first H1R antagonists were introduced 
into therapy.  
 
1.2.1.2 Biosynthesis, metabolism and function 
In the body, histamine is formed from the amino acid L-histidine by the action of histidine 
decarboxylase (HDC).44 After liberation, histamine is rapidly cleaved by histamine N-
methyltransferase (HNMT)45 or diamine oxidase (DAO).46 As a neurotransmitter, histamine 
plays a crucial role in brain functions, including circadian rhythm, nociception and locomotor 
activity.47 Furthermore, histamine regulates secretion of pituitary hormones, gastrointestinal 
and circulatory functions, and it is involved in inflammatory reactions and the modulation of 
the immune response.47 Histamine is mainly stored in the granules of mast cells48 and 
basophils49 and can be released in large amounts upon degranulation in response to various 
stimuli. Another depot are the enterochromaffin-like (ECL) cells in the stomach. Histamine 
released from ECL cells, regulates gastric acid secretion from parietal cells.50 The effects of 
histamine are mediated by four histamine receptor (HxR) subtypes, termed H1R, H2R, H3R 
and H4R, all of them belonging to class A GPCRs. 
 
1.2.2 The four histamine receptors and their ligands 
1.2.2.1 The histamine H1R 
The H1R is mainly expressed in mammalian brain, on smooth muscle and endothelium cells 
and on lymphocytes.51 On immune cells, the H1R is often co-expressed along with the H2R, 
complicating detailed studies of both receptors due to the lack of selectivity of some 
ligands.52 The H1R preferentially couples to the Gαq protein, resulting in an increase in 
intracellular Ca2+. H1R-mediated biological effects comprise vasodilatation, 
bronchoconstriction, modulation of endothelial barrier function, as well as pain and itching as 
a consequence of insect stings.53 The first H1R antagonists, usually referred to as “classical 
antihistamines” (e.g. mepyramine, diphenhydramine) against allergic diseases, were already 
established in the 1940s. These 1st generation H1R antagonists are highly lipophilic 
compounds, able to pass the blood brain barrier and to cause sedation. For that reason, 
antagonists such as cetirizine and loratadine were developed that cross the blood brain 
barrier to a much lower degree. This 2nd generation of antihistamines still represents 
blockbuster drugs for the treatment of allergic disorders (Fig 1.5).54  
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Fig. 1.5. Chemical structures of selected H1R antagonists 
 
The only H1R agonist in clinical use is betahistine (Fig. 1.6), a drug for the treatment of 
Meniere`s disease.55 Highly potent H1R agonists were developed as pharmacological tools. 
Potent agonists, superior to histamine, were obtained by structural optimization of 2-
phenylhistamines.56,57 The most successful approach to potent and selective H1R agonists 
resulted in histaprodifen derivatives, especially suprahistaprodifen.58-61  
 
 
 
Figure 1.6. Chemical structures of selected H1R agonists 
 
1.2.2.2 The histamine H2R 
Up to the late 1940s, scientists had no explanation why some of the histamine-mediated 
effects, for example the positive chronotropic response and the stimulation of gastric acid 
secretion, could not be antagonized by the classical antihistamines.62,63 In 1966, Ash and 
Schild postulated the existence of a second receptor subtype,64 which was pharmacologically 
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characterized and termed H2R in 1972 by the Nobel laureate Sir James Black.65 The H2R is 
located in mammalian brain, on parietal cells, on human neutrophils and eosinophils, in 
cardiac-, airways and uterus tissue.52,66 The H2R canonically couples to the Gαs protein 
resulting in the activation of PKA and in an increase in cAMP.67 After burimamide,65 the first 
antagonist used to define the H2R, H2R antagonists with increased affinity, e.g. cimetidine, 
famotidine and ranitidine, revolutionized the treatment of gastric and duodenal ulcer (Fig. 
1.7).68 Nowadays, these drugs have been replaced by proton pump inhibitors. Nevertheless, 
there is a great interest in CNS permeable H2R ligands to elucidate the role of the H2R in the 
CNS.63  
 
 
 
Figure 1.7. Chemical structures of selected H2R antagonists 
 
The guanidine derivative impromidine was the first highly potent H2R agonist. A large number 
of impromidine analogues has been synthesized and characterized with respect to H2R 
agonism.69 Impromidine was the first H2R agonist clinically tested in patients suffering from 
severe catecholamine-refractory congestive heart failure.70,71 Structural modification of 
impromidine led to arpromidine, in which the cimetidine-like moiety was replaced by a more 
lipophilic pheniramine-like structure. Such compounds showed up to 400 times the potency 
of histamine.72 With respect to oral bioavailability, the strongly basic guanidine (pKa~13) was 
replaced by an acylguanidine (pKa~8). Surprisingly, agonistic potency was retained or even 
increased (e.g. UR-Bit24).73,74 A tremendous increase in potency was achieved according to 
the bivalent ligand approach. Bivalent H2R agonists (e.g. UR-AK381) were up to 4000 times 
more potent than histamine and are the most potent H2R agonists known so far (Fig. 1.8).75 
Highly selective H2R agonists might be beneficial for patients suffering from acute myeloid 
leukemia (AML).76,77 In myeloid cells histamine facilitates T-cell mediated killing of tumor cells 
and is therefore used as an orphan drug in combination with interleukin 2 (IL2) for 
maintenance treatment of AML.78  
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Figure 1.8. Chemical structures of selected H2R agonists 
 
1.2.2.3 The histamine H3R 
In 1983, Schwartz and coworkers suggested the existence of a third histamine receptor. 
They discovered that histamine was able to inhibit its own release from cerebral neurons and 
that this effect was antagonized by burimamide at nanomolar concentrations, which was far 
below the concentration necessary to block the H2R.79,80 The H3R is predominantly located in 
neurons where it acts as an autoreceptor regulating the synthesis and release of histamine. 
Additionally, the H3R also occurs as a hetero-receptor on non-histaminergic neurons, 
controlling the release of other neurotransmitters including dopamine, acetylcholine and 
GABA.63 In the periphery, the receptor is expressed in the gastrointestinal tract, the airways 
and the cardiovascular system.81 The H3R couples to Gi proteins and has been shown to 
interfere with various transduction pathways apart from the modulation of the AC activity, for 
example activation of PLA2 and inhibition of K+-induced Ca2+ activation.82 The first potent H3R 
antagonists were thioperamide and clobenpropit, which turned out to be additionally highly 
potent H4R ligands. Moreover, as imidazole-type ligands, these compounds harbor the risk of 
drug-drug interactions due to interactions with cytochrome P-450 enzymes. With the 
discovery of high constitutive activity, numerous H3R antagonists had to be re-classified as 
inverse agonists. To reduce the off-target effects and to improve the drug-like properties, the 
imidazole ring was replaced mainly by a variety of secondary and tertiary amines, including 
cyclic amine moieties (e.g. piperazino, pyrrolidino and morpholino).83 Potential therapeutic 
implications for H3R antagonists (Fig. 1.9) include obesity and numerous CNS disorders 
such as schizophrenia, epilepsy and Alzheimer`s disease. Very recently, the first H3R inverse 
agonist pitolisant was introduced as an orphan drug for patients suffering from 
narcolepsy.84,85 
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Fig 1.9. Chemical structures of selected H3R antagonists/inverse agonists 
 
Modifications of histamine by mono- or dimethyl substitution resulted in more potent and 
selective H3R agonists (Fig. 1.10), such as (R)-α-methylhistamine. A further improvement 
regarding selectivity over the H4R was achieved with immethridine86 and methimepip87. All of 
the H3R agonists represent histamine derivatives, which carry the risk of drug-drug 
interactions. Bioisosteric replacement of the imidazole moiety in H3R agonists harbors a 
potential for new drugs, for example, for the treatment of migraine, ischemic arrhythmias, 
asthma or diabetes mellitus.88,89  
 
 
 
Figure 1.10. Chemical structures of selected H3R agonists 
 
1.2.2.4 The histamine H4R 
In 1994, Raible and coworkers suggested the existence of a novel histamine receptor on 
human eosinophils, based on a histamine induced calcium response.90 This hypothesis was 
corroborated by several workgroups, which independently cloned the H4R.91-95 The H4R was 
reported to be expressed in bone marrow and immunocytes, such as mast cells, eosinophils 
and monocytes.52 The identification of the H4R in the CNS96 was not confirmed by several 
workgroups.97 Additionally, according to a recently published study,  there is no evidence for 
the expression of the H4R in human monocytes.98 Presumably, the erroneous detection of 
the H4R in brain and monocytes was due to the use of unspecific antibodies and unreliable 
data on mRNA expression.97-100 The H4R is a Gi coupled receptor and mediates an increase 
in intracellular Ca2+ concentration. The indole derivative JNJ7777120 was the first selective 
and potent non-imidazole H4R antagonist described in the literature and has been widely 
used as a reference compound in vitro and in vivo.101 Surprisingly, JNJ7777120 turned out to 
be a biased agonist, stimulating H4R mediated β-arrestin recruitment.102 Five H4R 
antagonists (e.g. UR-63325 [undisclosed structure], PF-3893787103, JNJ39758979104) 
(Fig.1.11) entered clinical trials for the treatment of allergic rhinitis, allergic asthma, atopic 
dermatitis and rheumatoid arthritis.105 Despite significantly antipruritic effects in human, the 
clinical trial of JNJ39758979 was terminated due to two agranulocytosis cases.106,107 
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Figure 1.11. Chemical structures of selected H4R antagonists 
 
In contrast to H4R antagonists, the potential therapeutic value of H4R agonists (Fig 1.12) is 
still a matter of speculation. Regardless of that, further investigation of the 
(patho)physiological role of the H4R requires selective and potent H4R agonists as molecular 
tools. Due to the high sequence homology with the H3R (~ 58 % identity in the TM regions)94 
the design of selective H4R proved to be rather challenging. The cyanoguanidine OUP-16 
was the first ligand with improved (approximately 30-fold) H4R selectivity. Structural 
optimization of imidazolylalkylguanidines led to the highly potent and selective H4R agonists, 
like e.g. UR-PI376.108 One of the most potent H4R agonists known so far was identified 
among a series of 2-arylbenzimidazoles.109 Potencies and efficacies of numerous H4R 
agonists are depending on the species considered.110 In this context, oxime-type 
compounds, structurally derived from JNJ7777120, proved to be of special value. The Z-
configured isomers have comparable agonist potencies on human and rodent H4Rs.111 
 
 
 
Figure 1.12. Chemical structures of selected H4R agonists 
 
1.3 GPCR dimerization and bivalent ligands 
1.3.1 GPCR dimerization 
Over a long period of time, it has been assumed that GPCRs exist and function as 
monomers. However, there is growing evidence that GPCRs are able to form dimers or 
oligomers. The first receptor shown to form dimers was the GABAB receptor. Only when 
coexpressed with GABAB2, the GABAB1 receptor is capable of forming a functional GABAB 
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receptor.112-114 Meanwhile, many GPCRs are known to form hetero- and homodimers, 
respectively (for reviews, cf. Agnati et al. 2003, Hiller et al. 2013).115,116 Receptor dimerization 
can induce distinct ligand binding properties. For example, it was shown for δOR and µOR 
coexpressing cells that there was a significant increase in binding of µOR ligands in the 
presence of δOR antagonists.117 This phenomenon can be explained by positive 
cooperativity: binding of one ligand to the first receptor molecule increases the interaction of 
the second ligand to the second receptor protomer (Fig. 1.13A). Receptor dimerization can 
alter signaling, e.g., induce a switch in G protein coupling. For example, the D1R canonically 
couples to Gαs, and the D2R couples to Gαi, whereas heterodimers of the two receptors 
preferentially activate Gαq.118 It is noteworthy that dimerization can also cause a switch from 
G-protein activation to β-arrestin signaling.119 Furthermore, GPCR dimerization may have an 
influence on trafficking. For instance, coexpression of the α1D- and the α1B adrenoceptor led 
to a 10-fold increase in cell surface expression of the α1D-AR, suggesting that 
heterodimerization enhances the transport of α1D-AR to the cell membrane.120 Drugs 
selectively targeting receptor dimers might possess higher affinity and selectivity and/or an 
improved pharmacokinetic profile resulting in reduced side effects.121,122 
 
1.3.2 Bivalent ligands 
One possibility to target GPCR dimers is the bivalent ligand approach. Typically, the term 
“bivalent ligands” refers to molecules composed of two pharmacophoric moieties linked 
through a spacer.123 Based on the pioneering work of Porthogese and coworkers, who 
developed the first bivalent ligands for the investigation of the dimerization of opioid 
receptors,124-126 the bivalent ligand approach was successfully adopted for many GPCRs, 
including e.g. serotonin, histamine and dopamine,75,127-131 resulting in compounds with higher 
affinity and selectivity compared to their monovalent counterparts. The two pharmacophoric 
entities can either be structurally equal (homobivalent) or different (heterobivalent). 
Obviously, the length of the spacer is a key factor for bridging a receptor dimer (Fig. 1.13B). 
A very short or a very long spacer decreases the potential to bridge two vicinal receptor 
protomers.132 Porthogese et al. observed highest agonist potency at a spacer length of 18 
atoms (~20 Å).133 However, newer studies revealed that the optimum spacer length for 
bivalent ligands targerting receptor dimers depends on the dimer interface, the structure of 
pharmacophores and topicity of the point of attachments.116 Thus, bivalent ligands with 
clozapine as pharmacophore displayed highest affinity with a spacer length of 16 and 18 
atoms.134 Interestingly, the highest potency for bivalent H2R agonists was achieved with 
compounds bearing an octa- or hexamethylene chain, rather indicating to an additional 
binding site at the same receptor molecule (Fig. 1.13C).75  
 
 
 
Figure 1.13. Possible binding modes of bivalent ligands. (A) Binding to two receptor protomers (B) Bridging of a 
receptor dimer (C) Simultaneous binding to an orthosteric and allosteric binding site of the same receptor 
molecule (bitopic or dualsteric binding mode) (adopted and modified from Bonger et al. 2007).135 
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Previously, our workgroup applied the guanidine – acylguanidine bioisosteric approach to 
imidazolylpropylguanidine-type histamine H2 receptor (H2R) agonists73,136 and explored the 
bivalent ligand approach, taking into consideration the hypothesis that GPCRs, including 
histamine receptor subtypes, can form functionally active dimers. Acylation of the guanidine 
group reduced the basicity by 4-5 orders of magnitude. Surprisingly, agonistic potency was 
retained or even increased. In combination with a bivalent approach, this strategy resulted in 
highly potent H2R agonists. The binding mode of these compounds is far from being 
understood. The optimal spacer length of the most active bivalent H2R agonists is most 
probably insufficient to enable simultaneous occupation of the recognition sites of putative 
H2R dimers.75 Probably, the tremendous gain in potency results from interaction with an 
accessory binding site at the same receptor protomer.  
 
1.4 Functional selectivity and G-protein independent signaling 
Besides G-proteins, two additional protein families are known to interact with active state 
GPCRs: G-protein coupled receptor kinases (GRKs) and β-arrestins.137 Whereas originally, 
the role of these proteins was simply associated with desensitization, internalization and 
recycling of GPCRs,138 they are nowadays considered as alternative signal transducers.137,139 
Particularly, β-arrestins are known to interact with many proteins and protein kinases, leading 
to the phosphorylation of numerous targets.140,141  
Over the last decades, a growing number of experimental data supported the concept of 
“biased signaling” as a consequence of various active states of an individual receptor. 
According to the classical model, agonists are considered to have “linear efficacy”, i.e. a 
pharmacological activity resulting from a sequence beginning with receptor occupancy and 
G-protein activation.142 However, some ligands show “imbalanced efficacies” regarding the 
activation of different signaling pathways (Fig. 1.14A).141 Such ligands proved to be 
antagonists on one pathway, while simultaneously being agonists on another pathway.143,144 
To consider such a behavior, the classical two-state model was extended to a multiple-state 
model (Fig. 1.14B). According to the latter, a given ligand is capable of stabilizing a unique 
receptor conformation, either triggering the G-protein or the β-arrestin pathway.141,142,145,146  
 
 
 
Figure 1.14. (A) Concept of functional selectivity: A given ligand (1-4) stabilizes a unique active receptor 
conformation (R*1-R*4). The distinct receptor conformations differ in their capability to interact with different G-
proteins (G1-G3) and β-arrestins (βArr). As a result, effector systems (E1-E4) are regulated in a ligand specific 
manner (adopted from Seifert 2013).146 (B) Multiple-state model (L = ligand; Ran = distinct active receptor 
conformations; Ri =  inactive state of the receptor; Tn = distinct transducers) (adopted from Rajagopal et al. 
2010)29 
 
 
Chapter 1 
14 
 
The ability of a ligand to address either G-protein signaling or β-arrestin signaling is referred 
to as “functional selectivity”, “biased agonism” or “collateral efficacy” (Fig. 1.15).147,148 By 
now, functionally selective ligands were discovered for many GPCRs, e.g. for β-adrenergic 
receptors,149,150 dopamine D2 and D3 receptors151,152 and the histamine H4R.153,154 Such 
biased agonists harbor a great potential for the development of novel therapeutic agents with 
reduced adverse effects. Studies already revealed that the pharmacology of some of these 
functionally selective ligands was different from that of unbiased compounds.148,155,156 
 
 
 
Figure 1.15. Functionally selective ligands: (A) Binding of an unbiased ligand leads to G-protein activation and 
β-arrestin recruitment in a balanced manner. (B) Binding of a G-protein biased ligand. (C) Binding of a β-arrestin 
biased ligand (βArr = β-arrestin; GRK = G-protein receptor coupled kinase) (adopted from Rajagopal et al. 
2010).29 
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2.1 Dimeric carbamoylguanidine-type H2 receptor ligands 
A first aim of this doctoral thesis was the synthesis and the pharmacological characterization 
of a series of new dimeric (bivalent) H2R agonists in which acylguanidine moieties are 
replaced by carbamoylguanidine groups. From the chemical point of view, the major 
advantage of the carbamoylguandines consists in resistance against hydrolytic cleavage 
compared to the acylguanidines. Hence, the stability of representative examples of 
carbamoylated and acylated guanidines, respectively, was compared. 
With respect to confocal microscopy and investigations on the stoichiometry of ligand to 
receptor in case of bivalent agonist binding, a major goal of this work was the synthesis of a 
chain-branched dimeric ligand, enabling radio- and fluorescence labeling. 
 
 
2.2 Unraveling signaling pathways of the human histamine receptors 
H1R and H2R in HEK293T CRE Luc cells 
Due to a lack of data regarding functional selectivity of the H1R and the H2R, a second 
project of this thesis aimed at the development of a pharmacological tool kit for the 
investigation of alternative signaling pathways of the human H1 (hH1R) and the human H2 
receptor (hH2R). Although preferential coupling of hH1R and hH2R to Gαq and Gαs, 
respectively, had been taken for granted, alternative signaling pathways were proposed. 
Therefore, HEK293T cells were genetically engineered to stably co-express the firefly 
luciferase under the control of a cAMP response element (CRE) and the hH1R or the hH2R, 
respectively. Aiming at functional assays enabling a discrimination between different signaling 
pathways, the transfectants were investigated in a luciferase reporter gene assay, in the fura-2 
assay and in the aequorin assay. Moreover, the application of a TR-FRET based cAMP assay 
was planned. In order to unravel the underlying pathways selective G-protein inhibitors were 
used. 
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3.1 Introduction 
Previously, NG-acylated hetarylpropylguanidines were identified as potent histamine H2 
receptor (H2R) agonists.1-3 Surprisingly, an enormous increase in H2R potency was achieved 
by linking two acylguanidine moieties. The most potent of those dimeric compounds showed 
up to 5000-fold potency of histamine (depending on the type of assay and the respective H2R 
ortholog).3 The first generation of NG-acylated imidazolylpropylguanidines showed a lack of 
selectivity, especially towards histamine H3 (H3R) and histamine H4 receptors (H4R).4 
Selectivity for the H2R was achieved by bioisosteric replacement of the imidazole ring by an 
amino(methyl)thiazole moiety.2,3 Porthogese et al. suggested that the distance between the 
orthosteric binding sites of two dimerising receptor protomers is about 22 to 27 Å.6 In an 
approach to explore whether the bivalent H2R agonists bind to a receptor monomer or a 
receptor dimer, Birnkammer et al. investigated compounds with a spacer length between 6 
and 27 Å.3 The highest potency resided in compounds with an octa- or hexamethylene 
chain.3 Due to insufficient spacer length for interaction with the orthosteric binding pockets of 
dimeric H2R protomers, the gain in potency seems to result from the interaction with an 
additional binding site at the same receptor molecule. However, so far the binding mode of 
bivalent H2R agonists is not understood, and appropriate pharmacological tools to study the 
mode and stoichiometry of binding are not available.  
Acylguanidines turned out to 
undergo hydrolytic cleavage 
upon long-term storage in 
aqueous solution. Aiming at 
more stable dimeric H2R 
agonists, we replaced the 
acylguanidine moieties by 
carbamoylguanidine groups 
according to a bioisosteric 
approach (Fig. 3.1). Moreover, 
a branched linker enabled the synthesis of radiolabeled and fluorescent derivatives. The 
compounds were characterized in functional and binding studies on recombinant histamine 
receptors. In addition, selected agonists were investigated on human monocytes.  
 
3.2 Chemistry 
3.2.1 Homobivalent carbamoylguanidine-type H2R ligands 
The N-[3-(1-trityl-1H-imidazol-4-yl)propan-1-amine building block 3.6 (Scheme 3.1) was 
synthesized with minor modifications as previously described.1 After esterification of urocanic 
acid7 and hydrogenation of the double bond, the imidazole-NH was protected with a trityl 
moiety. The reduction of the ester group with LiAlH4 resulted in the alcohol 3.4, which was 
converted to the primary amine 3.6 by a Mitsunobu reaction.8 
 
Figure 3.1. Bioisosteric replacement of the acylguanidine moieties in 
dimeric H2 receptor agonists by carbamoylguanidine groups. 
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The tert-butyl [5-(3-aminopropyl)-4-methylthiazol-2-yl]carbamate building block 3.11 was 
prepared from 6-chlorohexan-2-one and phthalimide. The ketone was brominated and 
allowed to react with thiourea to give the thiazole 3.9. Boc-protection gave 3.10 and 
subsequent hydrazinolysis resulted in the primary amine 3.11 (Scheme 3.2).9 
 
 
 
 
 
The synthesis of the spacers started with the preparation of the mono-Boc protected 
isothiourea 3.13, a well-established guanidinylating reagent,10 as previously described 
(Scheme 3.3).2 
Scheme 3.1. Synthesis of the imidazolylpropylguanidine building block 3.6. Reagents and conditions: (i) 
anhydrous Na2SO4, H2SO4/conc., MeOH/abs, 30 h, reflux, 78 %; (ii) H2, Pd/C (10 %) cat., MeOH, 5 bar, 24 h, rt, 
99 %; (iii) CPh3Cl, NEt3, MeCN, 12 h, rt, 52 %; (iv) LiAlH4, THF/abs, Et2O/abs, 2 h, reflux, 81 %; (v) phthalimide, 
PPh3, DIAD, THF/abs, 24 h, rt, 68 %; (vi) N2H4・H2O, EtOH, 1 h, reflux, 84 % 
 
Scheme 3.2. Synthesis of the tert-butyl [5-(3-aminopropyl)-4-methylthiazol-2-yl]carbamate 3.11. Reagents and 
conditions: (i) phthalimide, K2CO3, DMF, 24 h, 80 °C, 39 %; (ii) Br2, dioxan/DCM, 1h, rt, 100 %; (iii) thiourea, 
DMF, 3 h, 100 °C, 62 %; (iv) Boc2O, NEt3, DMAP (cat.), CHCl3, 24 h, rt, 79 %; (v) N2H4・H2O, EtOH, 1 h, reflux, 
53 % 
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The guanidinylating reagents 3.14-3.18 were obtained from diamines and diisocyanates in 
one-pot reactions11 (Scheme 3.4). The diamines were treated with triphosgene to give the 
corresponding diisocyanates, which were allowed to react with mono-Boc-protected S-
methylisothiourea 3.13.  
The dimeric ligands 3.19-3.28 were prepared by treating the building blocks 3.6, 3.11 with 
the guanidinylating reagents 3.14-3.18 in the presence of HgCl2 and base.12 Treating the 
protected carbamoylguanidine-type intermediates with TFA gave compounds 3.19-3.28 
(Scheme 3.4), which were purified by preparative HPLC.  
 
 
 
 
 
 
Scheme 3.3. Synthesis of the N-tert-butoxycarbonyl-S-methylisothiourea 3.13. Reagents and conditions: (i) MeI 
(1 eq), MeOH, 1 h, reflux, 97 %; (ii) Boc2O (1 eq), NEt3 (1 eq), DCM, 24 h, rt, 61 % 
Scheme 3.4. Synthesis of the bivalent carbamoylguanidine-type ligands 3.19-3.28. Reagents and conditions: (i) 
triphosgene, DIPEA, DCM abs., 30 min, 0 °C  (ii) N-tert-butoxycarbonyl-S-methylisothiourea , 2.5 h, rt. 3.14: 83 
%, 3.15: 74 %, 3.16: 75 %, 3.17: 74 %, 3.18: 76 %; (iii) 3.6 or 3.11, HgCl2, NEt3, DMF or DCM abs., 12 h, rt; (iv) 
30 % TFA, DCM abs., 12 h, rt, 3.19: 7 %, 3.20: 10 %, 3.21: 8 %, 3.22: 20 %, 3.23: 27 %, 3.24: 14 %, 3.25: 30 %, 
3.26: 29 %, 3.27: 9 %, 3.28: 9 % 
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3.2.2 Toward bivalent fluorescence- and radioligands  
In view of radiolabeling and introduction of fluorophores, a branched linker comprising a 
primary amino group was synthesized. Starting from commercially available 
dicyclopropylketone, 1,7-dichloroheptan-4-one was obtained as recently described.13 After 
nucleophilic displacement of chlorine by azides, the C=C bond was formed by a Wittig 
reaction14 to yield 1-azido-4-(3-azidopropyl)-8-chlorooct-4-ene (3.32) (Scheme 3.5). Via the 
corresponding phthalimide (3.33), 3.32 was converted into the primary amine 3.34. The 
amino group was Boc-protected (3.35) and the azide groups were reduced with LiAlH4 to 
give the diamine 3.36, which was converted to the diisocyanate 3.37. The guanidinylating 
reagent 3.38 was prepared by analogy with the procedure for the preparation of 3.14-3.18.  
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Scheme 3.5. Synthesis of the branched building block 3.38. Reagents and conditions: (i) HCl gas, rt, 100 %; (ii) 
NaN3, DMF, 12 h, rt, 79 %; (iii) n-BuLi, THF abs, 15 h, -72 °C → rt, 19 %; (iv) phthalimide, Cs2CO3, KI (cat.), 
DMF, 60 °C, 12 h, 57 %; (v) N2H4・H2O, EtOH, 1 h, reflux, 88 %; (vi) Boc2O, NEt3, DCM, rt, 24 h, 97 %; (vii) 
LiAlH4, Et2O/abs, 2 h, reflux, 66 %; (viii) triphosgene, DIPEA, DCM abs., 30 min, 0 °C; (ix) N-tert-butoxycarbonyl-
S-methylisothiourea, 2.5 h, rt, 44% 
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The precursor (3.39; Scheme 3.6) of the labeled compounds was synthesized from 3.38 
according to the procedure described above for compounds 3.24-3.28 using 3.11 as building 
block. Compound 3.39 was coupled to three different fluorophores: the cyanine S2197 and 
the small pyrylium dyes Py-1 and Py-5 (Scheme 3.6).15,16 S2197 provided as succinimidyl 
ester, was coupled to the bivalent precursor in the presence of triethylamine to give 3.40. 
The pyrylium dyes reacted instantaneously in a ring transformation (color changes from blue 
into red) to give the positively charged N-substituted pyridinium compounds 3.41 and 3.42 
(Scheme 3.6).17 
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Scheme 3.6. Synthesis of compound 3.39 and preparation of the fluorescence ligands 3.40-3.42. Reagents and 
conditions: (a) 1) compd. 3.11, HgCl2, NEt3, DMF, 12 h, rt; 2) 30 % TFA, DCM abs., 12 h, rt, 21 %; (b) NEt3, DMF, 
rt, 2h, 3.40: 45 %, 3.41: 36 %, 3.42: 38 % 
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Compound 3.39 was acylated with “cold” succinimidyl propionate (cf. 3.43a) to optimize the 
reaction conditions for the propionylation with tritiated succinimidyl propionate (Scheme 3.7). 
This synthetic route afforded the radioligand 3.43b in a yield of 90 %. Purification by HPLC 
gave 3.43b in a radiochemical purity of 99 % (Fig. 3.2) with a specific activity of 70 Ci/mmol. 
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Figure 3.2. HPLC purity control with radiometric detection (A) and identity control (B) of 3.43b: simultaneous 
injection of 3.43a and 3.43b. Conditions: eluent A: MeCN + 0.04 % TFA; eluent B: aq. 0.05 % TFA + 5 % MeCN, 
gradient: 0 to 20 min: A/B 5/95 to 26/74, 20 to 30 min A/B 90:10, tR = 17,1 min 
 
3.3 Results and Discussion 
3.3.1 Stability of carbamoylguanidines compared to acylguanidines  
Acylguanidines are stable at acidic pH, but tend to decompose under alkaline conditions. The 
decomposition becomes very fast, when an intramolecular nucleophilic attack is possible as 
previously demonstrated for aminoalkanoylguanidines with half-lives between 19 s and 13 h 
at pH 10.4.18 Although the decomposition of acylguanidine-type H2R agonists such as 3.44 
(Fig. 3.3A) (provided by Dr. Anja Kraus)3 turned out to occur at a much slower rate, 
hydrolytic cleavage upon long-time storage in solution has to be taken into account. For 
comparison, the stability of compounds 3.25 (Fig. 3.3B), and 3.44 as representative 
examples of carbamoylated and acylated guanidines, respectively, was investigated at a 
concentration of 100 µM in phosphate buffered saline (PBS, pH 7.4) at room temperature. 
Scheme 3.7. Synthesis of the unlabeled (“cold”) propionamide 3.43a and the corresponding radiolabeled version 
3.43b. Reagents and conditions: (a) 1) NEt3, DMF, 2 h, 81 %; 2) DIPEA, DMF, 3 h, 90 % 
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After one week, around 55 % of compound 3.44 were decomposed, whereas 3.25 proved to 
be stable under the same conditions. 
 
 
Figure 3.3. Chromatograms of the H2R agonists 3.44 (A) and 3.25 (B) after different periods of incubation in PBS 
(pH 7.4) at rt. 
 
3.3.2 Pharmacological results and discussion 
The synthesized compounds were investigated on membrane preparations in the [35S] 
GTPγS binding assay at the human (h) and at the guinea pig (gp) H2R with regard to 
possible differences between species orthologs (Table 3.1, Fig. 3.4). The hH2R as well as 
the gpH2R were expressed as H2R-Gsαs fusion proteins in Sf9 insect cells. To test the 
selectivity of the compounds for the H2R compared to hH1R, hH3R, and hH4R, competition 
binding experiments were performed using membranes of Sf9 cells expressing the histamine 
receptor of interest (Table 3.2).  
 
3.3.2.1 H2R agonism in the GTPγS binding assay 
The prepared bivalent ligands 3.19-3.28, 3.39 and 3.43a were partial or full agonists at both, 
the hH2R and the gpH2R. In agreement with previous studies on guanidine- and 
acylguanidine-type H2R agonists,2,3,19,20 higher potencies and intrinsic activities were 
achieved at the gpH2R than at the hH2R. Compound 3.22 was 2500 times more potent than 
histamine at the gpH2R. Except for 3.24, ligands bearing an imidazole ring were superior to 
the corresponding aminothiazoles at the hH2R. Dimeric ligands with a spacer length of four 
methylene groups showed the lowest potency at the hH2R, whereas the gpH2R was less 
sensitive to variations in chain length. Interestingly, branching of the connecting chain hardly 
affected potency (cf. 3.39), though the maximal response decreased. Propionylation of the 
primary amino group in the side chain of 3.39 resulted in regaining potency and intrinsic 
activity at the hH2R (3.43a) (Table 3.1, Fig. 3.4). 
 
 
 
 
A new class of potent and selective agonists 
35 
 
 
 
 human H2R guinea pig H2R 
compd. pEC50 ± SEM Emax ± SEM Potrel pEC50 ± SEM Emax ± SEM Potrel 
HIS 
3.19 
3.20 
3.21 
3.22 
3.23 
3.24 
3.25 
3.26 
3.27 
     3.28 
3.39 
3.43a 
5.85 ±  0.06 
7.29 ±  0.08 
7.77 ±  0.02 
8.31 ±  0.08 
8.35 ±  0.07 
8.08 ±  0.09 
7.25 ±  0.11 
8.03 ±  0.02 
7.68 ±  0.03 
7.73 ±  0.15 
7.43 ±  0.12 
7.49 ±  0.10 
7.87 ±  0.12 
1.00 
0.97  ±  0.02 
0.88  ±  0.03 
1.03  ±  0.06 
1.01  ±  0.07 
0.70  ±  0.08 
0.96  ±  0.04 
0.92  ±  0.01 
0.90  ±  0.10 
0.80  ±  0.07 
0.64  ±  0.07 
0.66  ±  0.06 
0.73  ±  0.12 
1.0 
27.5 
83.2 
288.4 
316.0 
169.8 
25.1 
151.4 
67.6 
75.9 
38.0 
43.7 
104.7 
    6.07 ± 0.1421,b 
8.56 ± 0.04 
9.25 ± 0.14 
8.45 ± 0.03 
9.47 ± 0.09 
8.19 ± 0.07 
9.04 ± 0.13 
8.75 ± 0.15 
8.42 ± 0.19 
8.16 ± 0.07 
n.d. 
8.11 ± 0.06 
8.04 ± 0.05 
1.00 
0.99 ± 0.06 
0.96 ± 0.03 
0.87 ± 0.08 
1.01 ± 0.06 
0.95 ± 0.04 
1.04 ± 0.14 
1.09 ± 0.05 
0.97 ± 0.04 
0.80 ± 0.06 
n.d. 
0.97 ± 0.06 
0.89 ± 0.11 
1.0 
309.1 
1512.4 
239.6 
2508.8 
131.7 
932.0 
478.1 
223.6 
122.9 
n.d. 
109.5 
93.2 
 
 
 
 
 
Figure 3.4. Concentration-response curves of selected agonists at hH2R (A) and gpH2R (B) in the GTPγS assay. 
The increase in GTPγS binding is referred to the maximal response to histamine (HIS) = 100 %. Data are means 
± SEM of 2-6 independent experiments, each performed in triplicate. 
 
3.3.2.2 H2R affinities and receptor subtype selectivities 
The H2R affinity of the compounds was determined in competition binding studies. The pKi 
values were in good agreement with the pEC50 values, in particular when [3H]UR-DE2575 
was used as radioligand. Minor differences between functional and binding data became 
Table 3.1. a [35S]GTPγS binding assay on membranes of Sf9 cells expressing the hH2R-Gsαs and the gpH2R- 
Gsαs. Data were analyzed by nonlinear regression and were best fit to three-parameter sigmoidal concentration-
response curves. pEC50: -logEC50; Emax: maximal response relative to histamine (Emax = 1.0); Potrel: relative 
potency represents the ratio of EC50 values of test compound and histamine. Data shown are means ± SEM of 2-
6 independent experiments, each performed in triplicate. b Determined in a steady-state [32P]GTPase assay on 
Sf9 cells expressing the gpH2R- Gsαs. 
Table 3.1. Histamine H2 receptor agonism in the GTPγS assaya 
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obvious, when [3H]tiotidine was used for displacement. As suggested by Kelley et al.20 
[3H]tiotidine is able to address only a subpopulation of the H2R, which might explain this 
phenomenon.  
As expected, carbamoylguanidine-type ligands bearing two imidazole moieties were not 
selective for the H2R, but also showed high affinity for the H3R and the H4R. By contrast, the 
synthesized aminothiazoles preferred the H2R (Table 3.2). 
 
 
 
hH1R hH2R hH3R hH4R 
compd. pKi  ±  SEMb pKi ±  SEMc,d pKi  ±  SEMe,f pKi  ±  SEMg 
HIS 
3.19 
3.20 
3.21 
3.22 
3.23 
3.24 
3.25 
3.26 
3.27 
3.28 
3.39 
 3.43a 
  5.62 ± 0.0322 
6.31 ± 0.10 
5.84 ± 0.04 
6.60 ± 0.12 
6.66 ± 0.03 
6.56 ± 0.02 
6.08 ± 0.03 
6.07 ± 0.06 
5.81 ± 0.09 
5.80 ± 0.06 
5.89 ± 0.01 
5.80 ± 0.08 
6.36 ± 0.00 
6.27 ± 0.04c,19 
7.57 ± 0.01c 
7.87 ± 0.05c 
7.52 ± 0.04d 
8.47c, 8.52 ± 0.13d 
7.56 ± 0.05d 
7.76 ± 0.08c 
8.07 ± 0.05c 
7.55 ± 0.02c 
7.17 ± 0.13d 
7.21 ± 0.10d 
7.59 ± 0.01c 
7.94 ± 0.09c 
8.20 ± 0.0423 
8.55 ± 0.01f 
8.16 ± 0.05e, 8.52f 
8.77 ± 0.02f 
8.82 ± 0.03f 
8.21 ± 0.04f 
6.17 ± 0.10e, 6.17f 
5.94 ± 0.16e, 6.01f 
5.76 ± 0.09f 
6.00 ± 0.10f 
5.81 ± 0.07e 
6.56 ± 0.11f 
6.08 ± 0.08f 
  7.89 ± 0.0124 
7.02 ± 0.06 
7.12 ± 0.04 
7.81 ± 0.09 
8.27 ± 0.01 
7.58 ± 0.12 
5.29 ± 0.04 
5.69 ± 0.07 
5.55 ± 0.08 
6.26 ± 0.18 
5.97 ± 0.05 
6.08 ± 0.09 
5.96 ± 0.09 
 
 
 
 
  
Table 3.2. aCompetition binding assay on membranes of Sf9 cells expressing the hH1R plus RGS4, the hH2R-
Gsαs, co-expressing the hH3R plus Gαi2 plus Gβ1γ2 or co-expressing the hH4R plus Gαi2 plus Gβ1γ2. Incubation 
period was 60 min. Data were analyzed by nonlinear regression and were best fit to 3-parameter sigmoidal 
concentration-response curves. Data shown are means ± SEM of 2-6 independent experiments, each performed 
in triplicate. bDisplacement of 5 nM [3H]mepyramine (Kd= 4.5 nM); cDisplacement of 30 nM [3H]UR-DE257 (Kd= 31 
nM); dDisplacement of 10 nM tiotidine (Kd= 19.7 nM); eDisplacement of 15 nM [3H]histamine (Kd= 12.6 nM); 
fDisplacement of 3 nM [3H]Nα-methylhistamine (Kd= 3 nM); gDisplacement of 10 nM histamine (Kd= 10 nM); Note: 
Representative compounds were investigated for functional activity at the hH1R, hH3R and hH4R. In agreement 
with previous studies1-3 on bivalent H2R ligands, the carbamoylated imidazolylpropylguanidines behaved as 
agonists in the [35S]GTPγS assay (Sf9 membranes) at the H3R and the H4R respectively, whereas the 
corresponding amino(methyl)thiazolylpropylguanidines proved to be H3R and H4R antagonists and were 
antagonists at the hH1R (luciferase assay, HEK293 cells). hH1R, pKb ± SEM: 3.21: 6.48 ± 0.14; 3.22: 6.29 ± 0.21; 
3.25: 5.71 ± 0.06; 3.27: 5.69 ± 0.13; 3.43a: 5.32 ± 0.13. hH3R, pKb ± SEM: 3.25: 5.57 ± 0.05; 3.27: 5.86 ± 0.01; 
3.43a: 5.87 ± 0.06. hH4R: 3.21: pEC50 = 8.00 ± 0.04, Emax = 0.65 ± 0.03; 3.22: pEC50 = 8.04 ± 0.09, Emax = 0.86 ± 
0.08; 3.25: pKb = 5.30 ± 0.02; 3.27: pKb = 6.12 ± 0.11; 3.43a: pKb = 5.09 ± 0.22. 
 
 
Table 3.2. Binding data of the compounds 3.19-3.28, 3.39, 3.43a on human histamine receptor subtypesa 
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3.3.2.3 Investigation of the fluorescence ligands 3.40-3.42 and the radioligand 
3.43b 
The compounds 3.40-3.42 were investigated in a flow cytometric binding assay25 at 
HEK293T cells, transfected with the hH2R. None of these compounds bound in a saturable 
manner (Fig 3.5).  
 
 
Figure 3.5. Flow cytometric binding assay on HEK293T CRE Luc hH2R cells with ligands 3.40 (A) and 3.42 (B) 
as examples 
 
Confocal microscopy with 3.42 revealed that the fluorescence ligands enter the HEK293T 
cells in a receptor-independent manner (Fig 3.6).  
 
Figure 3.6. Confocal microscope images of HEK293T cells (not transfected with the hH2R) after 20 min of 
incubation, at room temperature, with the fluorescent ligand 3.42. 40000 cells were seeded 2 days prior to 
microscopy in Leibovitz L15 supplemented with 5 % FCS. A) Transmitted light; B) Autofluorescence; C) 
Transmitted light  D) 500 nM of 3.42. Images were acquired with a Zeiss Axiovert 200 M microscope; Plan 
Apochromat 60x/1.4W, 488 nm/ LP 560 nm. 
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Similarly, it was impossible to perform saturation binding studies with the radioligand 3.43b 
on Sf9 membranes (Fig. 3.7) and HEK293T (Fig. 3.8) cells because of high unspecific 
binding. Interestingly, lower unspecific binding was observed in the presence of competitors 
structurally similar to 3.43a, hinting at reversible binding to non-H2R sites at the cell 
membrane. Nevertheless, non-H2R mediated internalization of 3.43b into HEK293T cells is 
conceivable.  
 
Figure 3.7. Concentration-dependent binding of 3.43b to membranes of Sf9 cells expressing the hH2R-Gsαs 
fusion protein. Non-specific binding was determined in the presence of 100 µM famotidine as competitor (A) and 
10 µM 3.43a as competitor (B). 
 
 
 
Figure 3.8. Concentration-dependent binding of 3.43b to HEK293T cells expressing the hH2R. Non-specific 
binding was determined in the presence of 100 µM famotidine as competitor (A) and 10 µM 3.43a as competitor 
(B). 
 
Previously, it was shown that the cholesterol content of Sf9 insect cell membranes is 20-fold 
lower than in membranes of higher eukaryotic cells. Gimpl et al. demonstrated that the 
addition of cholesterol improved the specific binding of oxytocin to its receptor.26  
By analogy with this approach, the Sf9 cell membranes membranes were treated with 
cholesterol prior to investigating the binding of the radioligand 3.43b. Surprisingly, the 
addition of cholesterol resulted in saturable binding (Fig. 3.9A). However, unfortunately, 
there was no difference between membranes of Sf9 cells expressing the hH2R and wild-type 
Sf9 membranes (Fig. 3.9B), again suggesting that the radioligand binds in a reversible 
manner to off-targets in the cell membrane. Thus, radioligand 3.43b proved to be 
inappropriate for H2R quantification. 
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Figure 3.9. Concentration-dependent binding of 3.43b to cholesterol treated membranes of Sf9 cells 
expressing the hH2R-Gsαs fusion protein (A) and to wild-type membranes of Sf9 cells (B). Non-specific binding 
was determined in the presence of 10 µM 3.43a as competitor. 
 
In spite of that, affinities determined for various H2R ligands in competition binding 
experiments with 3.43b (membranes of Sf9 cells expressing the hH2R), were in the range of 
Ki values determined by displacement of [3H]UR-DE2575 (Fig. 3.10). However, it should be 
noted that, due to the low signal-to-noise ratio, the data determined with 3.43b as radioligand 
are less reliable. 
 
 
Figure 3.10. Displacement of the radioligand 
3.43b (c = 12 nM; Kd= 10.7 nM) by different H2R 
ligands. Kd value of the radioligand was set to the 
Ki value of the “cold” version 3.43a.  The assay 
was performed on Sf9 membranes expressing the 
hH2R-Gsαs fusion protein.  Data shown are 
representative displacement curves.  
 
 
 
compd. pKi value determined with 
3.43bb 
pKi value determined with 
UR-DE257c 
HIS 6.46  ± 0.18 6.27  ± 0.045 
famotidine 6.32  ± 0.15 6.87  ± 0.055 
UR-Bit243 8.12  ± 0.22 8.15  ±0.075 
amthamine 6.59  ± 0.12 6.61  ±0.075 
3.43a 7.33  ± 0.13 7.94  ± 0.09 
UR-DE925 7.81  ± 0.68 7.55  ± 0.035 
 
 
  Table 3.3. pKi values determined with 3.43b in comparison with UR-DE2575 
aCompetition binding assay on Sf9 membranes expressing the hH2R-Gsαs. The incubation period was 60 min. 
Data were analyzed by nonlinear regression and were best fit to 3-parameter sigmoidal concentration-response 
curves. Data shown are means ± SEM of 2-3 independent experiments, each performed in triplicate. 
bDisplacement of 12 nM 3.43b (Kd = 10.7 nM); cDisplacement of 30 nM [3H]UR-DE257 (Kd = 31 nM);  
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3.3.2.4 Investigation of H2R agonists in human monocytesa 
a Note: These experiments were performed by Kristin Werner in the laboratory of Professor Dr. Roland Seifert 
(Institute of Pharmacology, Medical School of Hannover, Carl-Neuberg-Str.1, D-30625 Hannover, Germany). 
 
Acute myeloid leukemia (AML) is an indication for post-consolidation therapy with histamine 
to prevent relapse.26, 27 It is assumed that histamine inhibits oxygen radical formation via H2R 
mediated inhibition of NADPH oxidase, resulting in the protection of T cells and NK cells.26 
Since histamine activates all four histamine receptor subtypes, the treatment is accompanied 
by serious side effects like itch, erythema, decrease in blood pressure and gastrointestinal 
problems.26, 27 Patients could benefit from selective H2R stimulation due to reduction of side 
effects mediated by the other histamine receptor subtypes.  
Compounds 3.20 and 3.25 were studied at the H2R in human monocytes regarding functional 
responses such as stimulation of cAMP formation and inhibition of fMLP-induced (formyl 
peptide) production of reactive oxygen species (ROS) (Fig. 3.11, Table 3.4). To avoid cell 
lysis as observed for such cationic amphilic compounds depending on the chain length of the 
linker (cf. section 3.3.2.7), compounds 3.20 and 3.25, which are among the most potent H2R 
agonists and proved to be nontoxic (cf. Fig 3.12) under the assay conditions, were selected.   
In a recently published study, it was shown that H2R agonists increase cAMP levels in a 
concentration-dependent manner in human monocytes.27 In accordance with these results, 
compounds 3.20 and 3.25 induced cAMP accumulation (Fig. 3.11A). Additionally, both 
ligands inhibited the fMLP-induced ROS production in a concentration-dependent manner via 
H2R stimulation (Fig 3.11B). 
 
 
Figure 3.11. Effects of histamine (HIS), 3.20 and 3.25 on cAMP accumulation (A) and fMLP-induced ROS 
production (B) in human monocytes. Samples were analyzed by HPLC-MS/MS. A: Data were normalized to the 
maximal effect of HIS and represent means ± SEM from three independent experiments. B: Data were normalized 
to the ROS release induced by fMLP and are expressed as means ± SEM from four different experiments 
performed in triplicate. Note: The influence of H2R agonists on ROS production had to be studied in an indirect 
way, i. e. after stimulation of the cells with fMLP (1 µM). In accordance with previous studies,27 the maximal effect 
of fMLP (set to 1.0 in Fig. 3.11B) was not fully restored in the presence of very low concentrations of histamine or 
H2R agonists. So far, we have no explanation for this phenomenon, which only minimally affects the inflections 
points of the concentration-response curves. In Table 3.4 the maximal responses (Emax) of 3.20 and 3.25 are 
given relative to the amplitude of the concentration-response curve of histamine defined as Emax = 1.0.   
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cAMP assay ROS assay 
compd. pEC50 Emax pIC50 Emax 
HIS 
3.20 
3.25 
5.39 ± 0.06 
7.03 ± 0.11 
7.27 ± 0.19 
1.00 
0.57 ± 0.03 
0.44 ± 0.04 
5.68 ± 0.13 
6.91 ± 0.19 
6.54 ± 0.27 
1.00 
0.78 ± 0.07 
0.83 ± 0.10 
 
 
 
Cytotoxicity of compounds 3.20 and 3.25 on monocytes was assessed by ethidium bromide / 
acridine orange (EBAO) staining. Acridine orange stains living and dead cells, whereas 
ethidium bromide only stains dead cells. Under the fluorescence microscope living cells 
appear green and dead cells orange. 
The monocytes from three different donors were incubated with the respective dimeric ligand 
for 2 h. The respective compounds at a concentration of 100 µM did not induce cell death 
(Fig. 3.12).  
 
 
Figure 3.12. EBAO staining of human monocytes. Monocytes were incubated with 100 µM of compounds 3.20 
[B, E, H] and 3.25 [C, F, I] for 2 h. Untreated cells served as control [A, D, G] (objective 20x).   Cytotoxicity 
studies have been performed with monocytes of two female [A – C, D – F] and one male [G – I] caucasian.  
Table 3.4. Data were analyzed by nonlinear regression and were best fit to 3-parameter sigmoidal concentration-
response curves. The maximal responses (Emax values) of 3.20 and 3.25 are referred to the efficacy of histamine 
defined as Emax = 1.00. Data shown are means ± SEM of three to four independent experiments.  
 
Table 3.4. Potencies and efficacies in the cAMP assay and in the reactive oxygen species (ROS) assay in 
human monocytesa 
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3.3.2.5 Stability of selected carbamoylguanidines in plasma 
With respect to future in vivo studies, 3.20 (Fig. 3.13) and 3.25 (Fig 3.14) were investigated 
regarding their stability in mouse plasma. Both compounds were stable during the incubation 
period of 24 h. 
 
Figure 3.13. Stability of 3.20 in plasma. Compound 3.20 was incubated in murine plasma over 24 h at 37 °C, and 
the samples were analyzed by HPLC (UV detection at 210 nm).  
 
 
Figure 3.14. Stability of 3.25 in plasma. Compound 3.25 was incubated in murine plasma over 24 h at 37 °C, and 
the samples were analyzed by HPLC (UV detection at 210 nm (A) and 260 nm (B)). 
 
3.3.2.6 Plasma protein binding 
3.3.2.6.1 Equilibrium dialysis 
Prior to the determination of plasma protein binding, recovery studies were performed with 
3.19 (Fig. 3.15A) and 3.24 (Fig 3.15B). Unfortunately, only around 40 % of the compounds 
were recovered, most probably due to adsorption to the regenerated cellulose membrane. 
Thus, equilibrium dialysis turned out to be an inappropriate method for the determination of 
plasma protein binding of the dimeric ligands. 
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Figure 3.15. Recovery studies for 3.19 (A) and 3.24 (B) after dialysis for 24 h. HPLC analysis, UV detection at 
210 nm. I) dialysis chamber 1: 200 µM solution of the tested compounds; II) dialysis chamber 2: PBS; III) 200 µM 
solution of the tested compounds  
 
3.3.2.6.2 Ultrafiltration 
Prior to plasma protein binding studies, control experiments were performed to determine the 
ability of the compounds to pass the membrane (Fig. 3.16). For each compound, this 
recovery value was considered in the calculation of plasma protein binding.  
 
Figure 3.16. Determination of plasma protein binding for compounds 3.19 (A), 3.20 (B), 3.24 (C), 3.25 (D). HPLC 
analysis, UV detection at 210 nm. I) 100 µM solution of the tested compounds; II) solution I after filtration 
(recovery); III) 100 µM solution of the tested compounds after incubation in 600 µM BSA  and filtration (plasma 
protein binding) 
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Table 3.5. Extent of plasma protein binding of selected compounds determined by ultrafiltration 
compd. recovery 
(without BSA) 
plasma protein binding  
3.19 87 % 33 % 
3.20 89 % 75 % 
3.24 80 % 64 % 
3.25 61 % 96 % 
 
In summary, the plasma protein binding strongly depended on the lipophilicity of the 
compounds. The most hydrophilic compound 3.19 showed the lowest extent of plasma 
protein binding, whereas 3.25, the most lipohilic compound in this series, exhibited the 
highest amount of plasma protein binding. These results should be taken into account for 
future in vivo studies.  
 
3.3.2.7 Cytotoxicity in the crystal violet based chemosensitivity assay 
Representative compounds (3.19, 3.23, 3.24 and 3.28) were investigated for cytotoxicity 
against HEK293T cells in a kinetic crystal violet based chemosensitivity assay over an 
incubation period of approximately 140 h and compared to vinblastin as reference(Fig. 3.17). 
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Figure 3.17. Effect of  3.19 (A), 3.23 (B), 3.24 (C) and 3.28 (D) on HEK293T cells in the crystal violet assay  
 
The cytotoxic effect of the bivalent ligands strongly depended on the length of the spacer. 
After initial cell damage, the two dimeric ligands 3.19 and 3.24, with a spacer length of four 
methylene groups, showed no cytotoxic effect up to a concentration of 30 µM. By contrast, 
3.23 and 3.28, with a spacer length of 10 methylene groups, showed strong cytotoxic to 
cytocidal effects even at the lowest concentration of 3 µM. Due to their polar basic 
pharmacophore and their lipophilic spacers, the dimeric ligands are of cationic amphiphilic 
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nature, implying a potential interaction with biological membranes. In accordance with 
previous data,28,29 cytotoxicity increased with the chain length of the spacer.  
 
3.4 Summary and conclusion 
The exchange of the acylguanidine moieties in bivalent H2R agonists by carbamoylguanidine 
groups resulted in compounds with retained potencies and intrinsic activities. Achieving up to 
2500 times the potency of histamine these compounds are among the most potent H2R 
agonists known so far. Unfortunately, H2R binding studies with fluorescence and radiolabeled 
ligands derived from the chain-branched precursor 3.39 failed due to pronounced cellular 
accumulation and high non-specific binding, respectively. In this respect, the results 
underline the fact that, regardless of high affinity of the “cold” form, applicability of the 
corresponding labeled version as a molecular tool cannot be taken for granted. 
Aminothiazoles were superior to the corresponding imidazoles in terms of histamine receptor 
subtype selectivity. Due to high potency and stability against hydrolytic cleavage, the new 
H2R agonists are promising pharmacological tools for investigations on the biological role of 
the H2R and are of potential value for in vivo studies on histamine receptors in the CNS. 
Regarding the properties of plasma protein binding and cytotoxicity, compounds bearing a 
short spacer should be favored in future for in vivo studies. In human monocytes the 
investigated compounds revealed high H2R agonist potency, suggesting this class of 
compounds to point a way to selective H2R agonists as potential agents for the treatment of 
AML.  
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3.5 Experimental section 
3.5.1 General Experimental conditions 
Unless otherwise indicated, chemicals and solvents were from commercial suppliers and 
were used as received. The fluorescence dye S2197 was from FEW Chemicals GmbH 
(Bitterfeld-Wolfen, Germany), the pyrylium dyes Py-1 and Py-5 were kindly provided by Prof. 
Dr. O. S. Wolfbeis (Institute of Analytical Chemistry, Chemo- and Biosensors, University of 
Regensburg, Germany). All of the solvents were of analytical grade or were distilled prior to 
use. THF and Et2O were distilled over sodium, DCM was stored over CaCl2 and was 
afterwards distilled from P2O5. For column chromatography silica gel 60 (Merck, 0.04-0.063 
mm) was used. Reactions were monitored by thin layer chromatography (TLC) on Merck 
silica gel 60 F254 aluminium sheets, and spots were visualized with UV light at 254 nm, 
iodine vapor or ninhydrin spray. NMR spectra were recorded on a Bruker Avance 300 (1H: 
300 MHz, 13C: 75.5 MHz) and a Bruker Avance 600 (1H: 600 MHz, 13C: 150.9 MHz) (Bruker, 
Karlsruhe, Germany) with deuterated solvents from Deutero (Kastellaun, Germany). LRMS 
was performed on a Finnigan ThermoQuest TSQ 7000 Instrument (Thermo Scientific, 
Waltham, MA) using an ESI source. HRMS was performed on an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an ESI 
or an APCI source. Melting points (mp) were measured on a Büchi B-540 apparatus using an 
open capillary and are uncorrected. Preparative HPLC was performed with a system from 
Knauer (Berlin, Germany) consisting of two K-1800 pumps, a K-2001 detector and the 
column was either a Eurospher-100 C18 (250 × 32 mm, 5 µm), a Nucleodur 100-5 C18 (250 
× 21 mm, 5 µm) (Macherey-Nagel, Düren, Germany) or in case of the fluorescence ligands a 
Phenomenex Kinetex (250 × 21 mm, 5 µm) (Phenomenex, Aschaffenburg, Germany). As 
mobile phase, mixtures of acetonitrile and 0.1 % aqueous TFA were used. The temperature 
was 30 °C, and UV detection was carried out at 220 nm. Prior to lyophilisation (Christ alpha 
2‐4 LD freeze dryer (Osterode, Germany), equipped with a RZ 6 rotary vane vacuum pump 
(Vacuubrand, Wertheim, Germany), acetonitrile was removed under reduced pressure. 
Analytical HPLC was performed on a system from Thermo Separation Products equipped 
with an SN400 controller, a P4000 pump, an AS3000 autosampler, and a Spectra Focus 
UV/Vis detector. The column was either a Eurospher-100 C18 (250 × 4 mm, 5.0 µm; Knauer, 
Berlin, Germany) or a YMC C8 Column (250 x 4.6 mm, 5.0 µm); YMC Europe GmbH, 
Dinslaken, Germany), thermostated at 30 °C. As mobile phase, mixtures of MeCN /aqueous 
TFA were used. Gradient (unless otherwise indicated): MeCN/TFA (0.05%) (v/v) 0 min: 5:95, 
30 min: 40/60, 31-41 min: 90:10; flow rate = 0.75 mL/min, t0 = 2.95 min (Eurospher), t0 = 2.55 
min (YMC); capacity factor k= (tR-t0)/t0. Absorbance was detected at 210 nm. Compound 
purities were calculated as the percentage peak area of the analyzed compound by UV 
detection at 210 nm. UV Spectra were recorded with a Cary Eclipse spectrofluorimeter 
(Varian, Mulgrave, Victoria, Australia). 
 
3.5.2 Chemistry: Experimental Protocols and Analytical data 
(E)-Methyl 3-(1H-imidazol-4-yl)propenoate (3.1).7 Urocanic acid (10.0 g, 72.40 mmol) and 
Na2SO4 (2.0 g, 14.08 mmol) were dissolved in 100 mL of anhydrous MeOH. Under external 
cooling H2SO4 conc. (6 mL) was added. The mixture was heated to reflux for 30 h and the 
solvent was removed under reduced pressure. The residue was dissolved in a small amount 
of water, and the solution was neutralized with saturated NaHCO3 solution. The mixture was 
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extracted with EA. After drying over Na2SO4, the solvent was evaporated. The crude product 
was used in the next step without further purification (Rf= 0.25 for DCM/MeOH 4.5:0.5). The 
product was obtained as a white solid (8.57 g, 78 %); mp = 94.6-103.5 °C. 1H NMR (300 
MHz, [D4]MeOH) δ (ppm) 3.75 (s, 3H), 6.39 (s, 1H), 6.45 (s, 1H), 7.42 (s, 1H), 7.77 (s, 1H). 
MS (ESI; MeOH) m/z (%) 153 (100) [M+H]+, 121 (8) [M+H-MeOH]+. HRMS (ESI): m/z [M+H]+ 
calculated for C7H9N2O2+: 153.0659, found 153.0658; C7H8N2O2 (152.15). 
 
Methyl 3-(1H-imidazol-4-yl)propanoate (3.2).30 To a solution of 3.1 (8.27 g, 54.35 mmol) in 
MeOH 1.0 g of Pd/C (10 %) was added at room temperature under stirring. The mixture was 
hydrogenated at 5 bar for 24 h. Afterwards, Pd/C was filtrated off, and the solvent was 
removed under reduced pressure. The procedure afforded the product as yellow oil (8.32 g, 
99 %). The crude product was used in the next step without further purification (Rf = 0.25 in 
DCM/MeOH 4.5:0.5, detection with iodine). 1H NMR (300 MHz, CDCl3) δ (ppm) 2.66 (t, 2H, J 
7.2 Hz), 2.92 (t, 2H, J 7.2 Hz,), 3.66 (s, 3H), 6.79 (s, 1H), 7.54 (s, 1H). MS (ESI; MeOH) m/z 
(%) 309 (1) [2M+H]+, 155 (100) [M+H]+, 123 (16) [M+H-MeOH]+. HRMS (ESI): m/z [M+H]+ 
calculated for C7H11N2O2+: 155.0815, found 155.0830; C7H10N2O2 (154.17). 
 
Methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate (3.3).31 To a suspension of 3.2 (8.32 g, 
53.98 mmol) and NEt3 (19.52 mL, 140.82 mmol) in 120 mL MeCN a solution of trityl chloride 
(13.57 g, 48.68 mmol) in MeCN was added dropwise under external cooling. The mixture 
was stirred for 12 h at room temperature. After removing the solvent under reduced pressure, 
water (300 mL) was added, and the suspension was stirred for 1 h. The solid was filtrated off 
and recrystallized from dry EtOH yielding 3.3 (10.10 g, 52 %) as a white solid (Rf = 0.9 in 
EA/7N NH3 4.5:0.5). mp= 145-146 °C (lit.28 mp 131 °C). 1H-NMR (300 MHz, CDCl3) δ (ppm) 
2.66 (t, 2H, J 7.4 Hz), 2.87 (t, 2H, J 7.5 Hz), 3.62 (s, 3H), 6.55 (s, 1H), 7.08 – 7.37 (m, 15H). 
MS (ESI; MeOH) m/z (%) 397 (69) [M+H]+, 243 (100) [Trt+]. HRMS (ESI): m/z [M+H]+ 
calculated for C26H25N2O2+: 397.1911, found 397.1918; C26H24N2O2 (396.48). 
 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol (3.4).31 Compound 3.4 (8.32 g, 20.98 mmol) was 
added in portions to a mechanically stirred suspension of LiAlH4 (1.52 g, 24.97 mmol) in 
freshly distilled THF under argon and external cooling. After the addition was complete, the 
mixture was allowed to warm to room temperature and heated to reflux for 2 h. The reaction 
was carefully quenched with 0.1 N NaOH. The residue was filtrated, and the solution was 
extracted with DCM. After drying over Na2SO4, the solvent was removed under reduced 
pressure, and the residue was purified by column chromatography (CHCl3/MeOH 95:5) to 
obtain 3.4 as a white solid (6.26 g, 81 %) (Rf = 0.33 in DCM/MeOH 9.5:0.5). mp= 119.5-
125.5 °C. (lit.28 mp 138 °C). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.79-1.94 (m, 2H), 2.67 (t, 
2H, J 6.7 Hz), 3.72 (t, 2H, J 5.7 Hz), 6.54 (s, 1H), 7.11-7.35 (m, 15H). MS (ESI; MeOH) m/z 
(%) 369 (89) [M+H]+, 243 (100) [Trt]+. HRMS (ESI): m/z [M+H]+ calculated for C25H25N2O+:  
369.1961, found 369.1964. C25H24N2O (368.47). 
 
2-[3-(1-Trityl-1H-imidazol-4-yl)propyl]isoindoline-1,3-dione (3.5).28,32 3.4 (6.26 g, 16.99 
mmol), phthalimide (2.50 g, 16.99 mmol) and triphenylphosphine (4.46 g, 17.00 mmol) were 
suspended in anhydrous THF and cooled to 0 °C. DIAD (3.44 g, 17.01 mmol) was added 
slowly. After complete addition of DIAD, the mixture was allowed to warm to room 
temperature, and stirring was continued for 3 h. The precipitate was filtered off and 
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recrystallized from THF/MeCN (50:50) yielding compound 3.5 as a white solid (5.75 g, 68 %) 
(Rf = 0.71 in EA/PE 4:1). mp = 215.9-220.8 °C (lit.33 217-219 °C). 1H-NMR (300 MHz, CDCl3) 
δ (ppm) 1.96- 2.10 (m, 2H), 2.63 (t, J 7.7 Hz, 2H), 3.72 (t, J 7.1 Hz, 2H), 6.61 (s, 1H), 7.10-
7.77 (m, 6H). 7.29-7.38 (m, 9H), 7.66-7.72 (m, 2H), 7.78-7.85 (m, 2H). MS (ESI; MeOH) m/z 
(%) 243 (26) [Trt+], 498 (100) [M+H]+, 1017 [2M+Na]+. HRMS (ESI): m/z [M+H]+ calculated for 
C33H28N3O2+:  468.2176, found 468.2176; C33H27N3O2 (497.60) 
 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (3.6).34 A mixture of 3.5 (5.50 g, 11.05 mmol) 
and hydrazine monohydrate (3.60 g, 71.89 mmol) in EtOH was heated to reflux for 1 h. After 
removable of insoluble material, the filtrate was evaporated. The residue was purified by 
column chromatography (eluent: DCM:MeOH:NH3 95:4:1). Compound 3.6 was obtained as a 
yellowish oil that solidified (3.41g, 84 %) (Rf = 0.13 in DCM/7N NH3 4.5:0.5). mp = 108.1-
112.9 °C (lit.32 mp 106-108 °C). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.62- 1.78 (m, 2H), 2.46 
(t, 2H, J 7.2 Hz), 2.67 (t, 2H, J 6.7 Hz), 6.39 (s, 1H), 6.94-7.19 (m, 15H). MS (ESI; MeOH) 
m/z (%) 368 (23) [M+H]+, 243 (100) [Trt+]. HRMS (ESI): m/z [M+H]+ calculated for C25H26N3+: 
368.2121, found 368.2124; C25H25N3 (367.49). 
 
2-(5-Oxohexyl)-1,3-dihydro-2H-isoindol-1,3-dione (3.7).35 6-Chlorohexan-2-one (13.30 g, 
98.81 mmol) and phthalimide (8.20 g, 55.73 mmol) were dissolved in DMF. The mixture was 
heated to 80 °C for 24 h. After cooling to room temperature, the solvent was reduced in 
vacuo. The residue was suspended in water and extracted with CHCl3. The combined 
organic layers were dried over Na2SO4 and evaporated under reduced pressure. The crude 
product was purified by column flash chromatography (eluent: DCM/MeOH 20:1) yielding 
compound 3.7 as a white solid (9.50 g, 39 %) (Rf = 0.15 in EE/PE 1:8); mp = 74.6 -78.6 °C 
(lit.28 mp 73-75 °C). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.54- 1.84 (m, 4H), 2.13 (s, 3H), 2.49 
(t, 2H, J 7.0 Hz), 3.69 (t, 2H, J 6.8 Hz), 7.67 (m, 2H), 7.79- 7.88 (m, 2H). MS (APCI; MeOH) 
m/z (%) 246 (100) [M+H]+. HRMS (APCI): m/z [M+H]+ calculated for C14H16NO3+: 246.1124, 
found: 246.1126. C14H15NO3 (245.27).  
 
2-(4-Bromo-5-oxohexyl)-1,3-dihydro-2H-isoindol-1,3-dione (3.8).35 To a solution of 3.7 
(6.26 g, 25.52 mmol) in dioxan and DCM (1.5:1), bromine (4.08 g, 25.54 mmol) was added 
slowly. Thereafter, the mixture was stirred at room temperature for 1 h. Subsequently, the 
mixture was washed twice with water and extracted with EA. The organic layer was dried 
over Na2SO4, and the solvent was removed under reduced pressure. The crude product 3.8 
was obtained as a yellow oil (8.27, 100 %) and used in the next step without further 
purification (Rf = 0.55 in EA/PE 1:2). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.54-1.84 (m, 4H), 
2.33 (m, 3H), 3.65-3.67 (m, 2H), 4.24-4.35 (m, 1H), 7.66-7.70 (m, 2H), 7.78-7.82 (m, 2H). MS 
(APCI; MeOH) m/z (%) 324 (100) [M+H]+. HRMS (APCI): m/z [M+H]+ calculated for 
C14H15BrNO3+: 324.0230, found: 324.0230. C14H14BrNO3 (324.17). 
 
2-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-1,3-dihydro-2H-isoindol-1,3-dione (3.9).35 To 
a solution of 3.8 (8.27 g, 25.51 mmol) in 50 mL of DMF, a solution of thiourea (1.94 g, 25.51 
mmol in 50 mL of DMF) was added. Subsequently, the mixture was heated to 100 °C for 3 h. 
The mixture was allowed to cool to room temperature, and DMF was removed in vacuo. A 
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mixture of EA/MeOH (1:1) was added, and the suspension was stirred for 30 min. 
Afterwards, the residue was filtered off, and washed with PE and EA, yielding compound 3.9 
(4.79 g, 62 %); (Rf = 0.45 in EA:PE 4:1). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.95-2.10 (m, 
2H), 2.25 (s, 3H), 2.76 (m, 2H), 3.76 (t, 2H, J 7.1 Hz), 7.68-7.76 (m, 2H), 7.80-7.91(m, 2H). 
MS (ESI; MeOH) m/z (%) 302.09 (1) [M+H]+.HRMS (ESI): m/z [M+H+]+ calculated for 
C15H16N3O2S+: 302.0958, found: 302.0962. C15H15N3O2S (301.36). 
 
tert-Butyl 4-methyl-5-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]thiazol-2-yl-
carbamate (3.10).35 To compound 3.9 (4.79 g, 15.89 mmol), dissolved in CHCl3, Boc2O (3.81 
g, 17.48 mmol), NEt3 (1.93 g, 19.07 mmol) and DMAP (cat.) were added. The mixture was 
stirred at room temperature overnight. The solvent was removed under reduced pressure, 
and the crude product was purified by flash chromatography (eluent: PE/EA 2:3). This 
afforded compound 3.10 as a colorless foam-like solid (5.04 g, 79 %) (Rf = 0.40 in EA/PE 
1:1). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.52 (s, 9H), 1.91-2.02 (m, 2H), 2.21 (s, 3H), 2.63-
2.77 (m, 2H), 3.68- 3.78 (m, 2H), 7.66-7.75 (m, 2H), 7.80-7.88 (m, 2H). HRMS (ESI): m/z 
[M+H+]+ calculated for C20H24N3O4S+: 402.1482, found: 402.1487. C20H23N3O4S (401.48). 
 
tert-Butyl 5-(3-aminopropyl)-4-methylthiazol-2-ylcarbamate (3.11).2 To a solution of 3.10 
(5.04 g, 12.55 mmol) in 100 mL of EtOH, hydrazine monohydrate (2.01 g, 40.15 mmol) was 
added, and the mixture was heated to reflux for 1 h. The mixture was allowed to cool to room 
temperature, and solid material was removed by filtration. The solvents were evaporated 
under reduced pressure, and the residue was purified by column chromatography (eluent: 
DCM/MeOH/NH3 95:4:1). Compound 3.11 was obtained as a yellow glassy solid (1.81 g, 53 
%). 1H-NMR (300 MHz, [D4]MeOH) δ (ppm) 1.53 (s, 9H), 1.70-1.83 (m, 2H), 2.17 (s, 3H), 
2.67-2.74 (m, 4H). MS (ESI; MeOH) m/z (%) 272 (100) [M+H]+, 216 (52) [M+H-C4H8]+, 172 
(23) [M+H-Boc]+, 108 (85), [M+2H-C4H8]2+. HRMS (ESI): m/z [M+H]+ calculated for 
C12H22N3O2S+: 272.1427, found 272.1430; C12H21N3O2S (271.38).  
 
S-Methylthiouronium iodide (3.12).36 Thiourea (9.20 g, 120.86 mmol) and methyl iodide 
(17.0 g, 119.77 mmol) were heated to reflux for 1 h in MeOH. Afterwards, the solvent was 
evaporated under reduced pressure, the crude product was suspended with Et2O, sucked off 
and washed twice with Et2O. Compound 3.12 was obtained as a white solid (25.11 g, 97 %). 
mp = 119.1-120.5 °C (lit.37 mp 117 °C). 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 2.57 (s, 3H), 
8.88 (s, 4H). MS (ESI; MeOH) m/z (%) 91 (100) [M+H]+. HRMS (ESI): m/z [M+H]+ calculated 
for C2H7N2S+: 91.0324, found 91.0325; C2H6N2S x I (218.06). 
 
N-tert-Butoxycarbonyl-S-methylisothiourea (3.13).36 To a solution of 3.12 (25.11 g, 
115.69 mmol) in DCM, NEt3 (11.74 g, 116.00 mmol) and Boc2O (25.37 g, 116.24 mmol) were 
added. The mixture was stirred for 24 h and subsequently washed with brine and water. The 
organic layer was dried over Na2SO4, and the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography (eluent: PE/EA 4:1). This afforded 
compound 3.13 as a white solid (13.43 g, 61 %) (Rf = 0.26 in PE/EA 4:1). mp = 82.1-85.0 °C 
(lit.36 mp 76-78 °C) 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 1.39 (s, 9H), 2.30 (s, 3H), 8.55 
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(s, 2H). MS (ESI; MeOH) m/z (%) 191 (10) [M+H]+, 135 (100) [M+H-C4H8]+. HRMS (ESI): m/z 
[M+H]+ calculated for C7H15N2O2S+: 191.0849, found 191.0849; C7H14N2O2S (190.26). 
 
N1,N4-Bis{[(tert-butoxycarbonylamino)(methylsulfanyl)methylene]aminocarbonyl}-
butane-1,4-diamine (3.14). To a solution of N-tert-butoxycarbonyl-S-methylisothiourea (855 
mg, 4.50 mmol)  NEt3 (30 µL, 0.22 mmol) in DCM was added dropwise a solution of 1,4-
diisocyanatobutane (300 mg, 2.14 mmol) in DCM. The solution was stirred for 2.5 h at room 
temperature. The solvent was removed under reduced pressure and the crude product was 
purified by column chromatography (eluent: DCM/EA 15:1) (Rf = 0.19 in Hex/EA 3:2). The 
product 3.14 was obtained as a white solid (928 mg, 83 %). mp= 144.9–146.1 °C. 1H-NMR 
(300 MHz, CDCl3) δ (ppm) 1.47 (s, 18H), 1.55- 1.65 (m, 4H), 2.29 (s, 6H), 3.22-3.26 (m, 4H), 
5.62 (t, 2H, J 6.0 Hz), 12.27 (s, 2H); 13C-NMR (75 MHz, CDCl3) δ (ppm) 14.4, 27.3, 28.1, 
39.8, 82.7, 151.2, 162.1, 167.6. MS (ESI) m/z (%) 521 (100) [M+H]+. HRMS (ESI): m/z 
[M+H]+ calculated for C20H37N6O6S2+: 521.2211, found 521.2214; C20H36N6O6S2 (520.67). 
 
N1,N6-Bis{[(tert-butoxycarbonylamino)(methylsulfanyl)methylene]aminocarbonyl}-
hexane-1,6-diamine (3.15). To a solution of N-tert-butoxycarbonyl-S-methylisothiourea (700 
mg, 3.68 mmol) and NEt3 (30 µL, 0.22 mmol) in DCM, a solution of 1,6-diisocyanatohexane 
(340 mg, 2.02 mmol) in DCM was added dropwise. The solution was stirred for 2.5 h at room 
temperature. The solvent was removed under reduced pressure, and the crude product was 
purified by column chromatography (eluent: DCM/EA 15:1) (Rf = 0.29 in Hex/EA 3:2). The 
product 3.15 was obtained as a white solid (820 mg, 74 %). Mp = 128.8–133.6 °C. 1H-NMR 
(300 MHz, CDCl3) δ (ppm) 1.34-1.39 (m, 4H), 1.46 (s, 18H), 1.50-1.56 (m, 4H), 2.29 (s, 6H), 
3.17-3.24 (m, 4H), 5.55 (t, 2H, J 5.8 Hz), 12.30 (s, 2H); 13C-NMR (75 MHz, [D4]MeOH) δ 
(ppm) 14.4, 26.7, 28.1, 29.7, 40.1, 82.7, 151.2, 162.1, 167.4. MS (ESI) m/z (%) 549 (100) 
[M+H]+. HRMS (ESI): m/z [M+H]+ calculated for C22H41N6O6S2+: 549.2524, found 549.2525; 
C22H40N6O6S2 (548.72). 
 
General procedure for the synthesis of the guanidinylating reagents (3.16-3.18).  
The respective diamine was dried overnight in vacuo, and the reactions were carried out in 
an argon-purged two-necked round bottom flask. The diamines (1 eq) were dissolved in 
freshly distilled DCM (8 mL), and DIPEA (5.6 eq) was added. This mixture was added 
dropwise under external cooling to a solution of triphosgene (1 eq) in anhydrous DCM over a 
period of 30 min. N-tert-Butoxycarbonyl-S-methylisothiourea (4 eq) was added, and stirring 
was continued for 2.5 h. The solvent was removed under reduced pressure and the crude 
product was purified by column chromatography (eluent DCM/ EA 15:1). 
 
N1,N7-Bis{[(tert-butoxycarbonylamino)(methylsulfanyl)methylene]aminocarbonyl}-
heptane-1,7-diamine (3.16). The title compound was prepared from heptane-1,7-diamine 
(262 mg, 2.01 mmol), DIPEA (1963 µL, 11.27 mmol), triphosgene (596 mg, 2.01 mmol) in 
anhydrous DCM and N-tert-butoxycarbonyl-S-methylisothiourea (1530 mg, 8.08 mmol) 
according to the general procedure (Rf = 0.29 in Hex/ EA 3:2). The product 3.16 was 
obtained as a colorless glassy solid (855 mg, 75 %). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.33 
(m, 6H), 1.46 (s, 18H), 1.49 (overlap with tert-Bu, 4H), 2.29 (s, 6H), 3.16-3.23 (m, 4H), 5.55 
(t, 2H, J 5.0 Hz), 12.31 (s, 2H); 13C-NMR (75 MHz, CDCl3) δ (ppm) 14.4, 26.9, 28.1, 29.1, 
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29.7, 40.2, 82.6, 151.2, 162.0, 167.3. MS (ESI) m/z (%) 563 (100) [M+H]+. HRMS (ESI): m/z 
[M+H]+ calculated for C23H43N6O6S2+: 563.2680, found 563.2690; C23H42N6O6S2 (562.75). 
 
N1,N8-Bis{[(tert-butoxycarbonylamino)(methylsulfanyl)methylene]aminocarbonyl}-
octane-1,8-diamine (3.17). The title compound was prepared from octane-1,8-diamine (400 
mg, 2.77 mmol), DIPEA (2701 µL, 15.50 mmol), triphosgene (823 mg, 2.77 mmol) and N-tert-
butoxycarbonyl-S-methylisothiourea (2108 mg, 11.08 mmol) according to the general 
procedure (Rf = 0.34 in Hex/ EA 3:2). The product 3.17 was obtained as a white solid (1183 
mg, 74 %). Mp = 116.4-119.2 °C. 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.32 (m, 8H), 1.47 (s, 
18H), 1.50 (m, 4H), 2.29 (s, 6H), 3.17-3.24 (m, 4H), 5.53 (t, 2H, J 5.6 Hz), 12.32 (s, 2H); 13C-
NMR (75 MHz, CDCl3) δ (ppm) 14.4, 27.0, 28.2, 29.3, 29.8, 40.3, 82.7, 151.3, 162.1, 167.4. 
MS (ESI) m/z (%) 577 (100) [M+H]+. HRMS (ESI): m/z [M+H]+ calculated for C24H45N6O6S2+: 
577.2837, found 577.2845; C24H44N6O6S2 (576.77). 
 
N1,N10-Bis{[(tert-butoxycarbonylamino)(methylsulfanyl)methylene]aminocarbonyl}-
decane-1,10-diamine (3.18). The title compound was prepared from decane-1,10-diamine 
(300 mg, 1.74 mmol), DIPEA (1697 µL, 9.74 mmol), triphosgene (517 mg, 1.74 mmol) and N-
tert-butoxycarbonyl-S-methylisothiourea (1325 mg, 6.97 mmol) according to the general 
procedure (Rf = 0.35 in Hex/ EA 3:2). The product 3.18 was obtained as a colorless glassy 
solid (798 mg, 76 %). 1H-NMR (300 MHz, [D4]MeOH) δ (ppm) 1.33 (m, 12H), 1.48-1.54 (m, 
22H), 2.32 (s, 6H), 3.14 (t, 4H, J 7.0 Hz); 13C-NMR (75 MHz, [D4]MeOH) δ (ppm) 14.4, 28.0, 
28.2, 30.4, 30.6, 41.0, 83.6, 152.1, 163.7, 167.2. MS (ESI) m/z (%) 605 (100) [M+H]+. HRMS 
(ESI): m/z [M+H]+ calculated for C26H49N6O6S2+: 605.3150, found 605.3154; C26H48N6O6S2 
(604.83). 
 
General procedure for the synthesis of the bivalent carbamoylguanidine-type ligands 
(3.19-3.28). 
The guanidinylating reagents (3.14-3.18) (1 eq) and 2.1 eq of 3-(1-trityl-1H-imidazol-4-
yl)propan-1-amine (3.6) or tert-butyl 5-(3-aminopropyl)-4-methylthiazol-2-ylcarbamate (3.11) 
were dissolved in DMF (unless indicated otherwise). NEt3 (5 eq) and HgCl2 (4 eq) were 
added to the mixture, and stirring was continued for 12 h. The precipitate was centrifuged, 
washed with DMF (unless otherwise indicated) and centrifuged for a second time. The 
bis(Boc)-bis(trityl)- (cf. imidazoles) or tetrakis(Boc)-protected intermediate (cf. amino-
thiazoles) was extracted with EA (unless indicated otherwise), purified by column 
chromatography (eluent: DCM/MeOH 100:1 to 50:1), and dried in vacuo. Subsequently, 
deprotection was performed by stirring with 30 % TFA in DCM for 12 h. The obtained 
carbamoylguanidine (cf. 3.19-3.28) was purified by preparative HPLC. 
 
1-(Amino{[3-(1H-imidazol-4-yl)propyl]amino}methylene)-3-{4-[3-(amino{[3-(1H-imidazol-
4-yl)propyl]amino}methylene)ureido]butyl}urea (3.19). The title compound was prepared 
from 3.14 (175 mg, 0.336 mmol), amine 3.6 (260 mg, 0.708 mmol), NEt3 (233 µL, 1.67 mmol) 
and HgCl2 (365 mg, 1.34 mmol) according to the general procedure, yielding 3.19 as a white 
fluffy, hygroscopic solid (21.88 mg, 7 %): RP-HPLC: 99 %, (tR = 11.75 min, k = 2.99); UVmax 
204 nm. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.57 (m, 4H), 2.03 (tt, 4H, 2J 7.0 Hz, 3J 7.6 
Hz), 2.84 (t, 4H, J 7.7 Hz), 3.23 (m, 4H), 3.36 (t, 4H, J 6.9 Hz), 7.36 (s, 2H), 8.80 (d, 2H, J 
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1.2 Hz); 13C-NMR (151 MHz, [D4]MeOH, trifluoroacetate) δ (ppm) 22.6, 27.7, 28.2, 40.3, 
41.4, 117.1, 134.4, 135.0, 155.6, 156.0, 163.3, 163.5. MS (ESI) m/z (%) 475 (29) [M+H]+, 
238 (75) [M+2H]2+. HRMS (ESI): m/z [M+H]+ calculated for C20H35N12O2+: 475.3000, found 
475.3003; C20H34N12O2 x 4 TFA (930.64). 
 
1-(Amino{[3-(1H-imidazol-4-yl)propyl]amino}methylene)-3-{6-[3-(amino{[3-(1H-imidazol-
4-yl)propyl]amino}methylene)ureido]hexyl}urea (3.20). The title compound was prepared 
from 3.15 (175 mg, 0.319 mmol), amine 3.6 (250 mg, 0.680 mmol), NEt3 (222 µL, 1.60 mmol) 
and HgCl2 (346 mg, 1.27 mmol) according to the general procedure, yielding 3.20 as a white 
fluffy hygroscopic solid (36.00 mg, 12 %): RP-HPLC: 98 %, (tR = 15.18 min, k = 4.15); UVmax 
205 nm. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.36-1.38 (m, 4H), 1.52-1.58 (m, 4H), 2.03 
(tt, 4H, 2J 7.1 Hz, 3J 7.5 Hz ), 2.84 (t, 4H, J 7.7 Hz), 3.20 (t, 4H, J 7.1 Hz,), 3.37 (t, 4H, J 6.9 
Hz), 7.37 (s, 2H), 8.81 (d, 2H, J 1.3 Hz); 13C-NMR (151 MHz, [D4]MeOH, trifluoroacetate) δ 
(ppm) 22.5, 27.4, 28.2, 30.3, 40.7, 41.4, 117.1, 134.3, 135.0, 155.5, 156.0. MS (ESI) m/z (%) 
617 (4) [M+H+TFA]+, 503 (22) [M+H]+, 252 (84) [M+2H]2+. HRMS (ESI): m/z [M+H]+ 
calculated for C22H39N12O2+: 503.3313, found 503.3314; C22H38N12O2 x 4 TFA (958.70). 
 
1-(Amino{[3-(1H-imidazol-4-yl)propyl]amino}methylene)-3-{7-[3-(amino{[3-(1H-imidazol-
4-yl)propyl]amino}methylene)ureido]heptyl}urea (3.21). The title compound was prepared 
from 3.16 (106 mg, 0.188 mmol), amine 3.6 (145 mg, 0.395 mmol), NEt3 (128 µL, 0.92 mmol) 
and HgCl2 (201 mg, 0.74 mmol) according to the general procedure, yielding 3.21 as a white 
fluffy hygroscopic solid (15.30 mg, 8 %): RP-HPLC: 97 %, (tR = 16.65 min, k = 4.65); UVmax 
205 nm. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.36 (m, 6H), 1.54 (m, 4H), 2.03 (tt, 4H, 2J 
7.0 Hz, 3J 7.5 Hz), 2.84 (t, 4H, J 7.7 Hz), 3.19 (t, 4H, J 7.1 Hz), 3.36 (t, 4H, J 6.9 Hz), 7.36 (s, 
2H), 8.80 (d, 2H, J 1.1 Hz);  13C-NMR (151 MHz, [D4]MeOH, trifluoroacetate) δ (ppm); 22.5, 
27.7, 28.2, 29.9, 30.4, 40.7, 41.4, 117.1, 134.3, 134.9, 155.5, 156.1. MS (ESI) m/z (%) 517 
(13) [M+H]+, 259 (41) [M+2H]2+. HRMS (ESI): m/z [M+H]+ calculated for C23H41N12O2+: 
517.3473, found 517.3473; C23H40N12O2 x 4 TFA (972.72). 
 
1-(Amino{[3-(1H-imidazol-4-yl)propyl]amino}methylene)-3-{8-[3-(amino{[3-(1H-imidazol-
4-yl)propyl]amino}methylene)ureido]octyl}urea (3.22). Compound 3.17 (175 mg, 0.303 
mmol) and amine 3.6 (234 mg, 0.637 mmol) were dissolved in DCM. NEt3 (210 µL, 1.51 
mmol) and HgCl2 (330 mg, 1.21 mmol) were added to the mixture. The mixture was 
centrifuged and the precipitate was washed with DCM and centrifuged for a second time. 
The solvent was removed under reduced pressure. Purification by column chromatography 
(eluent: DCM/MeOH 100:1 to 50:1) yielded 3.22 as a white fluffy hygroscopic solid (58.62 
mg, 20 %): RP-HPLC: 96 %, (tR = 18.80 min, k = 5.38); UVmax 205 nm.  1H-NMR (600 MHz, 
[D4]MeOH) δ (ppm) 1.35 (m, 8H), 1.46-1.66 (m, 4H), 2.03 (tt, 4H, 2J 7.0 Hz, 3J 7.5 Hz), 2.86 
(t, 4H, J 7.7 Hz), 3.19 (t, 4H, J 7.0 Hz), 3.39 (t, 4H, J 6.4 Hz), 7.39 (s, 2H), 8.83 (d, 2H, J 0.9 
Hz); 13C-NMR (151 MHz, [D4]MeOH, trifluoroacetate) δ (ppm) 22.5, 27.8, 28.2, 30.2, 30.4, 
40.8, 41.5, 117.1, 134.3, 134.9, 155.3, 155.9. MS (ESI) m/z (%) 531 (15) [M+H]+, 266 (47) 
[M+2H]2+. HRMS (ESI): m/z [M+H]+ calculated for C24H43N12O2+: 531.3626, found 531.3625; 
C24H42N12O2 x 4 TFA (986.75). 
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1-(Amino{[3-(1H-imidazol-4-yl)propyl]amino}methylene)-3-{10-[3-(amino{[3-(1H-
imidazol-4-yl)propyl]amino}methylene)ureido]decyl}urea (3.23). The title compound was 
prepared from 3.18 (150 mg, 0.248 mmol), amine 3.6 (191 mg, 0.520 mmol), NEt3 (172 µL, 
1.24 mmol) and HgCl2 (270 mg, 0.99 mmol) according to the general procedure, yielding 
3.23 as a white fluffy hygroscopic solid (68.83 mg, 27 %): RP-HPLC: 91 %, (tR = 22.73 min, k 
= 6.71); UVmax 205 nm.  1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.32 (m, 12H), 1.49-1.57 (m, 
4H), 2.02 (tt, 4H, 2J 7.0 Hz, 3J 7.6 Hz), 2.83 (t, 4H, J 7.7 Hz), 3.18 (t, 4H, J 7.0 Hz), 4H), 3.36 
(t, 4H, J 6.9 Hz), 7.36 (s, 2H), 8.80 (d, 2H, J 0.7 Hz); 13C-NMR (151 MHz, [D4]MeOH, 
trifluoroacetate) δ (ppm) 22.5, 27.8, 28.1, 30.3, 30.4, 30.5, 40.8, 41.4, 117.0, 134.3, 134.9, 
155.4, 156.0. MS (ESI) m/z (%) 559 (10) [M+H]+, 280 (27) [M+2H]2+. HRMS (ESI): m/z 
[M+H]+ calculated for C26H47N12O2+: 559.3939, found 559.3935; C26H46N12O2 x 4 TFA 
(1014.80). 
 
1-(Amino{[3-(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)-3-{4-[3-(amino{[3-
(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)ureido]butyl}urea (3.24). 
Compound 3.14 (200 mg, 0.384 mmol) and amine 3.11 (216 mg, 0.796 mmol) were 
dissolved in DCM. NEt3 (265 µL, 1.80 mmol) and HgCl2 (412 mg, 1.52 mmol) were added to 
the mixture. The mixture was centrifuged and the precipitate was washed with DCM and 
centrifuged for a second time. The solvent was removed under reduced pressure and the 
product was purified by column chromatography (eluent: DCM/MeOH 100:1 to 50:1), yielding 
3.24 as a white fluffy hygroscopic solid (53.34 mg, 14 %): RP-HPLC: 99 %, (tR = 15.61 min, k 
= 4.29); UVmax 205 nm and 265 nm. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.57 (m, 4H), 
1.90 (tt, 4H, 2J 7.0 Hz, 3J 7.3 Hz), 2.18 (s, 6H), 2.72 (t, 4H, J 7.6 Hz), 3.23 (m, 4H), 3.33 (t, 
4H, J 6.9 Hz); 13C-NMR (151 MHz, [D4]MeOH, trifluoroacetate) δ (ppm) 11.4, 23.6, 27.7, 
29.9, 40.34, 41.4, 118.4, 132.6, 155.6, 156.0, 170.3. MS (ESI) m/z (%) 567 (34) [M+H]+, 284 
(58) [M+2H]2+. HRMS (ESI): m/z [M+H]+ calculated for C22H39N12O2S2+: 567.2755, found 
567.2760; C22H38N12O2S2 x 4 TFA (1022.83). 
 
1-(Amino{[3-(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)-3-{6-[3-(amino{[3-
(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)ureido]hexyl}urea (3.25). 
Compound 3.15 (175 mg, 0.319 mmol) and amine 3.11 (177 mg, 0.652 mmol) were 
dissolved in DCM. NEt3 (215 µL, 1.55 mmol) and HgCl2 (378 mg, 1.24 mmol) were added to 
the mixture. The mixture was centrifuged and the precipitate was washed with DCM and 
centrifuged for a second time The solvent was removed under reduced pressure and the 
product was purified by column chromatography (eluent: DCM/MeOH 100:1 to 50:1), yielding 
3.25 as a white fluffy hygroscopic solid (99.34 mg, 30 %): RP-HPLC: 99 %, (tR = 18.12 min, k 
= 5.15); UVmax 203 nm and 265 nm. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.37 (m, 4H), 
1.48-1.62 (m, 4H), 1.89 (tt, 4H, 2J 7.0 Hz, 3J 7.4 Hz), 2.18 (s, 6H), 2.72 (t, 4H, J 7.5 Hz), 3.20 
(t, 4H,  J 6.9 Hz), 3.33 (t, 4H, J 6.8 Hz, overlap with solvent). 13C-NMR (75 MHz, [D4]MeOH, 
trifluoroacetate) δ (ppm) 11.4, 23.6, 27.4, 29.9, 30.3, 40.6, 41.4, 118.4, 132.6, 155.5, 156.0, 
170.3. MS (ESI) m/z (%) 595 (23) [M+H]+, 298 (38) [M+2H]2+. HRMS (ESI): m/z [M+H]+ 
calculated for C24H43N12O2S2+: 595.3068, found 595.3068; C24H42N12O2S2 x 4 TFA (1050.88). 
 
1-(Amino{[3-(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)-3-{7-[3-(amino{[3-
(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)ureido]heptyl}urea (3.26). The 
title compound was prepared from 3.16 (175 mg, 0.311 mmol), 3.11 (177 mg, 0.652 mmol), 
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NEt3 (215 µL, 1.55 mmol) and HgCl2 (338 mg, 1.24 mmol) according to the general 
procedure, yielding 3.26 as a white fluffy hygroscopic solid (95.46 mg,  29 %): RP-HPLC: 99 
%, (tR = 19.85 min, k = 5.74); UVmax 204 nm and 264 nm. 1H-NMR (600 MHz, [D4]MeOH) δ 
(ppm) 1.36 (s, 6H), 1.51-1.57 (m, 4H), 1.90 (tt, 4H, 2J 7.2 Hz, 3J 7.4 Hz), 2.18 (s, 6H), 2.72 (t, 
4H, J 7.6 Hz), 3.19 (t, 4H, J 7.1 Hz), 3.33 (t, 4H, J 6.9 Hz); 13C-NMR (151 MHz, [D4]MeOH, 
trifluoroacetate) δ (ppm) 11.4, 23.6, 27.7, 29.9, 30.0, 30.4, 40.8, 41.4, 118.4, 132.7, 155.5, 
156.0, 170.3. MS (ESI) m/z (%) 609 (23) [M+H]+, 305 (50) [M+2H]2+. HRMS (ESI): m/z 
[M+H]+ calculated for C25H45N12O2S2+: 609.3224, found 609.3226; C25H44N12O2S2 x 4 TFA 
(1064.91). 
 
1-(Amino{[3-(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)-3-{8-[3-(amino{[3-
(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)ureido]octyl}urea (3.27). The 
title compound was prepared from 3.17 (130 mg, 0.225 mmol), 3.11 (128 mg, 0.472 mmol), 
NEt3 (156 µL, 1.12 mmol) and HgCl2 (244 mg, 0.90 mmol) according to the general 
procedure, yielding 3.27 as a white fluffy hygroscopic solid (21.77 mg, 9 %): RP-HPLC: 98 
%, (tR = 21.69 min, k = 6.36); UVmax 204 nm and 264 nm. 1H-NMR (600 MHz, [D4]MeOH) δ 
(ppm) 1.34 (m, 8H), 1.50-1.56 (m, 4H), 1.90 (tt, 4H, 2J 7.0 Hz, 3J 7.4 Hz), 2.18 (s, 6H), 2.72 
(t, 4H, J 7.6 Hz), 3.19 (t, 4H, J 7.1 Hz), 3.33 (t, 4H, J 6.9 Hz). 13C-NMR (151 MHz, [D4]MeOH, 
trifluoroacetate) δ (ppm) 11.4, 23.6, 27.8, 29.9, 30.3, 30.4, 40.8, 41.4, 118.4, 132.6, 155.5, 
156.0, 170.3. MS (ESI) m/z (%) 623 (11) [M+H]+, 312 (21) [M+2H]2+. HRMS (ESI): m/z 
[M+H]+ calculated for C26H47N12O2S2+: 623.3381, found 623.3375; C26H46N12O2S2 x 4 TFA 
(1078.94). 
 
1-(Amino{[3-(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)-3-{10-[3-(amino-
{[3-(2-amino-4-methyl-thiazol-5-yl)propyl]amino}methylene)ureido]decyl}urea (3.28). 
The title compound was prepared from 3.18 (150 mg, 0.248 mmol), 3.11 (141 mg, 0.519 
mmol), NEt3 (172 µL, 1.24 mmol) and HgCl2 (269 mg, 0.99 mmol) according to the general 
procedure, yielding 3.28 as a white fluffy hygroscopic solid (24.25 mg, 9 %): RP-HPLC: 99 
%, (tR = 25.49 min, k =7.65); UVmax 205 nm and 263 nm. 1H-NMR (600 MHz, [D4]MeOH) δ 
(ppm) 1.32 (m, 12H), 1.50-1.56 (m, 4H), 1.90 (tt, 4H, 2J 7.0 Hz, 3J 7.3 Hz), 2.18 (s, 6H), 2.72 
(t, 4H, J 7.1 Hz), 3.19 (t, 4H, J 7.1 Hz), 3.33 (t, 4H, J 6.9 Hz). 13C-NMR (151 MHz, [D4]MeOH, 
trifluoroacetate) δ (ppm) 11.5, 23.6, 27.8, 29.9, 30.3, 30.4, 30.6, 40.8, 41.4, 118.4, 132.7, 
155.5, 156.0, 170.3. MS (ESI) m/z (%) 651 (4) [M+H]+, 326 (17) [M+2H]2+, 218 (27) [M+3H]3+, 
163 (42) [M+4H]4+. HRMS (ESI): m/z [M+H]+ calculated for C28H51N12O2S2+: 651.3694, found 
651.3684; C28H50N12O2S2 x 4 TFA (1106.99). 
 
1,7-Dichloroheptan-4-one (3.29).13 HCl gas (1fold excess) was passed through 
dicyclopropyl ketone (15.00 g, 136.16 mmol) for 30 min. After stirring for 3 h, HCl gas was 
passed through the mixture for another 30 min. The crude product was obtained as a brown 
oil (24.93 g, 100 %) and was used in the next step without any further purification. 1H-NMR 
(300 MHz, CDCl3): δ (ppm) 2.02 (m, 4H), 2.61 (t, 4H, J 7.0 Hz), 3.55 (t, 4H, J 6.3 Hz). 13C-
NMR (75 MHz, [D4]MeOH) δ (ppm) 27.6, 40.3, 45.2, 210.7. MS (APCI; MeOH) m/z (%) 183 
(100). HRMS (APCI): m/z [M+H]+ calculated for C7H13Cl2O+: 183.0337, found 183.0337. 
C7H12Cl2O (183.08).  
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1,7-Diazidoheptan-4-one (3.30). To a solution of 1,7-dichloroheptan-4-one (3.29) (3.40 g, 
18.57 mmol) in 50 mL DMF, sodium azide (3.62 g, 55.68 mmol) was added and stirred 
overnight at 60 °C. After cooling and addition of water (500 mL), the mixture was extracted 
with EA (3 x 100 mL). The combined organic phases were dried over sodium sulfate. 
Filtration and evaporation of the solvent yielded a yellow oil (2.87 g, 79 %). The crude 
product 3.30 was used in the next step without any further purification. 1H-NMR (300 MHz, 
CDCl3) δ (ppm) 1.86 (m, 4H), 2.52 (t, 4H, J 7.1 Hz), 3.31 (t, 4H, J 6.6 Hz). 13C-NMR (75 MHz, 
CDCl3) δ (ppm) 22.6, 39.0, 50.4, 208.2. MS (ESI; MeOH) m/z (%) 219 (46) [M+Na+], 197 (2) 
[M+H]+, 169 (100) [M+H-N2]+. HRMS (ESI): m/z [M+H]+ calculated for C7H13N6+: 197.1145, 
found 197.1138. C7H12N6(196.11). 
 
(4-Chlorobutyl)triphenylphosphonium bromide (3.31).38 Triphenylphosphine (38.24 g, 
0.14 mol) and 1-bromo-4-chlorobutane (25 g, 0.15 mol) were dissolved in anhydrous toluene 
(500 mL), and the mixture was heated to reflux overnight. The reaction mixture was cooled to 
room temperature. The white solid was filtered off, washed with toluene and hexane and 
dried in vacuo (38.68 g, 61 %); mp = 229-231 °C. 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.77-
1.90 (m, 2H), 2.21-2.30 (m, 2H), 3.66-3.77 (m, 2H), 3.71 (t, 2H, J 6.4 Hz), 3.94-4.04 (m, 2H), 
7.66-7.92 (bm, 15H). MS (ESI) m/z (%) 353 (100) [M]+. HRMS (ESI): m/z [M]+ calculated for 
C22H23ClP+: 353.1220, found 353.1222. C22H23ClP+ Br-(433.02). 
 
1-Azido-4-(3-azidopropyl)-8-chlorooct-4-ene (3.32). (4-Chlorobutyl)triphenylphosphonium 
bromide (3.31) (2.50 g, 5.76 mmol) was suspended in anhydrous THF (20 mL) under an 
atmosphere of argon and the mixture was cooled to -72 °C. n-Butyllithium (1.6 M in n-
hexane, 3.60 mL, 5.76 mmol) was added to the suspension and the mixture was allowed to 
warm up to -10 °C over a period of 45 min. The temperature was kept at -10 °C for 1.5 h and 
then cooled again to -72 °C. 1,7-diazidoheptan-4-one (1.13 g, 5.76 mmol) was added and the 
mixture was allowed to warm up to room temperature over a period of 60 min, stirring was 
continued overnight. After filtration of solid material and evaporation of the solvent, the 
product was purified by column chromatography using mixtures of Hex and EA as eluent (Rf 
= 0.45 for Hex /EA 4:1), affording 3.32 as yellow oil (300 mg, 19 %). 1H-NMR (300 MHz, 
[D4]MeOH) δ (ppm) 1.61-1.74 (m, 4H), 1.76-1.86 (m, 2H), 2.07-2.26 (bm, 6H), 3.26-3.31 
(overlap with solvent, m, 4H), 3.56 (t, 2H, J 6.5 Hz), 5.23 (t, 1H, J 7.3 Hz). 13C-NMR (75 MHz, 
CDCl3) δ (ppm) 25.0, 27.0, 27.4, 27.6, 32.7, 33.6, 44.6, 51.0, 51.2, 125.3, 138.0. MS (ESI) 
m/z (%) 243 (100) [M+H-N2]+. HRMS (ESI): m/z [M+H-N2]+ calculated for C11H20ClN4+: 
243.1376, found 243.1374; C11H19ClN6 (270.76). 
 
2-[8-Azido-5-(3-azidopropyl)oct-4-en-1-yl]isoindoline-1,3-dione (3.33). To a solution of 
3.32 (1.89 g, 6.98 mmol) and phthalimide (1.54 g, 10.47 mmol) in 40 mL DMF, Cs2CO3 
(5.00g, 15.34 mmol) and catalytic traces of KI were added. The mixture was stirred at 60 °C 
overnight. After cooling 400 mL 5 % NaOH were added and the product was extracted with 
EA. The combined organic phases were dried over Na2SO4. After filtration and evaporation, 
the crude product was purified by column chromatography using mixtures of Hex and EA as 
eluent (Rf = 0.45 for Hex/EA 2:1), affording 3.33 (1.51 g, 57 %) as yellow oil. 1H-NMR (300 
MHz, CDCl3) δ (ppm) 1.56-1.58 (m, 4H), 1.69-1.78 (m, 2H), 1.96-2.15 (m, 6H), 3.24 (td, 4H, 
2J 6.8, 3J 2.9 ), 3.65-3.73 (m, 2H), 5.21 (t, 1H, J 7.1 Hz), 7.75-7.67 (m, 2H), 7.80-7.87 (m, 
2H). 13C-NMR (75 MHz, CDCl3) δ (ppm) 25.1, 26.9, 27.2, 27.3, 28.7, 33.4, 37.7, 50.9, 51.1, 
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123.2, 125.7, 132.1, 133.9, 137.3, 168.4. MS (ESI) m/z (%) 404 (31) [M+Na+], 354 (100) 
[M+H-N2]+. HRMS (ESI): m/z [M+H-N2]+ calculated for C19H24N5O2+: 354.1925, found 
354.1925; C19H23N7O2 (381.44). 
 
8-Azido-5-(3-azidopropyl)oct-4-en-1amine (3.34). A mixture of 3.33 (1.00 g, 2.62 mmol) 
and hydrazine (0.50 g, 15.60 mmol) in ethanol was heated to reflux for 1h. Solid material was 
removed by filtration. After removing the solvent in vacuo, the product was purified by column 
chromatography (eluent: EA/MeOH/NH3 9/0.8/0.2 to EA/MeOH/NH3 8/1.5/0.5), (Rf = 0.14 for 
DCM
 
/ 7 N NH3 in MeOH 4:1). Compound 3.34 was obtained as yellow oil (580 mg, 88 %). 
1H-NMR (300 MHz, CDCl3) δ (ppm) 1.45-1.54 (m, 2H), 1.58-1.85 (m, 6H), 1.99-2.13 (m, 6H), 
2.70 (t, 2H, J 7.1 Hz), 3.26 (td, 4H, 2J 6.8, 3J 2.4) 5.20 (t, 1H, J 7.1). 13C-NMR (75 MHz, 
CDCl3) δ (ppm) 25.2, 27.3, 27.5, 33.3, 33.6, 39.5, 41.6, 51.0, 51.2, 126.6, 136.7. MS (ESI) 
m/z (%) 252 (100) [M+H]+. HRMS (ESI): m/z [M+H+]+ calculated for C11H22N7+: 252.1931, 
found 252.1925; C11H21N7 (251.34). 
 
tert-Butyl [8-azido-5-(3-azidopropyl)oct-4-en-1-yl]carbamate (3.35). A solution of di-tert-
butyldicarbonat (756 mg, 3.46 mmol) in DCM
 
was added dropwise to an external cooled 
solution of number 8-azido-5-(3-azidopropyl)oct-4-en-1amine (3.34) (870 mg, 3.46 mmol) 
and NEt3 (480 µL, 3.46 mmol) in DCM over a period of 1h. The mixture was stirred at room 
temperature for 24h. The solvent was removed in vacuo. The product was purified by column 
chromatography (eluent: Hex/EA 10/90 to Hex/EA 50/50), (Rf = 0.23 for Hex/EA 3:2) and 
obtained as pale yellowish oil (1.18 g, 97 %). 1H-NMR (300 MHz, CDCl3) δ (ppm) 1.44 (s, 
9H), 1.47-1.59 (m, 2H), 1.59-1.73 (m, 4H), 2.00-2.12 (m, 6H), 3.11 (t, 2H, J 6.9 Hz), 3.23-
3.30 (m, 4H), 4.54 (s, 1H), 5.19 (t, 1H, J 7.1 Hz). 13C-NMR (75 MHz, CDCl3) δ (ppm) 25.1, 
26.8, 27.3, 27.4, 28.5, 30.3, 33.5, 40.3, 51.0, 51.1, 79.1, 126.3, 137.0, 156.0. MS (ESI) m/z 
(%) 374 (26) [M+Na+], 324 (25) [M+H-N2]+, 268 (100) (M+H-C4H8]+. HRMS (ESI): m/z 
[M+Na+] calculated for C16H29N7O2Na+: 374.2275, found 374.2282; C16H29N7O2 (351.45). 
 
tert-Butyl [8-amino-5-(3-aminopropyl)oct-4-en-1-yl]carbamate (3.36). A solution of 3.35 
(200 mg, 0.57 mmol) in anhydrous diethyl ether was dropped to a stirred suspension of 
LiAlH4 (100 mg, 2.63 mmol) in anhydrous diethyl ether over 1 h. The mixture was heated to 
reflux for an additional hour. After cooling and quenching with a solution of 2 g Seignette salt 
in 12 g water (pH = 9-10), the organic phase was washed twice with 0.1 M KOH and the 
solvent was evaporated in vacuo. The crude product was used in the next step without any 
further purification (113 mg, 66 %). 1H-NMR (300 MHz, [D4]MeOH) δ (ppm) 1.42 (s, 9H), 
1.47-1.57 (m, 6H), 1.63 (s, 4H), 1.98-2.06 (m, 6H), 2.66 (td, 4H, 2J  7.1, 3J 2.5 ), 3.05-3.12 
(m, 2H), 4.67 (s, 1H), 5.11 (t, 1H J 7.0 Hz). 13C-NMR (75 MHz, CDCl3) δ (ppm) 25.1, 27.4, 
28.5, 30.4, 32.2, 32.4, 34.2, 40.4, 42.0, 42.3, 79.1, 124.4, 139.3, 156.1. MS (ESI) m/z (%) 
300 (40) [M+H]+, 244 (51) [M+H-C4H8]+, 200 (100) [M+H-Boc]+. HRMS (ESI): m/z [M+H+]+ 
calculated for C16H34N3O2+: 300.2646, found 300.2649; C16H33N3O2 (299.45). 
  
Chapter 3 
58 
 
tert-Butyl ({3-[4-({3-[(tert-butoxycarbonylimino)(methylsulfanyl)methyl]ureido}propyl)-
8-(tert-butoxycarbonylamino)oct-4-en-1-
yl]ureido}(methylsulfanyl)methylene)carbamate (3.38). The title compound was prepared 
from 3.36 (122 mg, 0.41 mmol), DIEA (393 µL, 2.3 mmol) and triphosgene (122 mg, 0.41 
mmol), giving tert-butyl [8-isocyanato-5-(3-isocyanatopropyl)oct-4-en-1-yl]carbamate (3.37) 
as intermediate. Compound 3.37 was not isolated but allowed to react with N-Boc-S-
methylisothiourea (310 mg, 1.63 mmol) according to the general procedure for the synthesis 
of the guanidinylating reagents (3.14-3.18). 3.38 was obtained as a yellowish oil (Rf = 0.37 in 
DCM) (131 mg, 44 %). 1H-NMR (300 MHz, [D4]MeOH) δ (ppm) 1.43 (s, 9H), 1.48-1.54 (m, 
20H), 1.59-1.66 (m, 4H), 2.03-2.07 (m, 4H), 2.08-2.12 (m, 2H), 2.33 (d, 6H, J 2.1 Hz), 3.03 (t, 
2H, J 7.0 Hz), 3.14 (m, 4H), 5.22 (t, 1H, J 7.1 Hz). 13C-NMR (75 MHz, CDCl3) δ (ppm) 14.4, 
26.1, 28.2, 28.8, 29.1, 29.3, 31.2, 35.1, 40.8, 41.1, 83.6, 126.3, 139.8, 152.2, 163.7, 163.72, 
167.2, 167.3. MS (ESI) m/z (%) 754 (14) [M+Na+], 732 (100) [M+H]+, 266 (69) [M+2H-
2Boc]2+. HRMS (ESI): m/z [M+H+]+ calculated for C32H58N7O8S2+: 732.3794, found 732.3794; 
C32H57N7O8S2 (731.97). 
 
1-(8-Amino-4-{[3-(amino{[3-(2-amino-4-methyl-thiazol-5-
yl)propyl]amino}methylene)ureido]propyl}oct-4-enyl)-3-[(amino{[3-(2-amino-4-methyl-
thiazol-5-yl)propyl]amino}methylene)]urea (3.39). The title compound was prepared from 
3.38 (111 mg, 0.15 mmol), 3.11 (86 mg, 0.317 mmol), NEt3 (105 µL, 0.76 mmol) and HgCl2 
(165 mg, 0.60 mmol) according to the general procedure for the synthesis of the bivalent 
carbamoylguanine-type ligands (3.19-3.28), yielding 3.39 as a white fluffy hygroscopic solid 
(34.80 mg, 21 %). RP-HPLC: 96 %, (tR  = 17.19 min, k = 4.83); UVmax 204 nm and 263 nm. 
1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.59-1.67 (m, 4H), 1.70 (m, 2H), 1.90 (tt, 4H, 2J 7.0 
Hz, 3J 7.3 Hz), 2.05-2.17 (bm, 6H), 2.18 (s, 6H), 2.72 (t, 4H, J 7.6 Hz), 2.90-2.94 (m, 2H), 
3.19 (m, 4H), 3.34 (t, 4H, J 6.8 Hz, overlap with solvent), 5.23 (t, 1H, J 7.1 Hz). 13C-NMR 
(151 MHz, [D4]MeOH, trifluoroacetate) δ (ppm) 11.4, 23.6, 25.6, 28.1, 28.8, 28.9, 29.1, 29.9, 
34.7, 40.41, 40.44, 40.8, 41.4, 118.4, 125.3, 132.6, 140.6, 155.6, 156.0, 170.3. MS (ESI) m/z 
(%) 678 (10) [M+H]+, 340 (23) [M+2H]2+. HRMS (ESI): m/z [M+H]+ calculated for 
C29H52N13O2S2+: 678.3803, found 678.3806. C29H51N13O2S2 x 5 TFA (1248.03). 
 
General procedure for the synthesis of the bivalent fluorescence ligands (3.40-3.42) 
The reactions were carried out in a 1.5-mL Eppendorf reaction vessel. The amine precursor 
3.39 (2 eq) was dissolved in 30 µL DMF and NEt3 (15 eq) was added. The fluorescence dyes 
(1 eq) were dissolved in 20 µL DMF and this solution was added to the mixture, the cup was 
rinsed two times with DMF (20 µL and 10 µL). The mixture was stirred for 2 h at room 
temperature and then the reaction was stopped by adding 20 µL of 10 % TFA. The crude 
products were purified by preparative HPLC. 
 
2-{(1E,3E)-5-[(Z)-1-(5-amino-12-{3-[3-(amino{[3-(2-amino-4-methylthiazol-5-
yl)propyl]amino}methylene)ureido]propyl}-1-(2-amino-4-methylthiazol-5-yl)-7,18-dioxo-
4,6,8,17-tetraazatricosa-5,12-dien-23-yl)-3,3-dimethylindolin-2-ylidene]penta-1,3-dien-1-
yl}-1,3,3-trimethyl-3H-indol-1-ium trifluoroacetate (3.40). The title compound was 
prepared from 3.39 (1.60 mg, 1.28 µmol), S2197 (422 µg, 0.64 µmol) and NEt3 (1.33 µL, 9.60 
µmol) according to the general procedure, yielding 3.40 as a dark blue solid (490 µg, 45 %): 
RP-HPLC: 99 %, (tR = 24.83 min, k = 7.42) (eluent: MeCN/TFA (0.05% aq.) 10:90, 30 min: 
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60/40, 31 min: 80:20, -41 min; flow rate = 0.75 mL/min). MS (ESI) m/z (%) 1143.8 (1) [M]+, 
571.9 (34) [M+H]2+, 381.6 (100) [M+2H]3+, 296.6 (24) [M+4H+MeOH]4+. C63H88F3N15O5S2 x 4 
TFA (1713.70). 
 
1-{8-[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]-5-{3-
[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]propyl}oct-
4-en-1-yl}-2,6-dimethyl-4-[(E)-2-(2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-
yl)vinyl]pyridin-1-ium trifluoroacetate (3.41). The title compound was prepared from 3.39 
(1.50 mg, 1.20 µmol), Py-1 (236 µg, 0.60 µmol) and NEt3 (1.25 µL, 9.00 µmol) according to 
the general procedure, yielding 3.41 as a red solid (332 µg, 36 %): RP-HPLC: 93 %, (tR = 
23.11 min, k = 6.84) (eluent: MeCN/TFA (0.05% aq.) 10:90, 30 min: 60/40, 31 min: 80:20, -41 
min; flow rate = 0.75 mL/min). MS (ESI) m/z (%) 965.7 (1) [M]+, 483.2 (82) [M+H]2+, 336.1 
(100) [M+2H+MeCN]3+, 322.4 (15) [M+2H]3+. C52H73F3N14O4S2 x 4 TFA (1536.45). 
 
1-{8-[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]-5-{3-
[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]propyl}oct-
4-en-1-yl}-4-{(1E,3E)-4-[4-(dimethylamino)phenyl]buta-1,3-dien-1-yl}-2,6-
dimethylpyridin-1-ium trifluoroacetate (3.42). The title compound was prepared from 3.39 
(2.00 mg, 1.60 µmol), Py-5 (294 µg, 0.80 µmol) and NEt3 (1.66 µL, 12 µmol) according to the 
general procedure, yielding 3.42 as a red solid (462 µg, 38 %): RP-HPLC: 96 %, (tR = 19.68 
min, k = 5.68) (eluent: MeCN/TFA (0.05% aq.) 10:90, 30 min: 60/40, 31 min: 80:20, -41 min; 
flow rate = 0.75 mL/min). MS (ESI) m/z (%) 939.6 (1) [M]+, 470 (90) [M+H]2+, 327 (100) 
[M+2H+MeCN]3+, 313 (11) [M+2H]3+. C50H71F3N14O4S2 x 4 TFA (1510.41). 
 
N-{8-[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]-5-{3-
[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]propyl}oct-
4-en-1-yl}propionamide (3.43a). The reaction was carried out in a 1.5-mL Eppendorf 
reaction vessel. Compound 3.39 (13.62 µmol, 17.00 mg) was dissolved in 30 µL DMF and 
NEt3 (102.20 µmol, 14.14 µL) was added. Succinimidyl propionate (16.36 µmol, 2.80 mg) 
was dissolved in 20 µL DMF and this solution was added to the mixture. The cup was rinsed 
a second time with 10 µL DMF and the reaction mixture was stirred for 2 h at room 
temperature. The reaction was stopped by adding 20 µL of 10 % TFA. The crude product 
was purified by preparative HPLC, yielding 3.43a as a white fluffy hygroscopic solid (13.18 
mg, 81 %): RP-HPLC: 94 %, (tR = 21.77 min, k = 7.54) (YMC C8 column); UVmax 204 nm and 
264 nm. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.12 (t, 3H, J 7.6 Hz), 1.54 (tt, 2H, 2J 7.0 Hz, 
3J 7.4 Hz), 1.62 (m, 4H), 1.90 (tt, 4H, 2J 7.3 Hz, 3J 7.4 Hz), 2.03-2.11 (bm, 6H), 2.16-2.21 (m, 
8H), 2.72 (t, 4H, J 7.6 Hz), 3.14-3.20 (m, 6H), 3.33 (t, 4H, J 6.9 Hz), 5.23 (t, 1H, J 7.1 Hz). 
13C-NMR (151 MHz, [D4]MeOH, trifluoroacetate) δ (ppm) 10.6, 11.4, 23.6, 26.1, 27.9, 28.8, 
29.1, 29.2, 30.2, 30.7, 34.7, 40.1, 40.4, 40.8, 41.4, 118.4, 126.6, 132.6, 139.3, 155.5, 156.0, 
170.3, 177.0. MS (ESI) m/z (%) 734.4 (10) [M+H]+, 367.7 (23) [M+2H]2+, 245.5 (77) [M+3H]3+. 
HRMS (ESI): m/z [M+H]+ calculated for C32H56N13O3S2+: 734.4065, found 734.4068. 
C32H55N13O3S2 x 4 TFA (1190.08).  
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N-{8-[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]-5-{3-
[3-(amino{[3-(2-amino-4-methylthiazol-5-yl)propyl]amino}methylene)ureido]propyl}oct-
4-en-1-yl}-2,3-ditritiopropionamide (3.43b).  
Succinimidyl [2,3-3H2]propionate was from Hartmann Analytic (Braunschweig, Germany), 
provided in EA (as = 2.96 TBq/mmol, 80 Ci/mmol; av = 18.5 GBq/mL, 5 mCi/mL). The reaction 
was carried out in a 1.5 mL Eppendorf reaction vessel. The precursor 3.39 (0.375 µmol, 468 
µg) was dissolved in a mixture of 50 µL DMF and DIPEA
 
(5.625 µmol, 0.96 µL). This mixture 
was added to the solved succinimidyl [2,3-3H]propionate (41.46 nmol, 3.32 mCi). The EA was 
removed in a vacuum concentrator for about 45 min. Afterwards 9 µL EA and 1 µL DIPEA 
were added, and the mixture was stirred for 3 h with a magnetic stirrer at room temperature. 
80 µL 2 % of aq. TFA and 280 µL Millipore water were added. The product was isolated with 
a Waters HPLC system (column: YMC – Triart C18 (250 x 6.0mm x 5 µm). Eluent: mixtures 
of MeCN and 0.04% TFA (A) and 0.05 % aq. TFA (B), gradient 0 to 20 min A/B 5:95 to 
30/70. The retention time of the radioligand was 18.4 min and the eluates were collected in a 
1.5-mL reaction vessel. The combined fractions were concentrated in a vacuum concentrator 
to a volume of around 600 µL.  
Quantification: The concentration of the radioligand was determined by a 4 point calibration 
with 3.43a. The solutions for the calibration were prepared freshly prior to the injection. All of 
the solutions were prepared separately in mobile phase from a 20 µM solution of 3.43a. 
Eluent: mixtures of MeCN and 0.04 % TFA (A) and 0.05 % aq. TFA (B), gradient: 0 to 20 min 
A/B 5:95 to 26/74 (column: Phenomenex Luna C18 (150 x 4.6mm x 3µm). The molarity of the 
solution of 3.43b was calculated from the peak areas of the standards.  
Determination of the specific activity: 10 aliquots of the diluted radioligand in mobile phase 
were counted in 3 mL of Rotiszint eco plus (Roth, Karlsruhe, Germany) in a LS 6500 liquid 
scintillation counter (Beckmann-Coulter, München). The calculated specific activity was 2.60 
tBq/mmol (70.15 Ci/mmol). The concentration was adjusted to 1 mCi/ml by adding 1291 µL 
of a mixture of Millipore water and EtOH (60 : 40). This yielded in a concentration of 14.25 
µM.  
The radioligand was obtained in a yield of 90 % (37.34 nmol, 44.41 µg) with a radiochemical 
purity of 99 %. C32H55N13O3S2 x 4 TFA (1190.08). 
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3.5.3 Pharmacological Protocols 
3.5.3.1 GTPγS binding assay 
[35S]GTPγS was from PerkinElmer Life Science (Boston, USA) or Hartmann Analytic 
(Braunschweig, Germany). Sf9 membranes expressing the hH2R-Gsαs or the gpH2R- Gsαs 
were thawed and sedimented by centrifugation at 13.000 g (4 °C) for 10 min. The 
membranes were resuspended in cold (4 °C) binding buffer BB (12.5 mM MgCl2, 1 mM 
EDTA and 75 mM Tris/HCl, pH 7.4) so that the final concentration was 1 µg of protein per 1 
µL BB. Experiments were performed in 96-well plates (PP microplates 96 well, Greiner Bio-
One, Frickenhausen, Germany) in a total volume of 100 µL, containing 10 µg of membrane, 1 
µM GDP, 0.05 % BSA, 20 nCi [35S]GTPγS and the investigated ligands at various 
concentration (dissolved in water). During the incubation period of 90 min, at room 
temperature, the plates were shaken at 250 rpm. Afterwards, bound [35S]GTPγS was 
separated from free [35S]GTPγS by filtration through GF/C filters using a 96-well Brandel 
harvester (Brandel Inc., Unterföhring, Germany). Filter- bound radioactivity was either 
quantified by liquid scinitillation counting or the filters were dried overnight and MeltiLex solid 
scintillator was melted onto the filtermats. Scintillation counting was performed with the 
MicroBeta21450 PlateCounter (Perkin Elmer, Rodgau, Germany). 
 
3.5.3.2 Competition binding experiments 
[3H]mepyramine, [3H]tiotidine, [3H]histamine and [3H]Nα-Methylhistamine were from Hartmann 
analytic (Braunschweig, Germany). Sf9 membranes (general procedures for the generation 
of recombinant baculoviruses, culture of Sf9 cells and membrane preparation have been 
described elsewhere39)
 
were thawed and sedimented by centrifugation at 13.000 g and 4 °C 
for 10 min. The membranes were resuspended in cold (4 °C) binding buffer (BB: 12.5 mM 
MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4) so that the final concentration was 2-6 µg 
of protein per 1 µL BB. Experiments were performed in 96-well plates (PP microplates 96 
well, Greiner Bio-One, Frickenhausen, Germany) in a total volume of 100 µL containing 20-
60 µg of membrane, 0.05 % BSA, the respective radioligand and the investigated ligands at 
various concentrations (dissolved in water). During the incubation period of 60 min at room 
temperature, the plates were shaken at 250 rpm. Afterwards, bound radioligand was 
separated from free radioligand by filtration through, PEI covered, GF/C filters using a 96-
well Brandel harvester (Brandel Inc., Unterföhring, Germany). After two washing steps with 
binding buffer, filter pieces were punched and transferred into untapped 96-well sample 
plates 1450-401 (Perkin Elmer, Rodgau, Germany). Each well was supplemented with 200 
µL of scintillation cocktail (Rotiscint Eco plus, Roth, Karlsruhe, Germany) and incubated in 
the dark for 12 h. Radioactivity was measured with a Micro Beta2 1450 scintillation counter 
(Perkin Elmer, Rodgau, Germany). 
 
3.5.3.3 Studies on human monocytes 
The present study was approved by the Ethics Committee of the Hannover Medical School. 
Monocytes were isolated from peripheral blood of healthy human volunteers using density 
gradient centrifugation and magnetic activated cell sorting. To study the H2R mediated 
responses in human monocytes, increases in cAMP levels were analyzed via reversed 
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phase HPLC coupled to mass spectrometry (HPLC-MS/MS). For this purpose, 5 × 105 cells 
were treated with the ligands (1 nM – 100 µM) in the presence of 100 µM IBMX at 37 °C for 
10 min. Inhibition of fMLP-induced production of ROS was investigated using the lucigenin 
chemiluminescence assay: 1 × 105 cells loaded with the chemiluminescence dye lucigenin 
were pre-incubated with the ligands (1 nM – 100 µM) at 37 °C for 5 min. After adding fMLP (1 
µM), the chemiluminescence was recorded at 37 °C for 60 min. These methods have been 
described in detail in Werner et al.27  
 
3.5.3.4 EBAO staining 
Cytotoxicity of the compounds was assessed by ethidium bromide / acridine orange (EBAO) 
staining. Monocytes (2.5 × 105 cells/ml) were incubated with 100 µM of compounds 3.20 and 
3.25 in RPMI-medium supplemented with 10 % (v/v) bovine calf serum, 100 U/ml penicillin, 
100 µg/ml streptomycin, 2 mM L-glutamine and 1 % (v/v) NEA at 37 °C in a humidified 
atmosphere with 5 % (v/v) CO2. After 2 h cells were stained with 50 µg/ml EBAO solution and 
cell viability was determined by fluorescence microscopy using a Zeiss Axiovert 200 M 
microscope (Carl Zeiss, Jena, Germany).  
 
3.5.3.5 Stability in plasma 
Mouse plasma was prepared as previously described.40 The stock solutions of the 
compounds (10 mM) were prepared in water and were diluted 5:100 in mouse plasma. The 
samples were vortexed and incubated at 37 °C. At different periods of time an aliquot was 
taken and deproteinated with two parts of ice-cold acetonitrile. The samples were shaken for 
24 h at 700 rpm. Afterwards, they were centrifuged for 5 min at 13.000 g. Finally, 60 µL of the 
supernatant were diluted 1:5 with 0.05 % aq. TFA and filtered (Phenex-NY 4 mm Syringe 
Filters 0.2 µm; Phenomenex; Aschaffenburg, Germany). Prior to HPLC analysis the samples 
were stored at -20 °C. HPLC analysis was performed as described before (cf. section 3.5.1) 
(column: Eurospher-100). Gradient mode: MeCN/TFA (0.05%) (v/v) 0 min: 10:90, 30 min: 
60/40, 31-41 min: 80:20; flow rate = 0.75 mL/min. 
 
3.5.3.6 Plasma protein binding 
3.5.3.6.1 Recovery after equillibrium dialysis                                                                                                    
Dialysis was performed with DispoEquilbrium Dialyzer with a molecular weight cut off of 5000 
Da (Harvard Apparatus, Hollliston, USA). Recoveries tests were determined as follows: The 
compounds were diluted in PBS (pH 7.4) to a final concentration of 200 µM. 70 µL of this 
solution were added to the sample chamber. The second chamber was filled with PBS. The 
samples were shaken at 500 rpm and incubated at 37 °C for 24 h. Afterwards, the amount of 
compound in both samples was determined by HPLC analysis. HPLC analysis was 
performed as described before (cf. section 3.5.1) (column: Eurospher-100). Gradient mode: 
MeCN/TFA (0.05%) (v/v) 0 min: 10:90, 30 min: 60/40, 31-41 min: 80:20; flow rate = 0.75 
mL/min.  
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3.5.3.6.2 Ultrafiltration 
Ultrafiltration was performed with Nanosep® Centrifugal Devices (modified polyethersulfone 
membrane) from Pall GmbH (Dreieich, Germany) with a molecular weight cut off of 10000 
Da. Prior to plasma protein binding studies, recovery studies were performed. Therefore, 250 
µL of a 100 µM test solution in PBS were incubated in the centrifugal devices at 37 °C for 
one hour. After centrifugation (10 min, 16.000 g), 40 µL of this solution were analyzed by 
analytical HPLC. Moreover, 40 µL of the non-incubated solution were analyzed by HPLC, 
and the two peak areas were compared. Plasma protein binding was performed with a 
solution of 600 µM BSA (analytical grade, Sigma Aldrich) in PBS. The test compounds were 
diluted in the BSA solution to a final concentration of 100 µM. This mixture was incubated in 
the centrifugal devices at 37 °C for one hour. Thereafter, it was centrifuged (10 min, 16.000 
g) and 40 µL of the filtrate were analyzed by analytical HPLC. HPLC analysis was performed 
as described before (cf. section 3.5.1) (column: Eurospher-100). Gradient mode: MeCN/TFA 
(0.05%) (v/v) 0 min: 10:90, 15 min: 35/65; flow rate = 0.75 mL/min.  
 
3.5.3.7 Crystal violet based chemosensitivity assay 
The assay was performed as previously described.41 Accordingly, HEK293T cells in DMEM 
were seeded into 96 well plates (Greiner, Frickenhausen, Germany) at a density of 15 cells 
per microscopic field (magnification: 320-fold). The cells were allowed to attach overnight, 
and the test compounds were added at the desired concentrations. As a control, cells were 
treated with medium containing only the respective solvent. After various incubation periods 
the cells were fixed with 1 % glutardialdehyde solution and stored at 4 °C. At the end of the 
assay, cells were stained with crystal violet. Prior to measurement, excess dye was removed 
by washing the cells with water, and cell-bound dye was extracted with 70 % EtOH. 
Absorbance was measured at 580 nm using a GENios Pro microplate reader (Tecan, 
Salzburg, Austria). Drug effects were expressed as corrected T/C- values, according to 
following equation: 
 


	. 	% = 	
 − 
 − 
	× 100 
 
Where T = mean absorbance of treated cells, C = mean absorbance of controls and C0 = 
mean absorbance of the cells when the test compounds were added (t = 0). 
When the absorbance was less than that at t = 0, the cytocidal effect was calculated 
according to following equation: 
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4.1 Introduction 
The histamine H1R is a GPCR that interacts with Gαq proteins to activate PLC. The activation 
of PLC results in the formation of IP3 and subsequent mobilization of intracellular Ca2+.1 It is 
worth mentioning that in some tissues histamine is capable of stimulating receptor independent 
inositol phospholipid hydrolysis.2-5 The H2R canonically couples to the Gαs protein, resulting in 
an increase in intracellular cAMP due to the activation of AC.1 In addition to activation of PLC 
and AC, respectively, both receptors have been reported to trigger differential signaling 
pathways.6-8  
In several cells, histamine induces an increase in intracellular Ca2+ mediated by the H2R.6 It 
was shown, for example in HL-60 promeylocytes that the histamine mediated Ca2+ signal was 
predominantly induced by the H2R.8 Another study on transfected rat hepatoma cells reported 
that the H2R is linked to both, the adenylate cyclase and the [Ca2+]i signaling system.9 
In addition to the inositol phospholipid pathway, the H1R is known to activate other signaling 
pathways. In this context it was shown that stimulation of the H1R in CHO and HEK293 cells 
led to an increase in cAMP.7,10,11 Furthermore, Fitzsimons et al. demonstrated that an activation 
of the H1R increased cAMP levels in benign papilloma in mice.12 
In order to investigate differences in H1R- and H2R signaling, HEK293T cells were genetically 
engineered, stably expressing the firefly luciferase under the control of a cAMP response 
element (CRE) and the hH1R or the hH2R, respectively. The transfectants were investigated in 
functional assays that allowed for the identification of the underlying pathways.  
Alternative signaling pathways resulting in CRE binding protein (CREB) phosphorylation are 
shown in Fig. 4.1. 
 
 
 
Figure 4.1. Alternative signaling pathways resulting in the phosphorylation of the cAMP response element binding 
protein (CREB). 
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4.2 Materials and Methods 
All chemicals were from commercial suppliers. The Gαq inhibitor UBO-QIC was from the 
Institute of Pharmaceutical Biology in Bonn (Germany), and the stock solution (10 mM) was 
prepared in DMSO. Pertussis toxin (PTX) was from List. Biologicals (Campbell, USA) (stock 
solution: 0.5 µg/µL in water), Rp-cAMP-S, Rp-8-Br-cAMP-S (stock solutions: 10 mM in water) 
and gallein (stock solution: 10 mM in DMSO) were from Santa Cruz Biotechnology 
(Heidelberg, Germany) and forskolin (stock solution: 10 mM in DMSO) was from Sigma 
Aldrich (Taufkirchen, Germany). The Lance®cAMP assay kit was from Perkin Elmer (Boston, 
USA). 
 
4.2.1 Cell culture 
HEK293T CRE Luc cells stably expressing either the hH1R or the hH2R were cultured in 
Dulbecco`s Modified Eagle Medium (DMEM) (Sigma-Aldrich) containing L-glutamine (Sigma-
Aldrich), 4500 mg/L glucose, 3.7 g/L NaHCO3 (Merck, Darmstadt, Germany), 110 mg/L 
sodium pyruvate (Serva, Heidelberg, Germany), 10 % fetal calf serum (FCS) (Biochrom, 
Berlin, Germany) and the selection antibiotics G418 (600 µg/mL) (Biochrom) and hygromycin 
b (250 µg/mL) (MoBiTec GmbH, Göttingen, Germany). DMEM for cells expressing mtAeq 
contained additional zeocin (400 µg/mL) (InvivoGen SAS, Toulouse, France). Cells were 
incubated in culture flasks from Sarstedt (Nümbrecht, Germany) at 37 °C in water saturated 
atmosphere containing 5 % CO2. For passaging, the cells were treated with 0.05 % trypsin / 
0.02 % EDTA (PAA, Pasching, Austria) in phosphate buffered saline (KCl 2.7 mM; KH2PO4 
1.5 mM; NaCl 137 mM; Na2HPO4 5.6 mM; NaH2PO4 1.1 mM in Millipore water, pH 7.4, all 
chemicals were from Merck). After detachment, the cells were resuspended in 5 mL DMEM, 
the suspension was centrifuged (10 min, 300 g) and the cells were diluted with fresh medium 
twice a week.  
 
4.2.2 Stable transfection of HEK293T CRE Luc cells with the pcDNA3.1(+)-
hH1R vector 
The pcDNA3.1(+)-hH1R vector was from Missouri S&T cDNA Resource Center (Rolla, USA). 
The parental HEK293T CRE Luc cell line was kindly provided by Dr. Uwe Nordemann.13 One 
day before transfection, the cells were detached with 5 mL trypsin and 5 mL DMEM 
supplemented with 10 % FCS. The suspension was centrifuged (300 g, 10 min) and 
resuspended in medium. Afterwards, 2 mL of the cell suspension were seeded into a 6-well 
flat bottom plate (Sarstedt, Nümbrecht, Germany) at a density of 500,000 per mL. The next 
day, prior to transfection, the plasmid was linearized with PvuI (New England Biolabs, 
Frankfurt am Main, Germany) for 2 h at 37 °C. The linearized vector was purified with a PCR 
purification KIT (Quiagen, Leipzig, Germany) according to the manufacturer’s instructions. An 
amount of 2 µg of DNA was diluted with serum-free DMEM, and 6 µL of the transfection kit 
FuGene HD (Roche Diagnostics GmbH, Mannheim, Germany) were added. After vortexing, 
the mixture was incubated for 15 min before it was added to the cells. The medium was 
removed after 32 h, and the cells were pooled into a 25-cm2 culture flask with DMEM 
containing 10 % FCS and hygromycin b. After another 24 h, the medium was replaced by 
fresh medium, supplemented with G418.  
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4.2.3 Stable transfection of HEK293T CRE Luc cells with the pcDNA3.1(+)-
hH2R vector 
The transfection was performed according to section 4.2.2. The pcDNA3.1(+)-hH2R vector 
was from Missouri S&T cDNA Resource Center (Rolla, USA). 
 
4.2.4 Stable transfection of HEK293T CRE Luc hH1R cells with the 
pcDNA3.1(-)mtAEQ plasmid 
The transfection was performed according to section 4.2.2 with minor modifications. The 
medium was removed 24 h after transfection, and the cells were pooled in a 75-cm2 culture 
flask with DMEM + 10 % FCS. Selection was started the next day by adding medium 
containing hygromycin, G418 and zeocin. The pcDNA3.1(-)mtAEQ vector was kindly 
provided by Dr. Ralf Ziemek.14 
 
4.2.5 Stable transfection of HEK293T CRE Luc hH2R cells with the 
pcDNA3.1(-)mtAEQ vector 
The transfection was performed according to section 4.2.2. 
 
4.2.6 Stable transfection of HEK293T CRE Luc-SF-hH4R-His6 with 
pGL4.29[luc2P/CRE/Hygro] plasmid 
The cells were kindly provided by Dr. Uwe Nordemann.13 
 
4.2.7 Whole cell radioligand binding assay 
The whole cell radioligand binding assay was performed as described previously15 with minor 
modifications. Cells were grown in a 75-cm2 flask to a confluency of around 80 %. They were 
detached with 5 mL of trypsin and resuspended in 5 mL of Leibovitz´s L15 medium 
(Invitrogen, Darmstadt, Germany). After centrifugation, the cells were resuspended in 
Leibovitz´s L15 at a density between 1.0 mio – 2.25 mio per mL. In case of the H1R, 
unspecific binding was detected in the presence of 3 µM azelastine. As radioligand 
[3H]mepyramine (specific activity: 20 Ci mmol-1) (Hartmann Analytics, Braunschweig, 
Germany) was used. For saturation binding experiments performed with HEK CRE Luc hH2R 
cells, unspecific binding was detected in the prescence of 10 µM famotidine and [3H]UR-
DE257 (specific activity: 63 Ci mmol-1)16 was used as radioligand. For economic reasons, 
[3H]UR-DE257 was diluted with unlabeled UR-DE257. Samples were completed by adding 
80 µL of the cell suspension. The plates were shaken at 250 rpm at room temperature for 60 
min. After the incubation period, unbound radioligand was separated by filtration through PEI 
coated GF/C filters using a 96-well Brandel harvester (Brandel Inc., Unterföhring, Germany). 
After two washing steps with cold binding buffer, filter pieces were punched out and 
transferred into 96-well sample plates 1450-401 (Perkin Elmer, Rodgau, Germany). Each 
well was supplemented with 200 µL of scintillation cocktail (Rotiscint Eco plus, Roth, 
Karlsruhe, Germany). The plate was sealed with permanent plateseal (Perkin Elmer, 
Rodgau, Germany) and incubated in the dark for 12 h. Radioactivity was measured with a 
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Micro Beta2 1450 scintillation counter (Perkin Elmer, Rodgau, Germany). Data were 
analyzed with GraphPadPrism 5, and specific binding was calculated by subtraction of non-
specific binding from the total binding. 
 
4.2.8 Luciferase reporter gene assay 
The assay was performed as previously described with minor modifications.13 One day prior 
to the experiments, the cells were adjusted to a density of approximately 800,000 per mL in 
DMEM without phenol red (Sigma Aldrich) supplemented with 5 % FCS. 160 µL of the cell 
suspension were seeded into flat bottom 96-well plates (Greiner, Frickenhausen, Germany) 
per well. In case of pertussis toxin (PTX), the cell suspension contained 0.5 µg/mL of PTX. 
The cells were allowed to attach overnight. After addition of 20 µL of the respective inhibitor, 
the cells were pre-incubated for 2 hours (UBO-QIC and gallein) or one hour (Rp-cAMP-S and 
Rp-8-Br-cAMP-S), respectively, at 37 °C and in water saturated atmosphere containing 5 % 
CO2. Afterwards, 20 µL of a 10 fold concentrated histamine solution were added, and the 
cells were incubated for another 5 h. All wells contained the same amount of DMSO or water.  
The medium was discarded, and 80 µL of lysis buffer (25 mM Tricine (Sigma Aldrich); 
Glycerol 10 % (v/v) (Merck); EGTA, 2 mM (Sigma Aldrich); 1 % (v/v) TritonTM X-100 (Serva); 
MgSO4 × 7 H2O, 5 mM (Merck); DTT, 1 mM (Sigma), the pH was adjusted to 7.8 with HCl) 
were added to each well. The plates were shaken at 600 rpm for 15 min. Afterwards, 40 µL 
of the lysate were transferred into white 96-well plates (Greiner, Frickenhausen, Germany). 
Luminescence was measured with a GENios Pro microplate reader (Tecan, Salzburg, 
Austria). Light emission was induced by injecting 80 µL of the assay buffer (25 mM Gly-Gly, 
(Sigma Aldrich); MgSO4 × 7 H2O, 15 mM; KH2PO4, 15 mM (Merck); EGTA, 4 mM; ATP 
disodium salt, 2 mM (Sigma Aldrich); DTT, 2 mM; D-luciferin potassium salt, 0.2 mg/mL 
(Synchem, Felsberg, Germany); pH was adjusted to 7.8 with HCl). Luminescence [RLU] was 
measured for 10 s. The data were analyzed with GraphPadPrism 5 and best fitted to 3-
parameters sigmoidal concentration-response curves. pKb values were calculated according 
to the Cheng-Prusoff equation.17 
 
4.2.9 Fura-2 Ca2+ assay 
The assay was performed as described previously.18 After detachment of the cells with 
trypsin/EDTA and DMEM, the cells were centrifuged at 300 g for 10 min. The medium was 
discarded, and the cells were counted. To three volumes of the cell suspension, prepared in 
loading buffer (HEPES (Serva), 25 mM; NaCI, 120 mM; KCl, 5 mM; MgCI2, 2 mM; CaCl2,1.5 
mM; glucose 10 mM; pH was adjusted to 7.4), one volume of loading dispersion (1 mLof 
loading dispersion contained: 2 % BSA (Serva); 5 µL of Pluronic (Sigma); 4 µL of Fura-2 
(VWR, Ismaning, Germany) was added, so that the final cell density was 1.0 mio cells per 
mL. The suspension was incubated in the dark for 30 min. Thereafter, the suspension was 
centrifuged, the cells were resuspended in loading buffer and allowed to stand in the dark for 
another 30 min. The cells were washed twice with loading buffer and adjusted to a final 
density of 1.0 mio cells per mL. The assay was performed either in acrylic cuvettes (VWR) 
using an LS50 B spectrofluorimeter (Perkin Elmer)18 or in transparent 96-well microplates 
(Greiner) using a GENios Pro microplate reader.15 Assays in the antagonist mode were 
always performed in cuvettes, and the cells were preincubated with the respective antagonist 
for 15 min. The data were analyzed with GraphPadPrism 5 and were best fitted to 3-
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parameter sigmoidal concentration-response curves. pKb values were calculated according 
to the Cheng-Prusoff equation.17  
 
4.2.10 Aequorin assay 
The assay was performed as described previously.14 Cells were detached with trypsin/EDTA 
and DMEM without phenol red and centrifuged at 300 g for 10 min. Thereafter, they were 
adjusted to a density of 10 mio per mL in DMEM without phenol red, and coelenterazin 
(Biotrend, Köln, Germany) was added, so that the final concentration was 2 µM. The 
suspension was incubated in the dark for 2 h. The cell suspension was diluted 1:20 with 
loading buffer (cf. 4.2.9), and the suspension was incubated in the dark under gentle stirring 
for additional 3 h. In the agonist mode, 18 µL (10-fold concentrated) of the test compound 
(diluted in loading buffer) were added in a white 96-well plate (Greiner), and luminescence 
was measured for 43 s with a GENios Pro microplate reader by injecting 162 µL of the cell 
suspension. Subsequently, 20 µL of a 1 % Triton 100-X solution was injected, and light 
emission was recorded for additional 22 s. In the antagonist mode, 2 µL (100-fold 
concentrated) of the respective antagonist were incubated with 178 µL of the cell suspension 
for 15 min. Luminescence was measured by injecting 20 µL of agonist solution (10-fold 
concentrated) for 43 s and subsequent addition of 20 µL of a 1 % Triton X-100 for additional 
22 s. The fractional luminescence was calculated by dividing the area of the first peak 
(injection of the cell suspension, respectively agonist solution) by the sum of the total area of 
peak 1 and peak 2 (Triton X-100 injection) using Sigma Plot 11.0 software. The data were 
analyzed with GraphPadPrism 5 and were best fitted to 3-parameter sigmoidal 
concentration-response curves. pKb values were calculated according to the Cheng-Prusoff 
equation.17 
 
4.2.11 cAMP assay  
The Lance cAMP assay was performed according to the manufacturer´s (Perkin Elmer, 
Rodgau, Germany) instruction with minor modifications. The kit contains a Europium complex 
and a cAMP-specific antibody labeled with an Alexa dye. Furthermore, the kit includes 
biotinylated cAMP and cAMP standards. The Europium-labeled cAMP tracer complex is 
formed by the tight interaction between biotin-cAMP and Eu-streptavidin. In this arrangement 
Eu-streptavidin can be excited at wavelengths of 320 or 340 nm and the energy is 
transferred to the Alexa dye. Time-resolved fluorescence energy transfer (TR-FRET) can be 
measured at a wavelength of 665 nm. In the presence of cAMP the FRET emission at 665 
nm will decrease in a concentration dependent manner. 
The cells were detached with trypsin and DMEM + 5 % FCS and were centrifuged (300 g, 10 
min). The cells were washed with PBS + 0.1 % BSA and centrifuged again. The cells were 
resuspended in PBS + 0.1 % BSA + 0.05 mmol/l IBMX (Sigma Aldrich) and adjusted to the 
required cell number (cf. 4.3.1.5.1.2). The antibody was added to the cell suspension (1:100), 
5 µL of the antibody/cell mixture were dispensed into white 96-well plates (Greiner), and 5 µL 
of the test compounds diluted in PBS + 0.1 % BSA were added. Prior to incubation at room 
temperature in the dark for 1 h, the plate was centrifuged at 200 g for 1 min. After 45 min, the 
detection mix was prepared (cf. table 4.1) and incubated for 15 min. Subsequently, the 
samples were completed by adding 5 µL of detection buffer and the plate was incubated in 
the dark for one additional hour.  
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Table 4.1. Preparation of the detection mix 
solution 1 1 µL of Eu-W8044 labeled streptavidin 
(Eu-SA) to 85 µL of cAMP detection buffer 
solution 2 1 µL of biotin-cAMP to 4 µL of detection buffer 
solution 3 5 µL of solution 1 to 615 µL of detection buffer 
(vortex) 
detection mix solution 3 to solution 2 
 
TR-FRET was measured in a GENios Pro microplate reader (instrument settings cf. 
4.3.1.5.1.1). 
 
4.3 Results and Discussion 
4.3.1 Investigation of HEK293T CRE Luc cells expressing the hH1R 
4.3.1.1 Saturation binding assay using HEK293T CRE Luc hH1R cells 
Receptor expression was confirmed by saturation binding assays using whole cells. The 
quantitative analysis of the saturation binding resulted in around 500,000 receptors per cell 
for the HEK293T hH1R (Fig. 4.2A). The obtained Kd value of 7.8 ± 2.8 nM was in the same 
range as data determined on Sf9 membranes.19 The corresponding Scatchard plot was 
linear, indicating that the radioligand binds to a single binding site (Fig 4.2B). 
 
 
 
Figure 4.2. (A) Representative saturation binding experiment on HEK293T CRE Luc hH1R cells, performed in 
triplicate. Non-specific binding of [3H]mepyramine was determined in the presence of 3 µM azelastine. (B) The 
corresponding Scatchard plot of the saturation binding experiment was best fitted by linear regression (r2= 0.95).  
 
 
4.3.1.2 Luciferase reporter gene assay using HEK293T CRE Luc hH1R cells 
Reporter gene assays are available for Gαq/11, Gαi/o and Gαs coupled receptors. Upon 
stimulation of GPCRs, the Gα subunit dissociates from the Gβγ
 
dimer and both of them 
influence second messengers. These second messengers often regulate gene 
transcription.20  
To discriminate between different signaling pathways, HEK293T cells were stably transfected 
with a CRE-linked firefly luciferase and the hH1R or hH2R (cf. section 4.3.2.2), respectively.  
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It is well known that an activation of the cAMP pathway leads to the stimulation of gene 
expression due to the phosphorylation of CREB by PKA.21,22 However, the activation of 
CREB can also be induced in a cAMP independent manner by an increase in the intracellular 
Ca2+ concentration, particularly via Ca2+-calmodulin-dependent kinase (CAM kinase) IV, and 
to a lesser extent, by CAM kinases I and II.23-25 In fact, the activation of the hH1R in HEK293T 
CRE Luc cells by histamine induced an increase in the expression of luciferase (Fig. 4.3A). 
The pEC50 value was 6.87 ± 0.06, which is in good agreement with reported data from 
different assays.26 The response to histamine was inhibited by the H1R antagonist azelastine 
(Fig. 4.3B). The pKb value of azelastine was 8.34 ± 0.08 and in accordance with data from 
other functional assays,27 confirming that the transcription of the luciferase is mediated by the 
H1R (cf. section 5.3.4/5.3.5). 
 
Figure 4.3. Luciferase activity in HEK293T CRE Luc hH1R cells induced by histamine (HIS) (A) and inhibition of 
the HIS signal by azelastine (B). The response was normalized to the maximal effect induced by HIS. Data are 
means ± SEM of 3-4 independent experiments, each performed in triplicate. 
 
4.3.1.2.1 Effect of Gαq inhibition on the H1R dependent luciferase activity   
To verify the involvement of Gαq, the selective Gαq inhibitor UBO-QIC, a cyclic depsipeptide 
from Ardisia crenata sims,28 was investigated (Fig 4.4). UBO-QIC is structurally closely 
related to YM254890.28 Presumably, these compounds inhibit the GDP-GTP exchange in 
Gαq.29  
 
  
 
 
 
Figure 4.4. (A) Chemical structure of the Gαq inhibitor UBO-QIC from Ardisia crenata Sims (B) (adopted from 
Wikipedia). 
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In the presence of 1 µM UBO-QIC the concentration-response curve of histamine was 
rightward shifted and the maximal response was reduced by approximately 50 % (Fig. 4.5). 
The depression of the maximum effect of histamine (100 µM) was the same (50 %) in the 
presence of 10 µM UBO-QIC (data not shown), indicating that a further reduction of 
luciferase activity cannot be achieved by UBO-QIC at concentrations >1 µM. These results 
suggest that Gαq-mediated activation of Ca2+-calmodulin-dependent kinases is not the only 
pathway triggered by H1R activation. 
 
 
Figure 4.5. Luciferase activity in HEK293T CRE Luc hH1R cells in the absence and presence of the Gαq inhibitor 
UBO-QIC. The response was normalized to the maximal effect induced by histamine (HIS). Data are means ± 
SEM of 3 independent experiments, each performed in triplicate. 
 
4.3.1.2.2 Effect of pertussis toxin on the H1R dependent luciferase activity 
Besides the inhibition of the ACs, depending on the particular receptor and the cell type, 
activation of the Gi/o family can result in an increase or decrease in the intracellular 
concentration of Ca2+,30  presumably mediated by the βγ subunit. In case of the H4R, it was 
shown that the increase in intracellular Ca2+ was induced via the activation of PLC.31 By 
contrast, the activation of the H3R leads to a decrease in intracellular Ca2+, presumably via 
the inhibition of P/Q-, N-type Ca2+ channels.32,33 
As the inhibition of the H1R mediated luciferase signal by UBO-QIC was incomplete, the 
involvement of the Gi protein was studied with pertussis toxin (PTX). Giα1, Giα2 and Giα3 are 
PTX-sensitive G-proteins, whereas GZα is insensitive to pertussis toxin.34 The A-protomer of 
the toxin ADP-ribosylates the Gαi subunit resulting in uncoupling of the receptor.35,36  
Surprisingly, in HEK293T CRE Luc hH1R cells, the maximum luciferase activity upon 
stimulation by histamine was increased in the presence of PTX (Fig 4.6).   
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Figure 4.6. Luciferase activity in HEK293T CRE Luc hH1R cells in the absence and presence of the Gi inhibitor 
PTX. The response was normalized to the maximal effect induced by HIS. Data are means ± SEM of 3 
independent experiments, each performed in triplicate. 
 
Unraveling the effect of PTX on the luciferase activity in the reporter gene assay is 
complicated due to the fact that both second messengers, Ca2+ and cAMP, are influenced by 
the Gi complex, and have contrary effects on the phosphorylation of CREB. With regard to 
cAMP, an inhibition of Gi is expected to result in an increase in luciferase activity. By contrast 
the influence of Gi inhibition on the intracellular Ca2+ concentration cannot be predicted.  
Indeed, there are hints that coupling of the H1R to Gi proteins in HEK293T CRE Luc cells is 
rather unlikely. Firstly, it was shown that the inhibition of the βγ subunit had no influence on 
the histamine-mediated luciferase expression (cf. section 4.3.1.2.4). In case of Gi 
involvement, one would expect either an increase or a decrease in the luciferase expression 
due to the alteration of the Ca2+ concentration via the βγ dimer. Secondly, a Gi-mediated 
increase in Ca2+ can be excluded, as it was shown that the increase in intracellular Ca2+ is 
only mediated by the Gq protein (cf. section 4.3.1.4).  
In principle, the increased luciferase expression in PTX-treated cells might reflect a certain 
constitutive activity of Gαi proteins. If so, inhibition of those proteins is expected to result in 
an increase in cAMP production, i. e., the basal luciferase activity of PTX-treated cells should 
be higher than the basal value of untreated cells. However, this does not apply for this 
experiment.  
A more likely explanation for the increased maximum effect in the luciferase assay is that 
PTX influences cellular responses in a Gi protein independent manner. For example, PTX is 
known to induce an increase in the cytoplasmic Ca2+ concentration.36-39  
Regardless of the possible explanation discussed above, coupling of the H1R to Gi proteins 
in HEK293T CRE Luc cells cannot be ruled out. 
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In order to verify that PTX was used at a sufficiently high concentration, HEK293T CRE Luc 
hH4R13 cells were treated 0.5 µg/ml with PTX. The next day, the PTX-intoxicated cells were 
stimulated with forskolin (FSK) (Fig 4.7) and histamine, whereas the non PTX-treated cells 
were incubated only with FSK (Fig. 4.8).  
 
 
 
Figure 4.7. Chemical structure of forskolin (FSK),  
a diterpene from Coleus forskohli Briq.40 
 
Figure 4.8. Representative luciferase assay at HEK293T 
CRE Luc hH4R cells in the absence and presence of 
PTX.  Experiment was performed twice in triplicate. 
 
The luciferase expression was in the same range in PTX-treated and untreated cells, 
respectively, indicating that the Gi signaling pathway was completely blocked with PTX at a 
concentration of 0.5 µg/mL. 
 
4.3.1.2.3 Effect of protein kinase A inhibitors on the H1R dependent luciferase activity 
To investigate, whether the H1R is capable of coupling to Gαs proteins, the effect of the 
protein kinase A (PKAI and PKAII) inhibitors Rp-cAMP-S and Rp-8-Br-cAMP-S (Fig. 4.9) was 
studied. 
 
 
 
Figure 4.9. Chemical structures of the PKA inhibitors Rp-8-Br-cAMP-S (A) and Rp-cAMP-S (B). 
 
These inhibitors are cell-permeable cAMP analogs and act as competitive antagonists of 
cAMP by interacting with the cAMP binding site of the PKA.41 Due to rather low affinity, the 
compounds were used at a concentration of 100 µM.  
In the presence of 100 µM Rp-cAMP-S and 100 µM Rp-8-Br-cAMP-S, the maximum 
luciferase signal was reduced by around 50 %. In combination with UBO-QIC the 
transcription of the luciferase was almost completely inhibited (Fig. 4.10), suggesting that the 
luciferase expression is, at least in part mediated by cAMP.  
However, it should be noted that the inhibitors are used at a high concentration, hence their 
selectivity cannot be taken for granted.  
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Figure 4.10. Luciferase assay on HEK293T CRE Luc hH1R cells in the absence and presence of 100 µM Rp-
cAMP-S, 100 µM Rp-8-Br-cAMP-S and 1 µM UBO-QIC. The response was normalized to the maximal effect 
induced by HIS. Data are means ± SEM of 2 independent experiments, each performed in triplicate. 
 
4.3.1.2.4 Effect of the Gβγ inhibitor gallein on the H1R dependent luciferase activity 
Previously, it was shown that the Gβγ dimer is capable of interacting with effector proteins. 
For instance, Gβγ can interfere with the cAMP pathway by activating AC,42 and it is also 
known to influence intracellular Ca2+ by interacting with PLC and Ca2+ channels.30,32 
The influence of the Gβγ subunit on the phosphorylation of CREB was studied by using 
gallein (Fig. 4.11/4.12). Gallein is supposed to be a reversible inhibitor of Gβγ with a Kd value 
of 422 nM.43  
 
 
Figure 4.11. Chemical structure of the Gβγ  
inhibitor gallein. 
Figure 4.12. Luciferase activity in HEK293T CRE Luc 
hH1R cells in the absence and presence of gallein (20 
µM). The response was normalized to the maximal effect 
induced by HIS. Data are means ± SEM of 2 
independent experiments, each performed in triplicate. 
 
Gallein had no influence on the luciferase assay performed with HEK293T CRE Luc hH1R 
cells, suggesting that the Gβγ dimer is not involved in the phosphorylation of CREB.  
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4.3.1.3 Investigation of hH1R expressing HEK293T cells in the fura-2 assay  
Changes in Ca2+ levels can be measured in a fura-2 assay. Fura-2 is a fluorescent dye that 
shows a shift of the excitation maximum upon binding of Ca2+ ions. Accordingly, this assay 
was used to verify whether the hH1R and the hH2R (cf. section 4.3.2.3), respectively, induce 
a Ca2+ signal upon stimulation.  
As expected due to Gαq coupling, the stimulation of the hH1R in HEK293T CRE Luc cells by 
histamine led to an increase in intracellular Ca2+ in a concentration dependent manner (Fig. 
4.13A). Histamine was about 10 times more potent (pEC50 = 7.34 ± 0.11) than on cells 
natively expressing the H1R, e.g. U373-MG cells. The histamine induced Ca2+ response was 
antagonized by H1R antagonist diphenhydramine (pKb = 7.37 ± 0.17) (Fig. 4.13B). 
 
Fig 4.13. (A) Intracellular increase in Ca2+ in HEK293T CRE Luc hH1R cells induced by histamine. (B) Inhibition 
of the histamine induced signal by diphenhydramine. The response was normalized to the maximal effect induced 
by HIS. Data are means ± SEM of 2-4 independent experiments, each performed in triplicate. 
 
 
 
4.3.1.4 Investigation of hH1R expressing HEK293T cells in the aequorin assay 
The aequorin assay is another assay to measure changes in the intracellular Ca2+ 
concentration. For this purpose, the HEK293T CRE Luc cells, expressing the hH1R or the 
hH2R (cf. section 4.3.2.4), were additionally transfected with mitochondrially targeted 
apoaeqorin (mtAEQ). The advantage of the aequorin assay in comparison to the fura-2 
assay is that the cells can be easily pre-incubated with the desired receptor antagonist or 
inhibitor of signaling. Previously, it was shown that cytoplasmatically and mitochondrially 
expressed apoaeqorin provide the same functional data.44 
In agreement with the fura-2 assay, the stimulation of the hH1R in HEK293T CRE Luc cells 
by histamine led to an increase in intracellular Ca2+ (pEC50 6.94 ± 0.15) (Fig. 4.14A). As 
expected, the histamine induced signal was antagonized by mepyramine (Fig. 4.14B).  
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Fig 4.14. (A) Aequorin assay on HEK293T CRE Luc hH1R cells with histamine ([Ca2+]m = mitochondrial calcium 
concentration). (B) Inhibition of the Ca2+ signal by mepyramine. The response was normalized to the maximal 
effect induced by HIS. Data are means ± SEM of 4 independent experiments, each performed in triplicate. 
 
When the cells were treated with UBO-QIC (1 µM) prior to stimulation of the H1R, the Ca2+ 
signal was completely blocked (Fig 4.15), confirming Gαq coupling of the hH1R. 
 
Fig 4.15. Aequorin assay on HEK293T CRE Luc hH1R cells in the presence and absence of the Gαq inhibitor 
UBO-QIC ([Ca2+]m = mitochondrial calcium concentration). The response was normalized to the maximal effect 
induced by HIS. Data are means ± SEM of 2 independent experiments, each performed in triplicate. 
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4.3.1.5 Investigation of hH1R expressing HEK293T cells in a cAMP assay 
The transfected cells were investigated in view of their ability to induce a cAMP signal upon 
stimulation of the respective receptor, using a Lance®cAMP assay from Perkin Elmer. The 
principle of the assay is shown in Fig 4.16.  
 
 
 
Fig 4.16. Principle of the Lance cAMP assay 
 
4.3.1.5.1 Optimization of cAMP assay parameters 
4.3.1.5.1.1 Instrument settings of the GENios Pro microplate reader 
Appropriate instrument settings of the microplate reader were determined by registering a 
cAMP standard curve (Fig. 4.17). For this purpose, cAMP standards were incubated for one 
hour in the dark with antibody solution (1:100). Thereafter, detection buffer was added, and 
the samples were incubated for an additional hour. Afterwards, the TR-FRET was measured 
at the microplate reader. 
Instrument settings: excitation wavelength 
340 nm (+/- 10 nm), emission wavelength 
670 nm (+/- 25 nm), mirror: dichroic 3, lag 
time: 50 µs, integration time: 2·103 µs, 
optimal gate. 
  
The pEC50 value of cAMP determined in 
this experiment was 8.67 ± 0.04, which was 
in perfect agreement with the pEC50 values 
indicated by Perkin Elmer (pEC50 8.43 – 
8.66).  
 
 
 
 
Figure 4.17. cAMP standard curve obtained with the 
Lance cAMP assay.  
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4.3.1.5.1.2 Optimization of the cell number 
Concentration-response curves of forskolin 
were constructed using different numbers 
of HEK293T CRE Luc hH2R cells per well 
(Fig. 4.18). As the highest signal-to-noise 
ratio was obtained with a cell number of 
1000 cells per well, the following assays 
were performed accordingly.  
 
 
 
4.3.1.5.1.3 cAMP assay on HEK293T CRE Luc hH1R cells 
Unfortunately, it was impossible to produce a cAMP signal upon stimulation of the H1R 
probably due to the low signal-to-noise ratio in this assay. Even if there is evidence to 
suggest that the H1R is capable of inducing a cAMP signal after stimulation (cf. section 
4.3.1.2.3), it should be taken into account that there might be another pathway involved in 
the phosphorylation of CREB.  
 
4.3.2  Investigation of HEK293T CRE Luc cells expressing the hH2R 
4.3.2.1 Saturation binding assay using HEK293T CRE Luc hH2R cells 
Receptor expression was verified by saturation binding assays. The quantitative analysis of 
the saturation binding resulted in around 2.5 million receptors per cell (Fig. 4.19A). The Kd 
value of 54.9 ± 8.1 nM for [3H]UR-DE257 was in the same range as data determined on Sf9 
membranes.16 The corresponding Scatchard plot was linear, indicating that the radioligand 
binds to a single binding site (Fig 4.19B). 
 
 
 
Figure 4.19. (A) Representative saturation binding experiment on HEK293T CRE Luc hH2R cells, performed in 
triplicate. Non-specific binding of [3H]UR-DE257 was determined in the presence of 10 µM famotidine. The 
radioligand was diluted 1:20 with unlabeled UR-DE257. (B) The corresponding scatchard plot of the saturation 
binding experiment was best fitted by linear regression (r2 = 0.90). 
 
 
Figure 4.18. Concentration-response curves of FSK on 
HEK293T CRE Luc hH2R cells as a function of cell 
number. 
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4.3.2.2 Luciferase reporter gene assay using HEK293T CRE Luc hH2R cells 
Agonist binding to a Gs-coupled receptor results in an increase in intracellular cAMP and 
hence in the activation of PKA. Subsequently, the catalytic unit of PKA enters the nucleus 
and phosphorylates CREB. Upon phosphorylation, CREB binds to CRE and activates the 
transcription of luciferase.22  
In the luciferase reporter gene assay the hH2R revealed high constitutive activity, probably 
due to a very high expression level of the receptor (2.5 million receptors per cell, cf. section 
4.3.2.1). The high basal levels were reduced by adding different concentrations of FSK, 
presumably via the activation of the inducible cyclic AMP early repressor (ICER). In this 
setting, histamine amplified the luciferase signal (Fig. 4.20), suggesting that this is not a 
cAMP-mediated response, but rather a Ca2+ mediated effect. It was recently shown that in 
certain cell lines, the cAMP response element modulator (CREM) expression was mediated 
by cAMP.45 The translation product of a short isoform of CREM is termed ICER. ICER binds 
to CRE and acts as a potent repressor of gene transcription.46  
 
Figure 4.20. Luciferase activity in HEK293T CRE Luc hH2R using different concentrations of forskolin. The 
response was normalized to the maximal effect induced by HIS. Data are means ± SEM of 5 independent 
experiments, each performed in triplicate. 
 
In an approach to reduce the constitutive activity of the H2R, the standard antagonists 
famotidine, ranitidine and cimetidine were investigated. All three compounds tested acted as 
inverse agonists (Fig 4.21). The pEC50 values were in the same order of magnitude as the 
pKi values reported,15 suggesting that the luciferase expression was mediated by the H2R. 
 
Figure 4.21. Inverse agonistic effect of famotidine, ranitidine and cimetidine in the luciferase reporter gene assay 
at HEK CRE Luc hH2R cells. Data are means ± SEM of 3 independent experiments, each performed in triplicate. 
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Due to the high constitutive activity of the H2R in this assay system, the signal-to-noise ratio 
was very poor (cf. Fig. 4.20). However, partial inhibition of the receptors with famotidine 
reduced the constitutive activity and allowed for the activation of the receptor with histamine 
(Fig 4.22). 
 
Figure 4.22. Comparison of the signal-to-noise ratio in the absence and presence of 100 nM famotidine.   
Results shown are representative data. 
 
4.3.2.2.1 Effect of Gαq inhibition on the H2R dependent luciferase activity   
To verify the hypothesis that the expression of luciferase is in part mediated by Ca2+, and to 
clarify, if the Ca2+ signal is triggered by IP3, the influence of the Gαq inhibitor UBO-QIC was 
investigated (Fig 4.23). 
 
Figure 4.23. Luciferase activity in HEK293T CRE Luc hH2R cells in the absence and presence of the Gαq 
inhibitor UBO-QIC. The response was normalized to the maximal effect induced by HIS. Data are means ± SEM 
of 3 independent experiments, each performed in triplicate. 
 
Interestingly, in the presence of 1 µM of the Gαq protein inhibitor UBO-QIC the maximal 
response was reduced by approximately 35 % and the curve was rightward-shifted, 
suggesting Gαq to be involved in the H2R stimulated luciferase expression. Increasing the 
inhibitor concentration to 10 µM did not result in a further reduction of the maximal response 
(data not shown). 
 
4.3.2.2.2 Effect of protein kinase A inhibitors on the H2R stimulated luciferase activity 
Supposed that the H2R is capable of coupling to Gαs and Gαq proteins, the luciferase 
expression should be completely inhibited in the presence of both, a Gαq inhibitor UBO-QIC 
and a PKA inhibitor such as Rp-cAMP-S or Rp-8-Br-cAMP-S. Therefore, the HEK293T CRE 
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Luc hH2R cells were pre-incubated with the respective inhibitors and afterwards stimulated 
with 100 µM histamine (Fig. 4.24).  
 
 
Figure 4.24. Luciferase activity in HEK CRE Luc hH2R cells in the presence or absence of Rp-cAMP-S, Rp-8-Br-
cAMP-S and UBO-QIC. The response was normalized to the maximal effect induced by HIS. Data are means ± 
SEM of 3 independent experiments, each performed in duplicate or triplicate. Increasing the signal-to-noise ratio 
was achieved by accessorily adding 100 nM famotidine. 
 
In the presence of 100 µM Rp-cAMP-S and Rp-8-Br-cAMP-S, the luciferase signal was 
reduced by around 44 %. Cells additionally treated with UBO-QIC showed no complete 
inhibition, but 32 % of the luciferase expression compared to the control, suggesting   
pathways other than the Gαq and Gαs mediated ones to be involved as well. 
4.3.2.2.3 Effect of pertussis toxin on the H2R stimulated luciferase activity 
To further investigate, whether the Ca2+ signal is at least, in part, mediated by Gi, the effect of 
PTX was studied (Fig 4.25).  
 
 
Figure 4.25. Luciferase activity in HEK293T CRE Luc hH2R cells in the absence and presence of the Gαi 
inhibitor PTX.  The response was normalized to the maximal effect induced by HIS in the absence of PTX. Data 
are means ± SEM of 2 independent experiments, each performed in triplicate. The high constitutive activity of the 
hH2R in HEK CRE Luc cells was reduced by accessorily adding 100 nM famotidine into each well. 
 
 
In agreement with the inhibition of the Gαi subunit in HEK293T CRE Luc hH1R cells (cf. 
section 4.3.1.2.2), the transcription of luciferase was higher in PTX-intoxicated cells 
compared to the non-pertussis treated cells.  
A reason for the increased luciferase expression in PTX-treated cells may be the PTX- 
mediated increase in intracellular Ca2+ (cf. section 4.3.1.2.2).36-39 
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4.3.2.2.4 Effect of the Gβγ inhibitor gallein on the H2R dependent luciferase activity 
 
To investigate the contribution of Gβγ  to 
the hH2R stimulated luciferase activity, 
the cells were pre-incubated with gallein 
(Fig 4.26). 
Gallein did not significantly influence the 
transcription of luciferase, suggesting 
that the Gβγ subunits are not involved in 
CREB phosphorylation.  
 
 
 
 
 
4.3.2.3 Investigation of hH2R expressing HEK293T cells in the fura-2 assay  
Indeed, the activation of the hH2R resulted in a Ca2+ signal as well (Fig. 4.27A). The pEC50 
value of histamine of 5.89 ± 0.11 was perfectly in agreement with the pEC50 value for 
histamine obtained with HEK293-hH2R-qs5 cells in the fura-2 assay.15 The effect of 
histamine was completely suppressed by famotidine (Fig. 4.27B), confirming that the Ca2+ 
response was mediated by the H2R. 
 
Fig 4.27. (A) Intracellular increase in Ca2+ in HEK293T CRE Luc hH2R cells induced by HIS. (B) Inhibition of the 
HIS induced signal by famotidine. The response was normalized to the maximal effect induced by HIS. Data are 
means ± SEM of 4 independent experiments, each performed in triplicate (A); inhibition with famotidine was only 
performed once. 
 
4.3.2.4 Investigation of hH2R expressing HEK293T cells in the aequorin assay 
The stimulation of the H2R in HEK293T CRE Luc cells by histamine led to an increase in 
intracellular Ca2+ in a concentration dependent manner (pEC50 5.47 ± 0.13) (Fig. 4.28A). 
Unfortunately, the signal-to-noise ratio was very low. Nevertheless, it was possible to 
antagonize the histamine induced Ca2+ response by famotidine (Fig 4.28B). 
 
Figure 4.26. Luciferase activity in HEK293T CRE Luc hH2R 
cells in the absence and presence of gallein (20 µM). The 
response was normalized to the maximal effect induced by 
HIS. Data are means ± SEM of 3 independent experiments, 
each performed in triplicate. 
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Fig 4.28. (A) Aequorin assay on HEK293T CRE Luc hH2R cells with HIS ([Ca2+]m = mitochondrial calcium 
concentration). (B) Inhibition of the Ca2+ signal by famotidine. The response was normalized to the maximal effect 
induced by HIS. Data are means ± SEM of 3-4 independent experiments, each performed in triplicate. 
 
In the presence of UBO-QIC, the H2R mediated Ca2+ signal was completely blocked (Fig. 
4.29). These data suggest that the H2R, at least in genetically engineered cells, is capable of 
activating Gαq proteins. 
 
Fig 4.29. Aequorin assay on HEK293T CRE Luc hH2R cells in the presence and absence of the Gαq inhibitor 
UBO-QIC ([Ca2+]m = mitochondrial calcium concentration). The response was normalized to the maximal effect 
induced by HIS. Data are means ± SEM of 2 independent experiments, each performed in triplicate. 
 
 
4.3.2.5 Investigation of hH2R expressing HEK293T cells in a cAMP assay 
 
As expected, the activation of the H2R led 
to an increase in intracellular cAMP in a 
concentration dependent manner (Fig 
4.30). The pEC50 value determined for 
histamine was 8.32 ± 0.13 corresponding to 
more than 100 times higher potency 
compared to other assays. This 
discrepancy may be attributed to the very 
high H2R expression level. Recently, it was 
reported that the pEC50 value, obtained in a 
cAMP assay on hH2R transfected HEK cells 
strongly depends on the receptor density.7  
 
Figure 4.30. cAMP assay on HEK293T CRE Luc hH2R 
cells.  The response was normalized to the maximal 
effect induced by HIS. Data are means ± SEM of 3 
independent experiments, each performed in triplicate. 
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4.4 Summary and conclusion 
HEK293T CRE Luc cells were stably transfected with the cDNA encoding the hH1R or the 
hH2R, respectively.  
H1 receptor. The stimulation of the H1R by histamine led to an expression of luciferase, 
presumably via the activation of CAM kinase IV. The inhibition of the Gαq protein with UBO-
QIC resulted in a reduction, but not in a complete inhibition of luciferase expression. In the 
presence of a combination of the Gαq inhibitor and PKA inhibitors (Rp-cAMP-S or Rp-8-Br-
cAMP-S), the luciferase transcription was almost completely inhibited. PTX increased the 
luciferase activity. Unfortunately, this effect could not be analyzed in detail due to the high 
complexity of cell signaling and crosstalk. A potential contribution of the Gβγ dimer was taken 
into account. However, the Gβγ inhibitor gallein did not show any effect in the luciferase 
reporter gene assay. Additionally, as demonstrated in an aequorin assay, the H1R mediated 
increase in intracellular Ca2+ is completely blocked by UBO-QIC and, thus, only mediated by 
Gαq. A quantitative detection of a cAMP signal in the LANCE cAMP assay failed, probably  
due to a low signal-to-noise ratio. It cannot be ruled out that the activation of the hH1R in 
genetically modified HEK293T cells is associated with additional pathways.  
H2 receptor. The investigation of the HEK293T CRE Luc hH2R cells revealed that the H2R is 
capable of activating Gαq, at least in H2R overexpressing cells. The luciferase expression 
was reduced in the presence of UBO-QIC. Additionally, inhibiting PKAI and PKAII resulted in 
a further decrease in the luciferase transcription. The hypothesis that the H2R additionally 
activates Gαq is supported by the results of fura-2 and aequorin assays, where histamine 
induced a Ca2+ signal. The Ca2+ signal is not mediated by Gαi, but via Gαq, as UBO-QIC 
completely inhibited the Ca2+ response in the aequorin assay. There was no hint to a 
contribution of the Gβγ complex to the transcription of luciferase, as gallein did not induce 
any effect in the luciferase reporter gene assay. It should be taken into consideration that a 
third signaling pathway is involved in the H2R mediated cellular response, most notably 
because it was impossible to entirely inhibit the luciferase expression in the presence of a 
combination of UBO-QIC plus Rp-cAMP-S or Rp-8-Br-cAMP-S. 
In summary, the genetically engineered HEK293T CRE Luc cells transfected with the 
receptor of choice provide a powerful pharmacological toolkit for the investigation of GPCRs 
and functionally selective ligands in a reporter gene assay and enabling the determination of 
both the Ca2+ and the cAMP mediated response (cf. graphical summary in Fig 4.31).  
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Figure 4.31. Genetically engineered HEK293T cells as a versatile assay platform 
 
Furthermore, such cells should be useful with respect to the deconvolution of holistic 
readouts from label-free assays, where the identification of the underlying pathways is a 
major challenge. 
 
  
Chapter 4 
90 
 
4.5 References 
1. Hill, S. J.; Ganellin, C. R.; Timmerman, H.; Schwartz, J. C.; Shankley, N. P.; Young, J. 
M.; Schunack, W.; Levi, R.; Haas, H. L. International Union of Pharmacology. XIII. 
Classification of histamine receptors. Pharmacol. Rev. 1997, 49, 253-278. 
2. Seifert, R.; Hageluken, A.; Hoer, A.; Hoer, D.; Grunbaum, L.; Offermanns, S.; 
Schwaner, I.; Zingel, V.; Schunack, W.; Schultz, G. The H1 receptor agonist 2(3-
chlorophenyl)histamine activates Gi proteins in HL-60 cells through a mechanism that 
is independent of known histamine-receptor subtypes. Mol. Pharmacol. 1994, 45, 
578-586. 
3. Bailey, S. J.; Lippe, I. T.; Holzer, P. Effect of the tachykinin antagonist, [D-Pro4, D-
Trp7,9,10] substance P-(4-11), on tachykinin- and histamine-induced inositol 
phosphate generation in intestinal smooth muscle. Naunyn Schmiedebergs Arch. 
Pharmacol. 1987, 335, 296-300. 
4. Claro, E.; Garcia, A.; Picatoste, F. Histamine-stimulated phosphoinositide hydrolysis 
in developing rat brain. Mol. Pharmacol. 1987, 32, 384-390. 
5. Donaldson, J.; Hill, S. J. Histamine-induced inositol phospholipid breakdown in the 
longitudinal smooth muscle of guinea-pig ileum. Br. J. Pharmacol. 1985, 85, 499-512. 
6. Kuhn, B.; Schmid, A.; Harteneck, C.; Gudermann, T.; Schultz, G. G proteins of the Gq 
family couple the H2 histamine receptor to phospholipase C. Mol. Endocrinol. 1996, 
10, 1697-1707. 
7. Esbenshade, T. A.; Kang, C. H.; Krueger, K. M.; Miller, T. R.; Witte, D. G.; Roch, J. 
M.; Masters, J. N.; Hancock, A. A. Differential activation of dual signaling responses 
by human H1 and H2 histamine receptors. J. Recept. Signal Transduct. Res. 2003, 
23, 17-31. 
8. Seifert, R.; Hoer, A.; Schwaner, I.; Buschauer, A. Histamine increases cytosolic Ca2+ 
in HL-60 promyelocytes predominantly via H2 receptors with an unique 
agonist/antagonist profile and induces functional differentiation. Mol. Pharmacol. 
1992, 42, 235-241. 
9. Delvalle, J.; Wang, L.; Gantz, I.; Yamada, T. Characterization of H2 histamine 
receptor: linkage to both adenylate cyclase and [Ca2+]i signaling systems. Am. J. 
Physiol. 1992, 263, G967-972. 
10. Leurs, R.; Traiffort, E.; Arrang, J. M.; Tardivel-Lacombe, J.; Ruat, M.; Schwartz, J. C. 
Guinea pig histamine H1 receptor. II. Stable expression in Chinese hamster ovary 
cells reveals the interaction with three major signal transduction pathways. J. 
Neurochem. 1994, 62, 519-527. 
11. Sanderson, E. M., Iredale, P.A., Hill, S.J. Role of Ca2+ ions in the stimulation of 
cAMP accumulation by histamine in CHO-K1 cells transfected with the bovine H1-
receptor. (Abstract) 
Br. J. Pharmacol. 1996, 117: 7P. 
12. Fitzsimons, C.; Molinari, B.; Duran, H.; Palmieri, M.; Davio, C.; Cricco, G.; Bergoc, R.; 
Rivera, E. Atypical association of H1 and H2 histamine receptors with signal 
transduction pathways during multistage mouse skin carcinogenesis. Inflamm. Res. 
1997, 46, 292-298. 
13. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; 
Buschauer, A. Luciferase reporter gene assay on human, murine and rat histamine 
H4 receptor orthologs: correlations and discrepancies between distal and proximal 
readouts. PLoS One 2013, 8, e73961. 
14. Ziemek, R.; Schneider, E.; Kraus, A.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, 
G.; Buschauer, A. Determination of affinity and activity of ligands at the human 
neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence. J. Recept. 
Signal Transduct. Res. 2007, 27, 217-233. 
15. Mosandl, J. Radiochemical and luminescence-based binding and functional assays 
for human histamine receptors using genetically engineered cells Doctoral Thesis, 
University of Regensburg 2009. 
Unraveling signaling pathways 
91 
 
16. Baumeister, P.; Erdmann, D.; Biselli, S.; Kagermeier, N.; Elz, S.; Bernhardt, G.; 
Buschauer, A. [3H]UR-DE257: Development of a tritium-labeled squaramide-type 
selective histamine H2 receptor antagonist. ChemMedChem 2015, 10, 83-93. 
17. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem. Pharmacol. 1973, 22, 3099-3108. 
18. Muller, M.; Knieps, S.; Gessele, K.; Dove, S.; Bernhardt, G.; Buschauer, A. Synthesis 
and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted omega-
guanidino- and omega-aminoalkanoic acid amides. Arch. Pharm. (Weinheim) 1997, 
330, 333-342. 
19. Strasser, A.; Striegl, B.; Wittmann, H.-J.; Seifert, R. Pharmacological profile of 
histaprodifens at four recombinant histamine H-1 receptor species isoforms. J. 
Pharm. Exp. Ther. 2008, 324, 60-71. 
20. Hill, S. J.; Baker, J. G.; Rees, S. Reporter-gene systems for the study of G-protein-
coupled receptors. Curr. Opin. Pharmacol. 2001, 1, 526-532. 
21. Zhang, X.; Odom, D. T.; Koo, S. H.; Conkright, M. D.; Canettieri, G.; Best, J.; Chen, 
H.; Jenner, R.; Herbolsheimer, E.; Jacobsen, E.; Kadam, S.; Ecker, J. R.; Emerson, 
B.; Hogenesch, J. B.; Unterman, T.; Young, R. A.; Montminy, M. Genome-wide 
analysis of cAMP-response element binding protein occupancy, phosphorylation, and 
target gene activation in human tissues. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 
4459-4464. 
22. Montminy, M. R.; Gonzalez, G. A.; Yamamoto, K. K. Regulation of cAMP-inducible 
genes by CREB. Trends Neurosci. 1990, 13, 184-188. 
23. Matthews, R. P.; Guthrie, C. R.; Wailes, L. M.; Zhao, X.; Means, A. R.; McKnight, G. 
S. Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate 
CREB-dependent gene expression. Mol. Cell. Biol. 1994, 14, 6107-6116. 
24. Sheng, M.; Thompson, M. A.; Greenberg, M. E. CREB: a Ca(2+)-regulated 
transcription factor phosphorylated by calmodulin-dependent kinases. Science 1991, 
252, 1427-1430. 
25. Berridge, M. J.; Lipp, P.; Bootman, M. D. The versatility and universality of calcium 
signalling. Nat. Rev. Mol. Cell Biol. 2000, 1, 11-21. 
26. Seifert, R.; Strasser, A.; Schneider, E. H.; Neumann, D.; Dove, S.; Buschauer, A. 
Molecular and cellular analysis of human histamine receptor subtypes. Trends 
Pharmacol. Sci. 2013, 34, 33-58. 
27. Seifert, R.; Wenzel-Seifert, K.; Burckstummer, T.; Pertz, H. H.; Schunack, W.; Dove, 
S.; Buschauer, A.; Elz, S. Multiple differences in agonist and antagonist 
pharmacology between human and guinea pig histamine H1-receptor. J. Pharmacol. 
Exp. Ther. 2003, 305, 1104-1115. 
28. Fujioka, M.; Koda, S.; Morimoto, Y.; Biemann, K. Structure of FR900359, a cyclic 
depsipeptide from ardisia-crenata sims. J. Org. Chem. 1988, 53, 2820-2825. 
29. Takasaki, J.; Saito, T.; Taniguchi, M.; Kawasaki, T.; Moritani, Y.; Hayashi, K.; Kobori, 
M. A novel Galphaq/11-selective inhibitor. J. Biol. Chem. 2004, 279, 47438-47445. 
30. Krauss, G. Biochemistry of Signal Transduction and Regulation. Wiley‐VCH, 
Weinheim 2014. 
31. Hofstra, C. L.; Desai, P. J.; Thurmond, R. L.; Fung-Leung, W. P. Histamine H4 
receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. 
Exp. Ther. 2003, 305, 1212-1221. 
32. Wettschureck, N.; Offermanns, S. Mammalian G proteins and their cell type specific 
functions. Physiol. Rev. 2005, 85, 1159-1204. 
33. Bongers, G.; Bakker, R. A.; Leurs, R. Molecular aspects of the histamine H-3 
receptor. Biochem. Pharmacol. 2007, 73, 1195-1204. 
34. Seifert, R.; Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: 
cause of disease and common property of wild-type receptors. Naunyn 
Schmiedebergs Arch. Pharmacol. 2002, 366, 381-416. 
35. Burns, D. L. Subunit structure and enzymic activity of pertussis toxin. Microbiol. Sci. 
1988, 5, 285-287. 
Chapter 4 
92 
 
36. Mangmool, S.; Kurose, H. G(i/o) protein-dependent and -independent actions of 
Pertussis Toxin (PTX). Toxins (Basel) 2011, 3, 884-899. 
37. Macintyre, E. A.; Tatham, P. E.; Abdul-Gaffar, R.; Linch, D. C. The effects of pertussis 
toxin on human T lymphocytes. Immunology 1988, 64, 427-432. 
38. Sommermeyer, H.; Resch, K. Pertussis toxin B-subunit-induced Ca2(+)-fluxes in 
Jurkat human lymphoma cells: the action of long-term pre-treatment with cholera and 
pertussis holotoxins. Cell. Signal. 1990, 2, 115-128. 
39. Lauckner, J. E.; Hille, B.; Mackie, K. The cannabinoid agonist WIN55,212-2 increases 
intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. 
Sci. U. S. A. 2005, 102, 19144-19149. 
40. Kavitha, C.; Rajamani, K.; Vadivel, E. Coleus forskohlii: A comprehensive review on 
morphology, phytochemistry and pharmacological aspects. Journal of Medicinal 
Plants Research 2010, 4, 278-285. 
41. Gjertsen, B. T.; Mellgren, G.; Otten, A.; Maronde, E.; Genieser, H. G.; Jastorff, B.; 
Vintermyr, O. K.; Mcknight, G. S.; Doskeland, S. O. Novel (Rp)-Camps Analogs as 
Tools for Inhibition of Camp-Kinase in Cell-Culture - Basal Camp-Kinase Activity 
Modulates Interleuktin-1-Beta Action. J. Biol. Chem. 1995, 270, 20599-20607. 
42. Federman, A. D.; Conklin, B. R.; Schrader, K. A.; Reed, R. R.; Bourne, H. R. 
Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. 
Nature 1992, 356, 159-161. 
43. Lehmann, D. M.; Seneviratne, A. M.; Smrcka, A. V. Small molecule disruption of G 
protein beta gamma subunit signaling inhibits neutrophil chemotaxis and 
inflammation. Mol. Pharmacol. 2008, 73, 410-418. 
44. Stables, J.; Green, A.; Marshall, F.; Fraser, N.; Knight, E.; Sautel, M.; Milligan, G.; 
Lee, M.; Rees, S. A bioluminescent assay for agonist activity at potentially any G-
protein-coupled receptor. Anal. Biochem. 1997, 252, 115-126. 
45. Molina, C. A.; Foulkes, N. S.; Lalli, E.; Sassone-Corsi, P. Inducibility and negative 
autoregulation of CREM: an alternative promoter directs the expression of ICER, an 
early response repressor. Cell 1993, 75, 875-886. 
46. Kemp, D. M.; George, S. E.; Kent, T. C.; Bungay, P. J.; Naylor, L. H. The effect of 
ICER on screening methods involving CRE-mediated reporter gene expression. J. 
Biomol. Screen. 2002, 7, 141-148. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
1 Application of the established 
luciferase reporter gene assay for 
the functional investigation of hH1R 
ligands 
 
Luciferase reporter gene assay for 
the functional investigation of hH1R 
ligands 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
94 
 
5.1 Introduction 
Over the past decade, numerous recombinant expression assay systems were established 
for HxRs in our workgroup.1-4 With respect to the H1R, for example, in an approach to develop 
a cell based assay for the H1R, potentially applicable to high throughput screening, the fura-2 
assay was adapted to the microtitre format.5 This approach succeeded only partially, since 
screening of agonists became possible, whereas the assays did not work reliably in case of 
antagonists.  
The aim of this sub-project was to explore the applicability of the established luciferase 
reporter gene assay (cf. chapter 4) to the functional investigation of H1R ligands. In reporter 
gene assays, signal amplification may occur due to the distal readout. Agonists may be more 
potent in the luciferase reporter gene assay compared to assays with a more proximal 
readout.6 Therefore, the results obtained from the luciferase assay were compared to 
reported functional and binding data.  
 
5.2 Material and Methods 
All chemicals were from commercial suppliers, unless otherwise indicated.  
 
5.2.1 Cell culture 
Cells were cultured as described in section 4.2.1. 
 
5.2.2 Stable transfection of HEK293T CRE Luc cells with the pcDNA3.1(+)-
hH1R vector 
The transfection is described in section 4.2.2. 
 
5.2.3 Luciferase reporter gene assay  
The assay is described in section 4.2.8. After addition of 20 µL of the 10 fold concentrated 
test compound (in water, DMEM or DMF; cf. section 5.3.3), the samples were completed by 
adding 20 µL of DMEM to a total volume of 200 µL. The cells were incubated at 37 °C  in 
water saturated atmosphere containing  5 % CO2 for 5 hours. 
 
5.2.4 Crystal violet based chemosensitivity assay 
The assay was performed as described in section 3.5.3.7. 
 
5.2.5 Selected test compounds 
5.2.5.1 H1R agonists 
All selected H1R agonists (Fig. 5.1), except for histamine, were synthesized in the laboratory 
of Professor Dr. Sigurd Elz (Institute of Pharmacy, University of Regensburg). The stock 
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solutions (10 mM) were prepared with water, except for the histaprodifen derivatives (stock 
solutions in 30 % DMSO or 100 % DMF). 
 
 
 
Figure 5.1. Chemical structures of the selected H1R agonists  
 
 
5.2.5.2 H1R antagonists 
The antidepressants, antipsychotic and antihistaminic compounds were from Sigma Aldrich 
(Taufkirchen, Germany), RBI (Natick, USA) or Biotrend (Köln, Germany) (Fig. 5.2). The stock 
solutions (10 mM) were prepared with water, except for clozapine (stock solution in 0.1 M 
HCl) and fexofenadine (stock solution in 50 % DMSO or 50 % DMF). The H1R was activated 
by 300 nM HIS. pKb values were calculated according to the Cheng-Prusoff equation.7 
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Figure 5.2. Chemical structures of the selected H1R antagonists  
 
5.3 Results and Discussion 
5.3.1 Quantification of hH1 receptors per cell 
Receptor expression was verified by saturation binding assays using whole HEK CRE Luc 
hH1R cells as described in section 4.3.1.1 Approximately 500,000 hH1R were expressed per 
cell.  
 
5.3.2 Optimization of the incubation period  
In case of HEK CRE Luc H4R cells, the optimal incubation period was determined for 5 h.6 
Likewise, 5 h seemed to be an appropriate incubation period for HEK CRE Luc hH1R cells. 
By analogy to the HEK CRE Luc hH4R cells, a maximum was reached after 8 h of incubation 
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and sustained over 30 h (data not shown). Nevertheless, an incubation period of 5 h was 
chosen, due to the potential risk of receptor internalisation after longer incubation periods.  
 
5.3.3 Effect of the solvent on the luciferase activity 
Due to the fact that not all of the selected compounds were soluble in water, the effects of 
DMSO (Fig. 5.3A) and DMF (Fig. 5.3B) were investigated.  
 
Figure 5.3. Influence of DMSO (A) and DMF (B) on the luciferase signal. Cells were incubated with the respective 
solvent and 10 µM HIS. The luciferase activity induced by 10 µM HIS was set to 100 %. Data are means ± SEM 
of 2 independent experiments, each performed in triplicate. 
 
DMSO at a concentration of 0.1 % reduced the maximum luciferase signal by approximately 
24 %, whereas in the presence of 2 % DMSO the signal was almost completely suppressed. 
In search for an alternative to DMSO, the effect of DMF was investigated. In contrast to 
DMSO, up to a final concentration of 3 % DMF the reduction of the maximum luminescence 
signal was only around 14 %. Therefore, DMSO was replaced by DMF as solvent. 
 
5.3.4 Functional characterization of H1R ligands 
A variety of structurally different agonists and antagonists (cf. section 5.2.5) was studied in 
the luciferase reporter gene assay. The pEC50 values of all investigated agonists were in 
agreement with data from literature (Table 5.1).  
The pEC50 values determined for histamine and 5.1 were comparable to the pEC50 values 
determined in the steady-state GTPase assay. By contrast, the pEC50 values of the 
phenylhistamine derivatives 5.2, 5.3 and 5.4, obtained in the luciferase reporter gene assay, 
correlated better with the pKi values of these compounds. As suggested by Seifert et al.,8 the 
structurally related compound 2-(3-chlorophenyl)histamine directly activates Gi proteins in 
HL-60 cells which might explain the low potency of the 2-phenylhistamines in the luciferase 
reporter gene assay. Indeed, direct activation of Gi proteins in HEK293T CRE Luc cells could 
not be confirmed for the tested phenylhistamine derivatives in HEK CRE Luc cells (data not 
shown). 
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 luciferase reporter gene 
assaya 
steady-state GTPase 
assayb,9 
competition 
bindingb,9 
compd. pEC50 ± SEM Emax ± SEM pEC50 ± SEM Emax ± SEM pKi ± SEM 
HIS 6.87 ± 0.06 1.00 6.92 ± 0.07 1.00   5.62 ± 0.0310 
5.1 7.49 ± 0.08 1.05 ± 0.03 7.75 ± 0.11 0.94 ± 0.06 6.43 ± 0.08 
5.2 5.12 ± 0.15 0.56 ± 0.07 6.14 ± 0.06 0.72 ± 0.04 5.36 ± 0.13 
5.3 5.46 ± 0.17 0.56 ± 0.05 6.75 ± 0.03 0.62 ± 0.01 5.86 ± 0.09 
5.4 5.81 ± 0.06 0.62 ± 0.02 6.71 ± 0.04 0.61 ± 0.02 5.83 ± 0.10 
Table 5.1. Potencies of H1 receptor agonists determined in the luciferase reporter gene assay compared to 
functional and binding data reported in literature 
aLuciferase reporter gene assay on HEK CRE Luc hH1R cells. Data were analyzed by nonlinear regression and 
were best fit to three-parameter sigmoidal concentration-response curves. pEC50: -logEC50; Emax: maximal 
response relative to histamine (Emax = 1.0). Data shown are means ± SEM of 2-5 independent experiments, each 
performed in triplicate. bData were taken from Straßer et al. (2009); pEC50 and pKi values determined on Sf9 
insect cell membranes. 
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In case of the H1R antagonists, the determined pKb values were in good agreement with both 
functional and binding data from literature (Table 5.2).  
 
Table 5.2. H1 receptor antagonism determined in the luciferase reporter gene assay compared to functional and 
binding data reported in literature 
 
 luciferase reporter gene 
assaya 
steady-state GTPase 
assayb,9 
competition bindingc,9 
compd. pKb ± SEM pKb ± SEM pKi ± SEM 
5.8 8.34 ± 0.08 8.77 ± 0.043 - 
5.9  7.88 ± 0.13* 7.81 ± 0.0511 7.78 ± 0.0312 
5.10 8.13 ± 0.10 8.24 ± 0.083 8.33 ± 0.0312 
5.11 8.51 ± 0.06 8.36 ± 0.1211 8.58 ± 0.1611 
5.12 8.55 ± 0.11 8.72 ± 0.033 - 
5.13 8.47 ± 0.12 8.54 ± 0.1611 8.86 ± 0.0711 
5.14 7.47 ± 0.03 - 7.45 ± 0.0712 
 
 
 
 
 
 
 
 
 
Figure 5.4. Concentration-response curves of H1R agonists (A) and antagonists (B) in the luciferase reporter 
gene assay.  
 
 
Unfortunately, it was not possible to quantify the hH1R agonist potencies of the histaprodifen 
derivatives in the luciferase reporter gene assay (Fig. 5.5), most probably due to cytolysis 
caused by these amphiphilic compounds (cf. section 5.3.5). 
 
aLuciferase reporter gene assay on HEK CRE Luc hH1R cells. Data were analyzed by nonlinear regression and 
were best fit to 3-parameter sigmoidal concentration-response curves. pKb values were calculated according to 
the Cheng-Prusoff equation (c(HIS) = 300 nM; *1 µM, EC50 (HIS) = 134 nM) . Data are means ± SEM of 2-4 
independent experiments, each performed in triplicate. bData were taken from Appl et al. (2012) or Seifert et al. 
(2003); pKb values determined on Sf9 insect cells, expressing the hH1R and co-expressing RGS4. cData were 
taken from Appl et al. (2012) or Wittmann et al. (2009) on Sf9 insect cells co-expressing the hH1R and RGS4. 
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Figure 5.5. Effects of the histaprodifen derivatives 5.5, 5.6 and 5.7 in the luciferase reporter gene assay (data 
from two representative experiments).  
 
 
Bakker et al.13 characterized 5.9 as an inverse agonist at the H1R. By contrast, in the present 
study, 5.9 acted as a neutral antagonist (Fig 5.6). It should be stressed that in HEK CRE Luc 
hH1R cells the H1R was devoid of constitutive activity. 
Constitutive activity of a receptor can vary depending on the cell systems.14 However, the 
most likely explanation for this difference is that Bakker et al. used cells co-expressing the 
H1R and the Gαq protein, as constitutive activity can be modulated by co-expressed G-
proteins.15 
 
 
Figure 5.6. Luciferase activity in HEK CRE Luc hH1R cells in the presence of compd. 5.9 (representative 
experiment). The luciferase activity remained unaffected at increasing concentrations of 5.9. Constitutive of the 
H1R was not detectable in this cellular system.   
 
 
5.3.5 Characterization of histaprodifen derivatives in the crystal violet based 
chemosensitivity assay 
To elucidate why the histaprodifen derivatives did not induce a luciferase signal at higher 
concentrations, the compounds were investigated in a crystal violet based chemosensitivity 
assay on HEK CRE Luc hH1R cells (Fig 5.7).  
Regardless of considerably longer incubation periods in the chemosensitivity assay, the 
results provided an explanation for the behavior of the compounds in the luciferase reporter 
gene assay (cf. Fig 5.5). Compound 5.5 were not cytotoxic up to a concentration of 10 µM, 
whereas compounds 5.6 and 5.7 revealed strong cytocidal effects at a concentration of 10 
µM. Additionally, at a concentration of 1 µM, 5.6 was less toxic than 5.7. These observations 
correlate with the amphiphilic character of these compounds and their potential to interact 
with cell membranes. 
  
Luciferase reporter gene assay for the functional investigation of hH1R ligands 
101 
 
 
Figure 5.7. Cytotoxicity of 5.5, 5.6 and 5.7 on HEK293T CRE Luc hH1R cells in the crystal violet assay. Vinblastin 
and DMSO as positive and negative controls. 
 
5.4 Summary and conclusion 
HEK293T CRE Luc cells were stably co-transfected with the human H1R, and the luciferase 
reporter gene assay was successfully established. By analogy with the luciferase assay for 
the H3R and the H4R, respectively, an incubation period of 5 h was chosen for the HEK CRE 
Luc hH1R cells. In contrast to studies on cells co-transfected with the cDNAs encoding 
receptor and Gαq proteins, respectively, the H1R did not display constitutive activity in this 
system.  
The established luciferase assay was successfully used for the characterization of 
structurally different agonists and antagonists. Furthermore, the reliability and accuracy of 
the assay were proven by comparing the results to data from literature.  
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Previously, our workgroup applied the bivalent ligand approach for the H2R by linking two 
acylguanidine moieties. This led to highly potent and selective H2R agonists. However, the 
acylguandines turned out to decompose upon long-term storage in aqueous solution, in 
particular under alkaline conditions. Based on this preceding work, the medicinal chemistry 
part of this thesis deals with the synthesis of stable bivalent H2R agonists in which the 
acylguanidine group was replaced by a bioisosteric carbamoylguanidine moiety. With respect 
to studying the mode and stoichiometry of binding of such bivalent compounds, the synthesis 
of a chain-branched dimeric ligand, enabling radio- and fluorescence labeling was 
considered.  
The prepared compounds were investigated in GTPγS binding assays on recombinant 
human and guinea pig H2R and by radioligand competition binding on human H1, H2, H3 and 
H4 receptors expressed in Sf9 insect cells. Moreover, representative compounds were 
studied on human monocytes, with regard to cAMP formation and the inhibition of fMLP 
induced reactive oxygen species. 
The bivalent carbamoylguanidine-type H2R ligands proved to be high affinity H2R agonists, 
equipotent with the corresponding carba analogs, the acylguanidines. Achieving up to 2500 
times the potency of histamine, these compounds are among the most potent H2R agonists 
known so far. Unlike the imidazole-type compounds, the bioisosteric aminothiazoles proved 
to be selective for the H2R over the other histamine receptor subtypes. Although the “cold” 
version of a synthesized propionamide derivative proved to be a potent and selective H2R 
agonist, the corresponding tritiated analog, due to a high degree of unspecific binding, was 
not applicable to saturation binding studies, making the determination of the number of 
binding sites impossible. Unfortunately, the fluorescently labeled ligands entered the cells in 
an H2R-independent manner.  
In human monocytes the investigated compounds induced cAMP accumulation and inhibited 
the fMLP-induced ROS production in a highly potent manner so that such compounds 
represent a good starting point for the development of selective H2R drugs for the treatment 
of AML. 
The bioisosteric and bivalent approach led to highly potent, selective and stable H2R agonists 
that proved to be useful pharmacological tools for functional studies on recombinant 
receptors and native cells. Regarding the bioanalytical and toxicological properties of the 
bivalent ligands, compounds bearing a short spacer should be preferred for future in-vivo 
studies.  
 
The second part of this work aimed at the establishment of cell-based functional assays for 
the discrimination between alternative signaling pathways activated by HxR stimulation. For 
this purpose, HEK293T CRE Luc cells were stably transfected with the cDNA encoding the 
hH1R or the hH2R, respectively. The transfectants were investigated in a luciferase reporter 
gene assay, in a fura-2 assay and in an aequorin assay. Moreover, a TR-FRET based cAMP 
assay was applied.  
The activation of the H1R led to an increase in the transcription of luciferase. In the presence of 
the selective Gαq inhibitor UBO-QIC the luciferase expression was reduced, whereas in 
combination with UBO-QIC and PKA inhibitors (Rp-cAMP-S and Rp-8-Br-cAMP-S) the 
luciferase activity was almost completely inhibited. The data obtained from the luciferase 
reporter gene assay suggested that the luciferase expression, mediated by the H1R, was at 
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least in part mediated by cAMP. Furthermore, it was shown that cells preincubated with UBO-
QIC were no longer capable of triggering a Ca2+ signal in the aequorin assay, upon activation 
of the H1R. Detection of a cAMP signal failed most probably due to a low signal-to-noise ratio, 
hence it should be taken into consideration that the activation of the hH1R is associated with 
additional pathways.  
The H2R revealed high constitutive activity in the luciferase reporter gene assay, probably 
due to a high expression level of the receptor in the cells. In the presence of UBO-QIC the 
luciferase activity was reduced. Additionally, it was shown in both Ca2+ assays that the 
activation of the H2R led to a Gαq mediated Ca2+ response.  
The data indicate that, regardless of preferential coupling of hH1R and hH2R to Gαq and Gαs, 
respectively, both receptors are capable of triggering differential signaling pathways, at least in 
genetically modified cells. In general, the stably co-transfected HEK293T CRE Luc cells 
represent a powerful pharmacological toolkit for: 
- The identification of alternative signaling pathways. 
- The investigation of GPCRs and the pharmacological characterization of functionally 
selective ligands. 
- The deconvolution of signals from label-free assays. 
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7.1 NMR spectra of compounds 3.19 and 3.24 
Appendix 
 
 
 
 
 
Figure 7.1. 1H NMR spectrum of 3.19 
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Figure 7.2. 13C NMR spectrum of 3.19 
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Figure 7.3. 1H NMR spectrum of 3.24 
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Figure 7.4. 13C NMR spectrum of 3.24 
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7.2 RP-HPLC chromatograms of compounds 3.19-3.28, 3.39-3.42, and 
3.43a 
 
 
 
Figure 7.5. Chromatogram of 3.19 
 
 
Figure 7.6. Chromatogram of 3.20 
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Figure 7.7. Chromatogram of 3.21 
 
 
Figure 7.8. Chromatogram of 3.22 
 
 
Figure 7.9. Chromatogram of 3.23 
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Figure 7.11. Chromatogram of 3.25 
 
 
Figure 7.12. Chromatogram of 3.26 
 
 
Figure 7.10. Chromatogram of 3.24 
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Figure 7.13. Chromatogram of 3.27 
 
 
Figure 7.14. Chromatogram of 3.28 
 
 
Figure 7.15. Chromatogram of 3.39 
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Figure 7.16. Chromatogram of 3.40 
 
 
Figure 7.17. Chromatogram of 3.41 
 
 
Figure 7.18. Chromatogram of 3.42 
 
Appendix 
117 
 
 
Figure 7.19. Chromatogram of 3.43a 
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Abbreviations 
Å     Ångström  
abs absolute 
AC adenylyl cyclase 
ADP adenosine diphosphate 
α1B-AR α1B adrenoceptor 
α1D-AR α1D adrenoceptor 
AML acute myeloid leukemia  
EBAO ethidium bromide/acridin orange 
APCI atmospheric-pressure chemical ionization 
aq. aqueos 
ATP adenosine triphosphate 
BB binding buffer 
Boc tert-butoxycarbonyl 
BSA bovine serum albumin 
CaM-kinase calcium/calmodulin-dependent protein kinase 
cAMP cyclic  adenosine monophosphate 
CHO chinese hamster ovary  
CNS central nervous system 
conc concentrated 
CRE cAMP response element 
CREB cAMP response element binding protein 
CREM cAMP response element modulator 
d day(s) or doublet 
D1R dopamine 1 receptor 
D2R dopamine 2 receptor 
DAO diamine oxidase 
DCM dichloromethane 
δ-OR δ opioid receptor 
DIAD diisopropyl azodicarboxylate 
DIPEA diisopropylethylamine 
DMAP 4‐(dimethylamino)pyridine 
DMEM Dulbecco’s modified eagle medium 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DTT dithiothreitol 
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EA ethylacetate 
EC50 molar concentration of the agonist causing 50 % of the maximal 
response 
ECL extracellular loop 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylenglycol-bis(aminoethylether)-N,N,N′,N′-tetraessigsäure 
Emax maximal response relative to histamine (1.00) 
eq equivalents 
ESI electrospray ionisation 
Et2O diethyl ether 
EtOH ethanol 
FCS fetal calf serum 
fMLP formyl-methionyl-leucyl-phenylalanine 
FRET fluorescence resonance energy transfer 
FSK forskolin 
GABA γ-aminobutyric acid 
GDP guanosine diphosphate 
GF/C a glass fibre filter grade  
gp guinea pig 
GPCR G-protein coupled receptor 
GRK G-protein coupled receptor kinase 
GTP guanosine triphosphate 
GTPγS guanosine 5'-thiotriphosphate 
h  hour(s) or human 
H1R histamine H1 receptor 
H2R histamine H2 receptor 
H2R-Gsαs fusion protein of the H2R and the short splice variant of Gsα 
H3R histamine H3 receptor 
H4R histamine H4 receptor 
HDC histidine decarboxylase 
HEK human embryonic kidney 
hex hexane 
HIS histamine 
HL60 human promyelocytic leukemia cells 
HNMT histamine N-methyltransferase 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
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HxR histamine receptors 
IBMX 3-isobutyl-1-methylxanthine 
ICER inducible cAMP early repressor 
IL2 Intracellular loop 2 or interleukin 2 
IP3 inositol-1,4,5-trisphosphate 
J coupling constant 
k capacity factor 
κ-OR κ opioid receptor 
Kd dissociation constant (saturation binding) 
Luc luciferase 
m multiplet 
M2R muscarinic M2 receptor 
M3R muscarinic M3 receptor 
MeCN acetonitrile 
MeOD deuterated methanol 
MeOH methanol 
min minute(s) 
mp melting point 
m-RNA Messenger ribonucleic acid 
mtAeq mitochondrial targeted aequorin 
µOR µ opioid receptor 
NADPH nicotinamide adenine dinucleotide phosphate 
n-BuLi n-butyllithium 
NHS N-hydroxysuccinimide 
NK cells natural killer cells 
NMR nuclear magnetic resonance 
PBS phoshpate buffered saline 
PCR polymerase chain reaction 
PE petrol ether 
pEC50 negative decadic logarithm of the molar concentration of the agonist  
causing 50 % of the maximal response 
PEI polyethyleneimine 
pKa negative decadic logarithm of the acid dissociation constant 
PKA protein kinase A 
pKb negative decadic logarithm of the dissociation constant (functional 
assay) 
pKi negative decadic logarithm of the  dissociation constant (competition 
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binding) 
PLA2 phospholipase A2 
PLC phospholipase C 
Potrel relative potency 
ppm parts per million 
PTX pertussis toxin 
q quartet 
R receptor 
RGS regulator of G-protein signaling 
ROS reactive oxygen species 
s singulet 
SEM standard error of the mean 
Sf9 Spodoptera frugiperda 
ß1-AR β1 adrenoceptor 
ß2-AR β2 adrenoceptor 
t triplet 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TM transmembrane  
t0 dead time 
tR retention time 
TR-FRET time-resolved fluorescence resonance energy transfer 
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